Polyvalent chimeric ospc vaccinogen and diagnostic antigen

ABSTRACT

A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian  Borrelia  infections.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention generally relates to a vaccine and diagnostic for Lyme'sdisease. In particular, the invention provides a chimeric polyvalentrecombinant protein comprising immunodominant epitopes of loop 5 and/oralpha helix 5 regions/domains of outer surface protein C (OspC) typesassociated with mammalian infections.

2. Background of the Invention

Lyme disease is the most common arthropod-borne disease in North Americaand Europe. It is caused by the spirochetes Borrelia burgdorferi, B.garinii and B. afzelii. Transmission to mammals occurs through the biteof infected Ixodes ticks [Burgdorfer et al, 1982, Benach et al., 1983].Considerable morbidity is associated with Lyme disease and there areareas in the United States and Europe where up to 3% of the populationis infected annually [Fahrer et al., 1991]. Infection results in amulti-systemic inflammatory disease with early stage symptoms that mayinclude erythema migrans, low-grade fever, arthralgia, myalgia, andheadache [Steere et al., 1977a]. Late stage clinical manifestations canbe severe and may include in part, arthritis [Steere et al., 1977a;Eiffert et al., 1998; Steere et al., 2004], carditis [Asch et al., 1994;Nagi et al., 1996 Barthold et al., 1991] and neurological complications[Nachman and Pontrelli, 2003; Coyle and Schutzer 2002]. In addition,Lyme disease has significant socio-economic costs, manifested byreductions in outdoor recreational and social activities due to concernsabout tick exposure.

Pharmacoeconomic studies indicate that a clear need exists for a Lymedisease vaccine, particularly in populations where the annual diseaserisk exceeds 1% [Meltzer et al., 1999; Shadick et al., 2001]. However,at the present time a vaccine is not commercially available. The firsthuman Lyme disease vaccine was the OspA-based LYMErix (GlaxoSmithKline);however, its tenure was short and, citing a drop in sales,GSKvoluntarily pulled it from the market in 2002. The decline in salescan be traced to concerns, real or perceived, of possible adverseeffects including a chronic inflammatory arthritis that couldtheoretically develop in HLA-DR4-positive recipients [Kalish et al.,1993]. While new OspA-based vaccinogens are being developed to mitigatethis potential complication [Koide et al., 2005; Willett et al., 2004],questions remain about the viability of an OspA-based vaccine. Oneconcern is the frequency of boosts required to maintain long termprotection. OspA is expressed in the tick midgut, is rapidlydownregulated upon tick feeding, and is not expressed in mammals[Gilmore et al., 2001; Schwan et al., 1995]. The mechanism of action ofOspA-based vaccines is to target spirochetes within the tick and preventtheir transmission [de Silva et al., 1999]. Since transmission occurswithin 48 hours of tick feeding, effective protection is dependent onhigh circulating titers of anti-OspA antibodies, necessitating frequentboosts. The inherent problems associated with OspA-based vaccines can beavoided by the use of antigens that are expressed at high levels duringearly infection and that elicit bactericidal antibody.

OspC has received considerable attention in Lyme disease vaccinedevelopment. It is a 22 kDa, surface exposed lipoprotein [Fuchs et al.,1992] encoded on a 26 kb circular plasmid that is universal amongisolates of the B. burgdorferi sensu lato complex [Marconi et al., 1993;Sadziene et. al., 1993]. Its expression is induced upon tick feeding andis maintained during early mammalian infection [Schwan, 2004], and it isgenetically stable during infection [Hodzic et al., 2000; Stevenson etal., 1994]. Anti-OspC antibodies have been demonstrated to protectagainst infection, but only against strains expressing OspC that isclosely related in sequence to the vaccinogen [Gilmore et al., 1996;Bockenstedt et al., 1997; Gilmore and Mbow, 1999; Mathiesen et al.,1998; Scheiblhofer et al., 2003; Jobe et al., 2003; Rousselle et al.,1998; Wallich et al., 2001; Mbow et al., 1999; Probert et al., 1997;Brown et al., 2005; Probert and LeFebvre 1994]. Analyses of OspCsequences have delineated ˜21 OspC phyletic clusters or types that aredifferentiated by letter designation (A through U) [Seinost et al.,1999; Wang et al., 1999]. While sequence variation within a cluster isgenerally less than 2%, between OspC types it can be as high as 22%[Wang et al., 1999; Theisen et al., 1995; Brisson and Dykhuizen, 2004].Such inter-type variation of epitopes most likely explains the limitedrange of protection afforded by vaccination with a single OspC type.

U.S. Pat. No. 6,248,562 (Jun. 19, 2001) to Dunn and Luft describeschimeric Borrelia proteins that consist of at least two polypeptidesfrom corresponding and/or non-corresponding proteins from the sameand/or different species of Borrelia. The chimeric polypeptidesincorporated in the chimeric proteins are derived from any Borreliaprotein from any strain of Borrelia and include OspA, OspB, OspC, OspD,p12, p39, p41, p66, and p93. The chimeric proteins can be used asimmunodiagnostic reagents and as vaccine immunogens against Borreliainfection. However, there is no reference to loop 5 and alpha 5 epitopespresent in OspC proteins.

U.S. Pat. Nos. 6,872,550 and 6,486,130 (Mar. 29, 2005, and Nov. 26,2002, respectively) both to Livey, describe constructs for use avaccines against Lyme disease which contain OspC antigens. However,there is no mention of the characterization of loop 5 and alpha 5epitopes in these patents.

U.S. Pat. No. 7,008,625 (Mar. 7, 2006) to Dattwyler et al. disclosesantigenic polypeptides of a variety of Borrelia strains and/or proteinswithin a single protein. The chimeric Borrelia proteins are made up ofpolypeptide fragments of the outer surface protein OspA and the outersurface protein OspC. These proteins can be effective against Lymeborreliosis as well as for immunodiagnostic reagents. However, there isno mention of the characterization of loop 5 and alpha 5 epitopes.

The publication “Recombinant Chimeric Borrelia Proteins for Diagnosis ofLyme Disease” (Maria J. C. Gomes-Solecki et al. 2000. J. Clin.Microbiol., 38: 2530-2535) is related to the two above-identifiedpatents. The authors engineered recombinant chimeras, each containingportions of the key antigenic proteins of Borrelia burgdorferi, OspA,OspB, OspC, flagellin (Fla or p41), and a protein p93. The paper isdirected to diagnosis, but describes applications to vaccinogens in theclosing paragraph. The authors mention that better chimeras can becreated with further study of the genetic variability of the importantepitopes but do not mention the loop 5 and alpha 5 epitopes of OspC.

The prior art has thus-far failed to provide a vaccine that affordsbroad protection against multiple OspC types for use in the preventionand/or treatment of Lyme disease.

SUMMARY OF THE INVENTION

The invention provides a chimeric polyvalent recombinant protein for useas a vaccine and diagnostic for Lyme disease. The invention is based inpart on the discovery and characterization of novel protective, epitopesfrom several different OspC phyletic groups (types), each of which isassociated with mammalian (e.g. human) Lyme disease infection.Identification of these epitopes made possible the construction of achimeric protein or proteins that comprises a plurality of epitopes fromdifferent OspC infective types. Thus, when used as a vaccine, thechimeric recombinant protein elicits broad protection against aplurality of Borrelia strains that express those OspC types, and areassociated with mammalian Lyme disease. In addition, the chimericprotein is useful as a diagnostic tool to identify individuals that haveantibodies to the epitopes, and to thus determine if an individual hasbeen exposed to or infected by the causative agent of Lyme disease. Insome embodiments of the invention, the epitopes are B-cell epitopesand/or immunodominant epitopes.

It is an object of this invention to provide a chimeric recombinantprotein comprising epitopes from loop 5 region or alpha helix 5 region,or both, of two or more outer surface protein C (OspC) types. In oneembodiment, the OspC types are selected from the group consisting ofSmar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461,DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, Cand T. In some embodiments, the chimeric protein has an amino acidsequence selected from the group consisting of SEQ ID NO: 250, SEQ IDNO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255,SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ IDNO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264,SEQ ID NO: 265, SEQ ID NO: 266, and SEQ ID NO: 267. In some embodiments,the OspC types are associated with invasive Borrelia infection.

The invention further provides a method for eliciting an immune responseagainst Borrelia in an individual in need thereof. The method comprisesthe step of administering to the individual a chimeric recombinantprotein comprising epitopes from loop 5 region or alpha helix 5 region,or both, of two or more outer surface protein C (OspC) types. In oneembodiment of the invention, the OspC types are selected from the groupconsisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko,PLj7, VS461, DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez,PWa, B, K, N, C and T. In some embodiments, the chimeric protein has anamino acid sequence selected from the group consisting of SEQ ID NO:250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO:259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, and SEQ ID NO: 267. In someembodiments, the OspC types are associated with invasive Borreliainfection.

The invention further provides a method for ascertaining whether anindividual has been exposed to or infected with Borrelia. The methodcomprises the steps of 1) obtaining a biological sample from theindividual; 2) exposing the biological sample to at least onerecombinant chimeric protein, wherein the at least one chimeric proteincomprises epitopes from loop 5 region or alpha helix 5 region, or both,of two or more outer surface protein C (OspC) types; and 3) determiningwhether antibodies in said biological sample bind to the at least onechimeric protein, wherein detection of antibody binding is indicative ofprior exposure to or infection with Borrelia. In one embodiment of theinvention, the OspC types are selected from the group consisting ofSmar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461,DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, Cand T. In some embodiments, the chimeric protein has an amino acidsequence selected from the group consisting of SEQ ID NO: 250, SEQ IDNO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255,SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ IDNO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264,SEQ ID NO: 265, SEQ ID NO: 266, and SEQ ID NO: 267. In some embodimentsof the invention, the OspC types are associated with invasive Borreliainfection.

The invention further provides antibodies to a chimeric recombinantprotein comprising epitopes from loop 5 region or alpha helix 5 region,or both, of two or more outer surface protein C (OspC) types. In oneembodiment of the invention, the OspC types are selected from the groupconsisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko,PLj7, VS461, DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez,PWa, B, K, N, C and T. In some embodiments, the chimeric protein has anamino acid sequence selected from the group consisting of SEQ ID NO:250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO:259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, and SEQ ID NO: 267. In someembodiments, the OspC types are associated with invasive Borreliainfection. The antibodies may be either polyclonal or monoclonal. In oneembodiment, the antibody is bactericidal for Borrelia spirochetes.

The invention further provides an immunogenic cocktail of chimericrecombinant proteins. Each chimeric recombinant protein in the cocktailcomprises epitopes from loop 5 region or alpha helix 5 region, or both,of two or more outer surface protein C (OspC) types.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Evolutionary relationships of OspC sequences derived from humanpatients in Maryland: OspC type identification. OspC genes were PCRamplified, sequenced, and a phylogram was constructed. Databasesequences representative of the 22 ospC types were included in theanalysis (accession numbers are indicated). The type designation(capital letters) assigned to each phyletic group is indicated by thecapital letters on each branch. Bootstrap values (1000 trials) aredisplayed at each node critical for group differentiation.

FIG. 2. Demonstration that the antibody response to OspC duringinfection is predominantly OspC type specific. Recombinant OspC proteinsof several OspC types (indicated in the figure) were generated,separated by SDS-PAGE, immunoblotted and screened with HRP conjugatedS-Protein or serum collected from mice infected with clonal isolates ofknown OspC type as indicated.

FIG. 3A-C. Localization of the immunodominant epitopes of type A OspC.Truncations of type A OspC were generated as S-Tag fusion proteins andexpressed in E. coli. Panel A presents a schematic of the OspCtruncations. The numbering reflects the residue numbering of B.burgdorferi B31MI OspC. In panel A, the ability of each truncatedprotein to bind infection antibody is indicated to the right by a (+) or(−). The numbers to the left indicate the amino acid residues thatcomprise each truncation. In panels B and C immunoblots of therecombinant proteins were screened with HRP-conjugated S-Protein toverify expression and loading or with serum from a mouse infected withB. burgdorferi B31MI (α-B31MI infection serum), a type A OspC producingstrain. For reference, the arrows in panels b and c indicate themigration position of recombinants that were not immunoreactive with theα-B31MI infection serum are indicated. Molecular mass markers areindicate to the right of each immunoblot.

FIGS. 4A and B. Comparative analysis of segments of the loop 5 and alpha5 epitopes at the inter- and intratype levels, shown in tabular form.

FIG. 5. Demonstration of a loop 5 antibody response in multiple animalsinfected with different type A OspC producing strains. Immunoblots ofeither 1) full length typeA OspC or 2) a fragment containing amino acids130-150 (which includes loop 5) were screened with infection sera. Thestrain used to generate the infection sera and the specific mouse (m)from which the sera were collected is indicated above each panel. Thetimepoint during infection when the sera were collected is alsoindicated. An equal amount of protein was immunoblotted for each and allwere exposed to film for the same amount of time.

FIG. 6. ELISAs: identification of serum samples harboring type A OspCtargeting antibody. r-type A full-length OspC, r-type A loop 5, andbovine serum albumin were used to coat the wells of ELISA plates. Thewells were screened with serum from human Lyme disease patients. Allassays were performed in triplicate, and the mean is presented alongwith the standard deviation. All methods were as described in the text.Serum from patient 15 which was determined to be IgG negative forantibody to B. burgdorferi B31MI served as a negative control.

FIGS. 7 A and B. Identification of the specific residues that comprisethe type A OspC loop 5 epitopes through PepSpot analysis. Overlappingpeptides that span the loop 5 domain were generated and spotted ontonitrocellulose. The immobilized peptides were then screened with serumfrom mice infected with a clonal population of a type A OspC-producingstrain (B31 MI) or with serum from human Lyme disease patients (asindicated). (A) Immunoblotting results for loop 5 domain; (B) peptidesequences.

FIG. 8. Demonstration that loop 5 is surface exposed and that antibodyto loop 5 is bactericidal. The IFAs and bactericidal assays wereconducted with antiserum generated against type A loop 5. (A) Theresults demonstrate the specificity of the anti-loop 5 antiserum.Whole-cell lysates of B. burgdorferi B31 MI, B. parkeri, and r-type Aloop 5 fragment were separated by sodium dodecyl sulfatepolyacrylamidegel electrophoresis, immunoblotted, and screened with anti-type A loop 5antiserum (1:1,000). Molecular masses of the protein markers are to theright of the figure.

FIGS. 9A and B. Generation of a tetravalent chimeric OspC testconstruct. A, A flow chart for the generation of the tetravalent ABKDchimeric vaccinogen constructs is shown in panel A. The type-specificOspC epitopes used in the ABKD chimeric vaccinogen are represented bydifferent bar shading. The loop 5 epitope of OspC type A and the alphahelix 5 epitope of types B, K and D were amplified in PCR round 1 andgel purified. These initial amplicons were then joined in subsequentrounds of PCR to produce the full chimeric construct. Since the termini(linker sequences) of the amplicons are complementary, afterdenaturation they can anneal to allow overlap extension followed by PCRamplification. The final amplicon was annealed into the pET46 Ek/LICvector. B, In panel B, the final protein sequence of the ABKD chimericvaccinogen construct is shown with constituent epitope-containingregions and linker sequences noted.

FIG. 10. Western blot demonstrating immunoreactivity of anti-ABKDantiserum with the ABKD chimeric vaccinogen and full length OspC.Immunogenicity was evaluated by immunoblotting the ABKD chimericvaccinogen, full length r-OspC proteins of types A, B, K and D (asindicated), and rBBN39 (negative control). The blots were screened withanti-His tag mAb to demonstrate approximately equal loading, or withrepresentative anti-ABKD antisera (indicated below). Molecular mass isshown on the right. A strong IgG response to A, B and K (but not D) wasobserved.

FIGS. 11 A and B. ELISA titration of the reactivity of sera from miceimmunized with the ABKD chimeric vaccinogen. A, Sera from micevaccinated with the ABKD chimeric vaccinogen (n=12) or sham immunizedwith PBS/adjuvant (n=3) were titrated for reactivity with the ABKDchimeric vaccinogen or rOspC protein of types A, B, K, and D. Panel Ademonstrates the titration of immunoreactivity of all sera to the ABKDchimeric vaccinogen construct (solid lines with a different symbol foreach mouse). No Ab response was observed in the sham vaccinated mice(dashed lines). B, Titrations of the specific response to each OspC typewere also completed (curves not shown), and the titers determined at ½max OD405 are shown in panel B (one point per mouse, horizontal line atthe mean titer). Control mice had no titer, and were not plotted.

FIG. 12. Immunoglobulin isotype profile of anti-ABKD antiserum. ELISAwells were coated with the ABKD chimeric vaccinogen construct (100ng/well) and probed with anti-ABKD antisera in duplicate (1:10000;n=12). Bound Ig was detected by biotinylated isotype-specific secondaryAb (Mouse Isotyping Kit; Zymed Laboratories) and HRP-conjugatedstreptavidin. Reactivity was quantified by measurement of the coloredproduct created by the HRP-mediated conversion of ABTS substrate.

FIG. 13A-E. Schematic representation of the construction of the ABKDvaccine variants. ABKDppa (Panel A) was constructed by amplification ofthe original construct using a reverse primer with a 5′ overhang to addthe C-terminal amino acids. ABKDgg (not shown) was made in an identicalmanner, but using the OCDH5ggLIC primer. ABKDD (Panel B), ADBK (PanelC), and ADBKD (Panel D) were all made by PCR amplification ofconstituent sequences using primers that added tails encoding linkersequences. The resultant PCR products were gel purified, and joined byoverlap annealing and extension. The final products were cloned into thepET-46 Ek/LIC vector. OspC type-specific epitope containing regions aredenoted by letter, and linker sequences by number (see inset for encodedamino acid sequences). Arrows denote primers, and 5′ overhanging LICtails or linker sequences are noted on the tail of each primer arrow.

FIG. 14. Coomassie stained SDS-PAGE gel of the chimeric vaccinogen testconstructs. Vaccinogen r-proteins were expressed in E. coli, affinitypurified by nickel chromatography, and quantified by the BCA method. Twoμg of the purified proteins were electrophoesed on a 15% SDS-PAGE gel(Criterion; Biorad) and stained with Coomassie G-250. No contaminatingproteins were noted, and there was minimal or no degradation of therecombinant proteins.

FIGS. 15 A and B. Assessment of mouse vaccine serum recognition of fulllength r-OspC. In panel A, r-OspC of types A, B, K, and D wereelectrophoresed and blotted to PVDF (type indicated at top; 500ng/lane), and were probed with a 1:2500 dilution of representative serafrom mice vaccinated with each of the variant constructs (indicated atleft). Secondary detection was by peroxidase-conjugated goat-anti-mouseIgG (1:40000) and chemiluminescence. Molecular masses are indicted atthe right. In panel B are the results of a quantitative ELISA titrationof mouse vaccine serum reactivity with full length r-OspC. Seragenerated against each vaccine construct (noted at bottom) were titratedagainst immobilized, full length, r-OspC of types A, B, K, and D. Alsoincluded are the titers from the ABKD construct dialyzed against PBS(ABKD*) [17]. Bars denote the mean titer against OspC types A (black), B(grey), K (open), and D (hatched). Titers from individual mice aredenoted by open triangles. Listed below are the mean numerical titers,as well as the titers indexed either to the corresponding titer of theABKD construct dialyzed against PBS (ABKD*) or against Arg/Glu buffer(ABKD).

FIG. 16A-C. Epitope-specific isotype responses to three vaccineconstructs. OspC types A, B, K, and D were immobilized on ELISA platesand probed with immune sera from mice vaccinated with the ABKD, ABKDD,or ADBKD constructs in duplicate. Bound Ig isotypes were detected withbiotinylated isotype-specific secondary antibodies andperoxidase-conjugated streptavidin.

FIG. 17. IFN-γ response of splenocytes from immunized mice to in vitrorestimulation with the immunizing antigen. Erythrocyte-free splenocytesfrom three mice immunized with each of the six vaccine constructs werecollected, pooled, and restimulated in triplicate with the originalimmunizing antigen (10⁷ cells mL⁻¹ in 24 well plates, antigen at 10 or 5μmL⁻¹). Triplicate control wells were administered 10 mg mL⁻¹ BSA or noprotein. After incubation (37° C., 5% CO₂) for 96 hours, cell freesupernatants were collected, and IFN-γ concentrations were determined byELISA. In all cases, the concentration of IFN-γ in the BSA and noprotein wells was below the detection limit of the assay.

FIGS. 18A and B. Assessment of the antibody response to the ABKDvaccinogen administered in Freund's adjuvants or alum. In panel A arethe results of a quantitative ELISA titration of IgG in mouse seragenerated against the ABKD vaccine emulsified in Freund's adjuvants(solid bars) or adsorbed to alum (hatched bars). The sera were titratedagainst immobilized ABKD vaccinogen or full length, r-OspC of types A,B, K, and D. In panel B is shown the isotype profile of the sera boundto immobilized ABKD vaccinogen. The bound Ig isotypes were detected withbiotinylated isotype-specific secondary antibodies andperoxidase-conjugated streptavidin.

FIG. 19. Distribution of pairwise comparisons of OspC protein sequenceidentity. OspC protein sequences from 280 Borrelia isolates were Clustalaligned using a PAM40 scoring matrix, and pairwise percent identitieswere calculated. The histogram interval is 1% and there were no percentidentities <50%.

FIG. 20A-C. Species, geographical and biological isolation data forassigned OspC types.

FIG. 21A-C. Consensus phylogenetic trees of representative OspC proteinsequences. OspC sequences including amino acids 20-200 (A), 20-130 (B),and 131-200 (C) were bootstrapped (n=1000), distances calculated, andneighbor joining trees created and reconciled to a consensus tree. TheVmp33 sequence of B. hermsii was used as an outgroup. Labels indicatethe species as B. burgdorferi (Bb), B. garinii (Bg), or B. afzelii (Ba),the isolate strain designation, the assigned OspC type (bold), and thenumber of identical OspC sequences from other strains represented bythis single sequence (in parentheses). Bootstrap support is shown at allnodes that differentiate between OspC types.

FIG. 22. Bootscan analysis of the OspC type PLj7 (B. afzelii) ospCsequence in comparison with OspC types Pki (B. garinii; solid blackline), F (B. burgdorferi; solid grey line), and M (B. burgdorferi;dashed black line). The bootscan window was 40 bases, with a 10 basestep. Comparison was by strict consensus with 100 bootstrap replicates.The graph has been simplified by showing only those peaks where the %permuted trees exceeds 50%, and the 70% level considered to representpossible recombination is indicated.

FIG. 23. Alignment of the epitope-containing region of OspC proteinsequences from all OspC types defined in this study. All sequenceswithin OspC types that differ by more than one amino acid are indicatedby a representative sequence. Identity threshold for shading is 80%.Secondary structural alpha helices and loops (corresponding to the B31structure) are shown below the alignment (Kumaran et al, 2001).

FIG. 24. Clustal X alignment of the parental OspC sequences used in theconstruction of the ABKD chimeric vaccinogen and physical location ofepitope-containing regions included in the vaccinogen. The locations ofthe epitope-containing region of OspC type A (loop 5 region, light greybox) and types B, K, and D (alpha helix 5 region) dark grey box) arehighlighted within a ClustalX alignment of the parent sequences.

FIG. 25A-J. Exemplary chimeric vaccinogens of the invention. Theconstruct title indicates the OspC type-specific loop 5 and helix 5epitopes incorporated in the construct, as well their order. The bold Xrepresents the position of optional linker sequences.

FIG. 26. Protein and DNA accession numbers of OspC from several Borreliastrains.

FIG. 27. Assessment of Lyme disease seroconversion in tick-challengeddogs using the chimeric A8.1 protein in an ELISA format. ELISA plateswere coated with 100 ng/well of A8.1 protein in carbonate buffer. Serafrom unchallenged (control) and tick-challenged dogs collected at weeks3, 4, and 5 post-challenge were diluted (1:250) and applied in duplicateto the ELISA plates. Following incubation, the bound dog Ig was detectedwith an IgG-specific, peroxidase-conjugated secondary antibody(1:20000). Reactivity was quantified using a TMB-based chromogen. Eachbar represents the mean data for an individual animal.

FIG. 28A-D. A, general epitope locations within a representativesequence of OspC from B. burgdorferi; B, epitope pattern in A9.1construct; C, epitope pattern in B9.1 construct; D, epitope pattern inC9.1 construct.

FIG. 29A-C. A, epitope pattern in A9.2 construct; B, epitope pattern inB9.2 construct; C, epitope pattern in C9.2 construct.

FIG. 30A-C. A, epitope pattern in A9.3 construct; B, epitope pattern inB9.3 construct; C, epitope pattern in C9.3 construct. “Loop” indicatesthe loop 5 region which includes helix 3.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

The present invention is based on the identification andcharacterization of novel protective, type-specific epitopes of OspCtypes that are associated with human Lyme disease infection. The novelepitopes are located within two domains (regions) in thecarboxyl-terminal half of OspC. Neither domain was previously identifiedas highly immunogenic. The first domain (referred to as “alpha helix 5region/domain” or “alpha 5 region/domain” or “helix 5 region/domain”herein) is located between residues 160 and 200, and contains secondarystructural elements including a portion of loop 6, alpha helix 5, andthe unstructured C-terminal domain (Kumaran et al., 2001). The seconddomain (“loop 5 region/domain” herein) is located between residues 131and 159 and contains secondary structural elements including a portionof alpha helix 3, loop 5 and alpha helix 4 (Kumaran et al., 2001). Eachof these regions contains at least one epitope that may be used in thepractice of the present invention. Epitopes from these two domains, orantigenic peptides or polypeptides from within these two regions, may beused in the practice of the present invention, either alone orpreferably in combination with other epitopes in a chimeric immunogen.In some embodiments of the invention, the epitopes are immunodominantepitopes. Typically, the epitopes are B-cell epitopes, although T-cellepitopes are not excluded.

Discovery of the novel epitopes, and mapping of the epitopes todifferent OspC types, has made possible the construction of multivalentchimeric proteins that contain a plurality of linear, type-specificimmunodominant epitopes from multiple OspC types. When used as avaccine, the multivalent (polyvalent) recombinant chimeric proteinelicits broad protection against infection with Borrelia spirochetesexpressing the OspC types that correspond to those in the chimericprotein, i.e. those Borrelia that are highly infective. In addition, thechimeric protein is useful as a diagnostic tool to identify individualsthat have antibodies to the epitopes contained in the chimeric protein,and to thus determine if an individual has been exposed to and/orinfected by a causative agent of Lyme disease.

In order to facilitate the understanding of the present invention, thefollowing definitions are provided:

Antigen: term used historically to designate an entity that is bound byan antibody, and also to designate the entity that induces theproduction of the antibody. More current usage limits the meaning ofantigen to that entity bound by an antibody, while the word “immunogen”is used for the entity that induces antibody production. Where an entitydiscussed herein is both immunogenic and antigenic, reference to it aseither an immunogen or antigen will typically be made according to itsintended utility. The terms “antigen”, “immunogen” and “epitope” may beused interchangeably herein.B-cell Epitope: a specific chemical domain on an antigen that isrecognized by a B-cell receptor, and which can be bound by secretedantibody. The term is interchangeable with “antigenic determinant”.Immunodominant epitope: The epitope on a molecule that induces thedominant, or most intense, immune response.Linear epitope: An epitope comprising a single, non-interrupted,contiguous chain of amino acids joined together by peptide bonds to forma peptide or polypeptide. Such an epitope can be described by itsprimary structure, i.e. the linear sequence of amino acids in the chain.Conformational epitope: an epitope comprised of at least some aminoacids that are not part of an uninterrupted, linear sequence of aminoacids, but which are brought into proximity to other residues in theepitope by secondary, tertiary and/or quaternary interactions of theprotein. Such residues may be located far from other resides in theepitope with respect to primary sequence, but may be spatially locatednear other residues in the conformational epitope due to proteinfolding.Loop 5 region/domain: The region of OspC that includes residues thatalign with residues 131 to 159 of the type A OspC sequences as denotedin FIG. 23. Strain B31 OspC secondary structural elements included inthe region are a portion of alpha helix 3, loop 5, and alpha helix 4, asdefined by Kumaran et al. (2001).Alpha helix 5 region/domain: The region of OspC that includes residuesthat align with amino acids 160 to 200 of the strain B31 (OspC type A)sequence as shown in FIG. 23, as well as the C-terminal portion of theprotein (amino acids 201-210 of the B31 sequence) not shown in FIG. 23.Strain B31 OspC secondary structural elements included in this regionare a portion of loop 6, alpha helix 5, and the unstructured C-terminaldomain, as defined by Kumaran et al. (2001).Protein: A linear sequence of from about 100 or more amino acidscovalently joined by peptide bonds.Polypeptide: A linear sequence of from about 20 to about 100 amino acidscovalently joined by peptide bonds.Peptide: A linear sequence of about 20 or fewer amino acids covalentlyjoined by peptide bonds.The terms “protein”, “polypeptide” and “peptide” may be usedinterchangeably herein.Chimeric protein: a recombinant protein whose primary sequence comprisesmultiple peptide, polypeptide, and/or protein sequences which do notoccur together in a single molecule in nature.Valency of a chimeric protein (e.g. “multivalent” or “polyvalent”)refers to the number of OspC type-specific epitope-bearing polypeptidesincluded in the chimeric vaccinogen. For example, a divalent chimera maybe composed of alpha helix 5 of type A and alpha helix 5 of type B, or,alpha helix 5 of type A and loop 5 of type A. There may be multipledistinct epitopes in each polypeptide epitope-bearing region.Original or native or wild type sequence: The sequence of a peptide,polypeptide, protein or nucleic acid as found in nature.Recombinant peptide, polypeptide, protein or nucleic acid: peptide,polypeptide, protein or nucleic acid that has been produced and/ormanipulated using molecular biology techniques such as cloning,polymerase chain reaction (PCR), etc.Type-specific: associated primarily with a single phyletic group.Invasive infection: An OspC protein is said to be “associated withinvasive infection” if Borrelia bearing the OspC type have been isolatedduring human infection from locations other than the skin surroundingthe initial inoculation by tick bite (e.g. from plasma, cerebrospinalfluid, etc.).

The invention thus provides recombinant chimeric proteins that comprisemultiple linear epitopes from the loop 5 and/or alpha helix 5 regions,at least two of which are from different OspC types that are associatedwith invasive infection. Preferably, antigenic epitopes representingfrom about 2 to about 20, and preferably from about 5 to about 13,different OspC types are included in a single chimeric protein. In someembodiments, the chimeric recombinant protein comprises epitopes from 5OspC types, or from 6 OspC types, or from 7 OspC types, or from 8 OspCtypes, or from 9 OspC types, or from 13 OspC types. While typically atleast two of the epitopes are different from one another in primarysequence and originate from different OspC types, it is also possible toinclude multiple copies of a single type of epitope in a chimera, or toinclude several sequences that are based on or derived from the originalsequence of the same OspC type. While the total number of linearepitopes in a chimera may vary somewhat, in general, the range will befrom about 10 to 30. In one embodiment of the invention, theimmunodominant epitopes are selected from two or more of OspC typesSmar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461,DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, Cand T. In one embodiment, the chimeric protein is tetravalent andcontains epitopes from types A, B, K and D. In another, embodiment, thechimeric protein is octavalent and contains epitopes from OspC types E,N, I, C, A, B, K and D. However, those of skill in the art willrecognize that epitopes from other combinations of OspC types may alsobe used, so long as the resulting chimera produces a suitable immuneresponse and/or is effective as a vaccine in preventing Lyme disease.Examples of other suitable combinations, as demonstrated by the numerousexamples disclosed herein, include but are not limited to: 1) A, B, K,D, E, N, C; 2) I, C, A, B, K, D; and 3) C, A, B, K, D.

In some embodiments, the chimeric protein has an amino acid sequenceselected from the group consisting of SEQ ID NO: 250, SEQ ID NO: 251,SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ IDNO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260,SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ IDNO: 265, SEQ ID NO: 266, SEQ ID NO: 267; or is an amino acid sequencewith at least 95%, 96%, 97%, 98%, 99% or more identity to any one of theamino acid sequences set forth in SEQ ID NOS: 250-267.

In further embodiments, at least one of the OspC types in the chimericrecombinant protein is associated with invasive Borrelia infection inhumans.

The invention further comprises a method for eliciting an immuneresponse against Borrelia in an individual in need thereof using thesechimeric recombinant proteins.

In a further embodiment, the invention provides diagnostic methods forascertaining whether an individual has been exposed to or infected withBorrelia. The methods comprise the steps of 1) obtaining a biologicalsample from said individual, 2) exposing the biological sample to atleast one recombinant chimeric protein as described herein; and 3)determining whether antibodies in the biological sample bind to the atleast one chimeric protein. Detection of antibody binding is indicativeof prior exposure to or infection with Borrelia.

In yet other embodiments, the invention provides antibodies to thechimeric recombinant proteins described herein; and immunogeniccocktails which include the chimeric recombinant proteins describedherein.

In some embodiments, both the loop 5 and alpha helix 5 regions will beincluded. For example, an “E, N, I, C, A, B, K, D” construct may containboth the loop 5 and helix 5 regions of each of OspC types E, N, I, C, A,B, K, and D. However, this need not be the case. For example, the loop 5region of type A and the alpha helix 5 regions of E, N, I, C, B, K, andD may be included; or only the loop 5 region for each OspC type may beincluded; or only the alpha helix 5 region; or other combinations may beincluded (e.g. loop 5 region of types E, N, I, and C and the alpha helix5 region of types A, B, K, and D. Many such combinations will occur tothose of skill in the art, and all such variations are intended to beencompassed herein.

Further, the linear order of the epitopes within a chimera may vary. Ingeneral, the order, from amino to carboxyl terminus, will be “loop 5region, alpha helix 5 region, loop 5 region, alpha helix 5 region . . .” etc. For example, in the case of the E, N, I, C, A, B, K, D construct,a preferred order is “E-type loop 5 region, E-type alpha helix 5 region;N-type loop 5 region, N-type alpha helix 5 region; 1-type loop 5 region,1-type alpha helix 5 region . . . ”, etc. along the length of thechimera, with the different OspC types and/or the different domainsoptionally separated by neutral linker sequences. However, this ordermay vary, depending, for example, on the elements that are chosen forinclusion in the chimera. Any order of OspC types and domains may beused, so long as the resulting chimera produces a suitable immuneresponse and/or is effective as a vaccine in preventing Lyme disease, orcan be effectively used in a diagnostic. Examples of exemplary chimerasequences are given in FIG. 25A-J. A key to the protein and DNAaccession numbers for OspC from several strains of Borrelia is presentedin tabular form in FIG. 26.

The amino acid sequences that are included in the chimeric protein maycomprise the alpha helix 5 and/or the loop 5 regions, or antigenicfragments thereof. By “antigenic fragment” we mean a segment of theprimary OspC sequence that contains at least one linear epitoperecognized during infection. Such an epitope, when expressed in arecombinant protein subunit of OspC, retains the ability to bindinfection-induced antibodies in a manner similar to the binding ofwild-type protein expressed at the cell surface. An individual antigenicfragment may contain more than one distinct epitope. Those of skill inthe art will recognize that measurement of the affinity or avidity ofantibodies for an epitope is somewhat imprecise, and that theaffinity/avidity can change significantly during the immune response,e.g. by affinity maturations/somatic hypermutataiton. In general,however, the affinity/avidity of binding of antibodies to the chimericprotein is in the range of at least about 50%, preferably about 60%,more preferably about 70%, even more preferably about 80%, and mostpreferably about 90-100% or even greater, than the affinity exhibited bynative, intact alpha 5 or loop 5. In general, the antigenic sequencesthat are included in the chimeric proteins will contain from about 20 toabout 100 amino acids, and preferably from about 30 to about 70 aminoacids, and the chimeric proteins themselves will contain a total of fromabout 160 to about 800 amino acids, and preferably from about 240 toabout 560 amino acids. Further, the antigenic sequences may be referredto herein as “epitopes”, whether or not they include an entire “natural”epitope, so long as they possess the antibody binding characteristicsdescribed herein.

Alternatively, appropriate antigen fragments or antigenic sequences orepitopes may be identified by their ability, when included in a chimericprotein, to elicit suitable antibody production to the epitope in a hostto which the chimeric protein is administered. Those of skill in the artwill recognize that definitions of antibody titer may vary. Herein,“titer” is taken to be the inverse dilution of antiserum that will bindone half of the available binding sites on an ELISA well coated with 100ng of test protein. In general, suitable antibody production ischaracterized by an antibody titer in the range of from about 100 toabout 100,000, and preferably in the range of from about 10,000 to about10,000,000. Alternatively, and particularly in diagnostic assays, the“titer” should be about three times the background level of binding. Forexample, to be considered “positive”, reactivity in a test should be atleast three times greater than reactivity detected in serum fromuninfected individuals. Preferably, the antibody response is protective,i.e. prevents or lessens the development of symptoms of disease in avaccinated host that is later exposed to Borrelia, compared to anunvaccinated host.

The amino acid sequence of one exemplary chimeric protein according tothe invention is presented in FIG. 9B. In this illustrative embodiment,the chimera contains loop 5 region amino acid sequences from Type AOspC, and alpha helix 5 regions sequences from OspC types B, K and D. Inthis case, the Type A OspC sequence is from strain LDP56, withnucleotide accession number EF053513 and protein accession numberABK41054; the Type B OspC is from strain LDP73, with nucleotideaccession number EF053525 and protein accession number ABK41066; theType K OspC is from strain LDP89, with nucleotide accession numberEF053523 and protein accession number ABK41064; and the Type D OspC isfrom strain LDP116, with nucleotide accession number EF053527 andprotein accession number ABK41068. Those of skill in the art willrecognize that OspC from many strains of Borrelia are known or may bediscovered, and may be used in the practice of the present invention.The sequences of exemplary chimeric constructs are set forth in orrepresented by the SEQ ID NOS: disclosed herein.

Those of skill in the art will recognize that, while in some embodimentsof the invention, the amino acid sequences that are chosen for inclusionin the chimeric protein of the invention correspond directly to theprimary amino acid sequence of the original or native sequence of theOspC protein, this need not be the case. The amino acid sequence of anepitope that is included in the chimeric protein of the invention may bealtered somewhat and still be suitable for use in the present invention.For example, certain conservative amino acid substitutions may be madewithout having a deleterious effect on the ability of the epitope toelicit an immune response. Those of skill in the art will recognize thenature of such conservative substitutions, for example, substitution ofa positively charged amino acid for another positively charged aminoacid; substitution of a negatively charged amino acid for anothernegatively charged amino acid; substitution of a hydrophobic amino acidfor another hydrophobic amino acid; etc. All such substitutions oralterations of the sequence of an epitope that is contained in thechimeric protein of the invention are intended to be encompassed by thepresent invention, so long as the resulting epitope still functions toelicit a suitable immune response. In addition, the amino acid sequencesthat are included in the chimeric proteins of the invention need notencompass a full length native epitope or epitope-containing domain.Those of skill in the art will recognize that truncated versions ofamino acid sequences that are known to be or to contain epitopes may,for a variety or reasons, be preferable for use in the presentinvention, so long as the criteria set forth for an epitope is fulfilledby the sequence. Amino acid sequences that are so substituted orotherwise altered may be referred to herein as “based on” or “derivedfrom” the original wild type or native sequence. In general, the OspCproteins from which the linear epitopes are “derived” or on which thelinear epitopes are “based” are the OspC proteins as they occur innature. These natural OspC proteins may alternatively be referred to asnative or wildtype proteins.

Such changes to the primary sequence may be introduced for any of avariety of reasons, for example, to eliminate or introduce a proteasecleavage site, to increase or decrease solubility, to promote ordiscourage intra- or inter-molecular interactions such a folding, ionicinteractions, salt bridges, etc, which might otherwise interfere withthe presentation and accessibility of the individual epitopes along thelength of the chimera. All such changes are intended to be encompassedby the present invention, so long as the resulting amino acid sequencefunctions to elicit a protective antibody reaction to the OspC type fromwhich the epitope originates. In general, such substituted sequenceswill be at least about 50% identical to the corresponding sequence inthe native protein, preferably about 60 to 70, or even 70 to 80, or 80to 90% identical to the wild type sequence, and preferably about 95 toabout 100% identical.

In some embodiments of the invention, the individual linear epitopes inthe chimeric vaccinogen are separated from one another by interveningsequences that are more or less neutral in character, i.e. they do notin and of themselves elicit an immune response to Borrelia. Suchsequences may or may not be present between the epitopes of a chimera.If present, they may, for example, serve to separate the epitopes andcontribute to the steric isolation of the epitopes from each other.Alternatively, such sequences may be simply artifacts of recombinantprocessing procedures, e.g. cloning procedures. Such sequences aretypically known as linker or space peptides, many examples of which areknown to those of skill in the art. See, for example, Crasto, C. J. andJ. A. Feng. 2000. LINKER: a program to generate linker sequences forfusion proteins. Protein Engineering 13(5): 309-312, which is areference that describes unstructured linkers. Structured (e.g. helical)sequence linkers may also be designed using, for example, existingsequences that are known to have that secondary structure, or usingbasic known biochemical principles to design the linkers. In addition,other elements may be present in the chimeric proteins, for exampleleader sequences or sequences that “tag” the protein to facilitatepurification or detection of the protein, examples of which include butare not limited to histidine tags, detection tags (e.g. S-tag, orFlag-tag), other antigenic amino acid sequences such as known T-cellepitope containing sequences and protein stabilizing motifs, etc. Inaddition, the chimeric proteins may be chemically modified, e.g. byamidation, sulfonylation, lipidation, or other techniques that are knownto those of skill in the art.

The invention further provides nucleic acid sequences that encode thechimeric proteins of the invention. Such nucleic acids include DNA, RNA,and hybrids thereof, and the like. Further, the invention comprehendsvectors which contain or house such coding sequences. Examples ofsuitable vectors include but are not limited to plasmids, cosmids, viralbased vectors, expression vectors, etc. In a preferred embodiment, thevector will be a plasmid expression vector.

The chimeric proteins of the invention may be produced by any suitablemethod, many of which are known to those of skill in the art. Forexample, the proteins may be chemically synthesized, or produced usingrecombinant DNA technology (e.g. in bacterial cells, in cell culture(mammalian, yeast or insect cells), in plants or plant cells, or bycell-free prokaryotic or eukaryotic-based expression systems, by otherin vitro systems, etc.).

The present invention also provides compositions for use in eliciting animmune response which may be utilized as a vaccine to prevent or treatBorrelia infection, particularly when manifested as Lyme disease (Lymeborreliosis). By eliciting an immune response, we mean thatadministration of the antigen causes the synthesis of specificantibodies (at a titer as described above) and/or cellularproliferation, as measured, e.g. by ³H thymidine incorporation. By“vaccine” we mean a chimeric protein that elicits an immune responsewhich results protection against challenge with Borrelia, either whollyor partially preventing or arresting the development of symptoms relatedto Borrelia infection (i.e. the symptoms of Lyme disease), in comparisonto a non-vaccinated (e.g. adjunct alone) control organisms. Thecompositions include one or more substantially purified recombinantchimeric proteins as described herein, and a pharmacologically suitablecarrier. The plurality of chimeric proteins in the composition may bethe same or different, i.e. the composition may be a “cocktail” ofdifferent chimeras, or a composition containing only a single type ofchimera. The preparation of such compositions for use as vaccines iswell known to those of skill in the art. Typically, such compositionsare prepared either as liquid solutions or suspensions, however solidforms such as tablets, pills, powders and the like are alsocontemplated. Solid forms suitable for solution in, or suspension in,liquids prior to administration may also be prepared. The preparationmay also be emulsified. The active ingredients may be mixed withexcipients which are pharmaceutically acceptable and compatible with theactive ingredients. Suitable excipients are, for example, water, saline,dextrose, glycerol, ethanol and the like, or combinations thereof. Inaddition, the composition may contain minor amounts of auxiliarysubstances such as wetting or emulsifying agents, pH buffering agents,and the like. The vaccine preparations of the present invention mayfurther comprise an adjuvant, suitable examples of which include but arenot limited to Seppic, Quil A, Alhydrogel, etc. If it is desired toadminister an oral form of the composition, various thickeners,flavorings, diluents, emulsifiers, dispersing aids or binders and thelike may be added. The composition of the present invention may containany such additional ingredients so as to provide the composition in aform suitable for administration. The final amount of chimeric proteinin the formulations may vary. However, in general, the amount in theformulations will be from about 0.01-99%, weight/volume.

The methods involve administering a composition comprising a chimericrecombinant protein in a pharmacologically acceptable carrier to amammal. The vaccine preparations of the present invention may beadministered by any of the many suitable means which are well known tothose of skill in the art, including but not limited to by injection,inhalation, orally, intranasally, by ingestion of a food productcontaining the chimeric protein, etc. In preferred embodiments, the modeof administration is subcutaneous or intramuscular. In addition, thecompositions may be administered in conjunction with other treatmentmodalities such as substances that boost the immune system,chemotherapeutic agents, and the like.

The present invention provides methods to elicit an immune response toBorrelia and to vaccinate against Borrelia infection in mammals. In oneembodiment, the mammal is a human. However, those of skill in the artwill recognize that other mammals exist for which such vaccinationswould also be desirable, e.g. the preparations may also be used forveterinary purposes. Examples include but are not limited to companion“pets” such as dogs, cats, etc.; food source, work and recreationalanimals such as cattle, horses, oxen, sheep, pigs, goats, and the like;or even wild animals that serve as a reservoir of Borrelia (e.g. mice,deer). The invention also provides a diagnostic and a method for usingthe diagnostic to identify individuals who have antibodies to theepitopes contained within the chimeric proteins of the invention. Abiological sample from an individual (e.g. a human, a deer, or othermammals susceptible to infection by Borrelia spirochetes) suspected ofhaving been exposed to Borrelia, or at risk for being exposed toBorrelia, is contacted with the chimeric proteins of the invention.Using known methodology, the presence or absence of a binding reactionbetween the chimeric protein and antibodies in the biological sample isdetected. A positive result (binding occurs, thus antibodies arepresent) indicates that the individual has been exposed to and/or isinfected with Borrelia. In this connection, depending on the goal of theanalysis, chimeras specific for any subset of interest of OspC types maybe constructed, i.e. all possible OspC types may or may not be includedin the diagnostic chimera.

Further, the diagnostic aspects of the invention are not confined toclinical use or home use, but may also be valuable for use in thelaboratory as a research tool, e.g. to identify Borrelia spirochetesisolated from ticks, to investigate the geographical distribution ofOspC types, etc.

The present invention also encompasses antibodies to the epitopes and/orto the chimeric proteins disclosed herein. Such antibodies may bepolyclonal, monoclonal or chimeric, and may be generated in any mannerknown to those of skill in the art. In a preferred embodiment of theinvention, the antibodies are bactericidal (borreliacidal), i.e.exposure of Borrelia spirochetes to the antibodies causes death of thespirochetes. Such antibodies may be used in a variety of ways, e.g. asdetection reagents to diagnose prior exposure to Borrelia, as a reagentin a kit for the investigation of Borrelia, to treat Borreliainfections, etc.

The following Examples are provided to illustrate various embodiments ofthe invention, but should not be considered as limiting in any way.

EXAMPLES Example 1 Demonstration of OspC Type Diversity in InvasiveHuman Lyme Disease Isolates and Identification of PreviouslyUncharacterized Epitopes that Define the Specificity of the OspCAntibody Response Introduction

Lyme disease is transmitted to humans through the bite of Ixodes ticksinfected with Borrelia burgdorferi, B. garinii or B. afzelii. Outersurface protein C (OspC) is thought to be an important virulence factorinvolved in the transmission process and possibly in the establishmentof early infection in mammals (Grimm et al, 2004; Parl et al, 2004;Schwan et al., 1995). OspC is a variable, ˜22 kDa, surface exposed,plasmid-encoded lipoprotein (Fuchs et al., 1992; Marconi et al., 1993;Sadziene et al., 1993). Crystal structures have been determined forthree OspC proteins (Eicken et al, 2001; Kumaran et al, 2001). Theprotein is largely helical with 5 alpha helices connected by variableloops. The loops have been postulated to form ligand binding domains(Eicken et al, 2001; Kumaran et al, 2001). Evidence suggests that OspCmay facilitate translocation of spirochetes from the tick midgut byserving as an adhesin that binds to unidentified receptors in thesalivary gland (Pal et al, 2004). Orthologs of OspC have been identifiedin several species of the relapsing fever group raising the possibilitythat the OspC related proteins carry out a similar role in otherBorrelia species (Marconi et al, 1993; Margolis et al, 1994). OspCexpression is environmentally regulated, induced by tick feeding, andOspC is a dominant antigen during early infection in mammals (Alversonet al, 2003; Schwan et al, 1998; Stevenson et al, 1995). Transcriptionis regulated, at least in part, by the RpoN/S regulatory network (Hubneret al, 2001). It should be noted that there are conflicting reportsregarding the precise details of the temporal nature of OspC expressionduring transmission and during early infection (Ohnishi et al., 2001;Schwan et al, 1995).

OspC exhibits significant genetic and antigenic diversity (Theisen etal, 1995; Theisen et al, 1993). Twenty one OspC phyletic groups(henceforth referred to as OspC types) have been delineated (Seinost etal., 1999; Wang et al, 1999). OspC types are differentiated by letterdesignations (A through U). Analysis of several hundred OspC amino acidsequences that are in the databases indicates that divergence betweenOspC types can be as high as 30% while within a type it is generallyless than 6%. Seinost et al. have hypothesized a correlation betweenOspC types A, B, I and K and invasive infections in humans (Seinost etal., 1999). Lagal et al. also reported that specific ospC variants, asdefined by single-strand conformation polymorphism analysis, correlatewith invasive human infections (Lagal et al, 2003). However, a recentstudy by Alghaferi and colleagues has called into question the strengthof this correlation (Alghaferi et al., 2005). The influence of OspC typeor sequence on function and the host-pathogen interaction represents animportant and fertile area of investigation. OspC has been investigatedfor use in Lyme disease vaccine development (Bockenstedt et al. 1997;Gilmore et al., 2003; Gilmore et al., 1999a; Probert et al., 1994;Theisen et al, 1993; Wilske et al, 1996). However, OspC variation andlimited knowledge of the antigenic structure of OspC have complicatedthese efforts. OspC has protective capability, but only against the samestrain (Bockenstedt et al. 1997; Gilmore et al., 1999; Gilmore et al.,1999b; Probert and LeFebvre, 1994; Wilske et al, 1996). This suggeststhat the protective epitopes reside within regions of the protein thatare highly variable in sequence.

The goals of this study were several fold. First, further assessment ofthe putative correlation between OspC type and invasive infections wassought by determining the OspC type of invasive and non-invasiveisolates recovered from a defined patient population in Maryland.Second, in an attempt to better understand the antibody response toOspC, determination of whether or not that response is type specific wassought. Finally, definition of the antigenic structure of OspC wassought by identifying epitopes that elicit an antibody response duringinfection in mice. The data presented here indicate that the number ofOspC types associated with invasive infection is greater than previouslypostulated (Seinost et al., 1999). In addition, we have identified twopreviously uncharacterized epitopes and have demonstrated that theantibody response to OspC appears to be type specific. These analysesprovide important information that enhance our understanding of the roleof OspC in Lyme disease pathogenesis and that will facilitate theconstruction of an OspC based vaccine.

EXPERIMENTAL PROCEDURES Bacterial Isolates, Cultivation and Generationof Infection Serum.

Lyme disease isolates recovered from human patients in Maryland wereemployed in these analyses (Table 1). Patients provided informed consentprior to the study as approved by the John Hopkins MedicineInstitutional Review Board. The spirochetes were cultivated in BSK-Hcomplete media (Sigma) at 33° C., monitored by dark-field microscopy andharvested by centrifugation. Clonal populations were generated for someisolates by sub-surface plating as previously described (Sung et al.,2000). To determine the ospC type of individual colonies, the ospC genewas PCR amplified, sequenced and comparative sequence analyses wereperformed (as described below). To generate antisera against a series ofclonal populations expressing OspC proteins of known type, 10³spirochetes were washed in phosphate buffered saline (PBS) and needleinoculated into C3H-HeJ mice (sub-cutaneous, between the shoulderblades; Jackson Labs). Infection of the mice was confirmed by real timePCR of ear punch biopsies at wk 2 or 4 post-inoculation using primerstargeting the flaB gene as previously described (Zhang et al., 2005).Blood was collected from each mouse at 0, 2, 4 and 8 wks by tail snipand the infection serum was harvested. Additional antisera and infectionserum used in these analyses have been described previously (McDowell et1, 2002).

TABLE 1 Bacterial isolates, source information and OspC type. B.burgdorferi Isolate Source OspC type B31MI Tick A 5A4 Clone derived fromB31MI A LDP56 Human blood A LDP61 Human blood A LDP60 Human blood ALDP80 Human blood A LDP76 Human blood A LDS106 Human skin A LDP73 Humanblood B LDS79 Human skin H LDS101 Human skin H LDP84 Human blood C LDP63Human blood N LDC83 Human CSF N LDP120 Human blood N LDP74 Human blood KLDS81 Human skin K LDS88 Human skin K LDP89 Human blood K LDP116 Humanblood D

DNA Isolation, OspC Typing and Computer Assisted Structural Analyses.

To determine the OspC type, total DNA was isolated from each strain aspreviously described (Marconi et al., 2003) and used as template for PCRwith the OspC20(+)LIC and OspC210(−)LIC primers (Table 2). PCR wasperformed using Expand High Fidelity polymerase (Roche) with thefollowing cycling conditions: Initial denaturation at 94° C. for 2minutes; 94° C. for 15 s, 50° C. for 30 s, 68° C. for 60 s for 10cycles; 94° C. for 15 s, 50° C. for 30 s, 68° C. for 60 s with anadditional 5 s added to each of the last 20 cycles; final elongation at68° C. for 7 minutes. The amplicons were recovered using QiaQuick PCRPurification kit (Qiagen), treated with T4 DNA polymerase to generatesingle strand overhangs, annealed into the pET-32 Ek/LIC vector(Novagen) and transformed into E. coli NovaBlue (DE3) cells (Novagen).The methods for these procedures were as described by the manufacturer.Colonies were selected for ampicillin resistance (50 μml-1) and screenedfor the ospC insert by PCR. Selected colonies were transferred into LBbroth (Fisher), cultivated at 37° C. with shaking (300 rpm) and theplasmids isolated using QiaFilter Midi Plasmid Isolation Kits (Qiagen).The ospC inserts were sequenced on a fee for service basis (MWGBiotech). The determined sequences were translated and aligned usingClustalX (35) with default parameters. To determine OspC type, aneighbor joining tree was created, and bootstrap values calculated (1000trials). The resultant phylogram was visualized with N-J Plotter.Additional OspC sequences available in the databases were included inthe analysis. Structural models for OspC were generated using the NCBImolecular modeling database files 1GGQ, 1F1M, and 1G5Z (4, 15) and CN3Dsoftware available at the website atncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml.

TABLE 2  Polymerase Chain Reaction Primers employed in this study.Primer Sequence ^(a) SEQ ID NO: ospC 20(+) LICGACGACGACAAGATTAATAATTCAGGGAA 163 AGATGGG ospC 40(+) LICGACGACGACAAGATTCCTAATCTTACAGA 165 AATAAGTAAAAAAAT ospC 60(+) LICGACGACGACAAGATTAAAGAGGTTGAAGC 165 GTTGCT ospC 80(+) LICGACGACGACAAGATTAAAATACACCAAAA 166 TAATGGTTTG ospC 100(+) LICGACGACGACAAGATTGGAGCTTATGCAAT 167 ATCAACCC ospC 130(+) LICGACGACGACAAGATTTGTTCTGAAACATTT 168 ACTAATAAATTAAAAG ospC 136(+) LICGACGACGACAAGATTAATAAATTAAAAGA 169 AAAACACACAGATCTTG ospC 142(+) LICGACGACGACAAGATTCACACAGATCTTGG 170 TAAAGAAGG ospC 151(+) LICGACGACGACAAGATTACTGATGCTGATGC 171 AAAAGAAG ospC 171(+) LICGACGACGACAAGATTGAAGAACTTGGAAA 172 ATTATTTGAATC ospC 191(+) LICGACGACGACAAGATTCTTGCTAATTCAGTT 173 AAAGAGCTTAC ospC 130(−) LICGACGACAAGCCCGGTTTAACATTTCTTAGC 174 CGCATCAATTTTTTC ospC 150(−) LICGACGACAAGCCCGGTTTAAACACCTTCTTT 175 ACCAAGATCTGT ospC 170(−) LICGACGACAAGCCCGGTTTAAGCACCTTTAGT 176 TTTAGTACCATT ospC 190(−) LICGACGACAAGCCCGGTTTACATCTCTTTAGC 177 TGCTTTTGACA ospC 200(−) LICGACGACAAGCCCGGTTTAGCTTGTAAGCTC 178 TTTAACTGAATTAGC ospC 210(−) LICGACGACAAGCCCGGTTTAAGGTTTTTTTGG 179 ACTTTCTGC ^(a) LIC tail sequences areunderlined

Generation of Recombinant Proteins.

To generate full length and truncations of OspC, primers were designedbased on the type A ospC sequence of B. burgdorferi B31MI (Fraser eta 1,1997). The primers possess tail sequences that allow for annealing intothe pET-32 Ek/LIC vector (Novagen), a ligase independent cloning (LIC)and expression vector. All LIC procedures were as previously described(Hovis et al, 2004). To verify the sequence of all constructs,recombinant plasmids were purified from E. coli NovaBlue (DE3) cellsusing QiaFilter Midi Plasmid Purification kits (Qiagen), and the insertswere sequenced (MWG Biotech).

SDS-PAGE and Immunoblot Analyses.

Proteins were separated in 12.5% Criterion Precast Gels (Biorad) bySDS-PAGE and immunoblotted onto PVDF membranes (Millipore) as previouslydescribed (Roberts et al, 2002). Expression of recombinant proteins wasconfirmed using S-Protein horseradish peroxidase (HRP) conjugate(Novagen), which detects the N-terminal S-Tag fusion that is carried byall recombinant proteins employed in this study. The HRP conjugatedS-Protein was used at a dilution of 1:10,000. For immunoblot analyses,serum collected from infected mice was used at a dilution of 1:1000. HRPconjugated goat anti-mouse IgG served as the secondary (Pierce) and wasused at a dilution of 1:10,000. General immunoblot methods were aspreviously described (Metts et al, 2003).

Results

ospC Typing Analysis of Isolates Recovered from Human Lyme DiseasePatients in Maryland.

ospC was successfully amplified from each of the isolates analyzed thatwere recovered from the human Lyme disease patients from Maryland. Thesequence of each amplicon was determined and comparative sequenceanalyses were performed to determine OspC type (FIG. 1). Representativesof several different OspC types including A (n=6), B (n=1), C (n=1), D(n=1), H (n=2), K (n=4) and N (n=3) were identified. It had beenpreviously reported that only OspC types A, B, I and K are associatedwith invasive infections in humans (Seinost et al., 1999). In thatstudy, invasive isolates were defined as those that were recovered fromblood, organs or cerebrospinal fluid whereas non-invasive isolates werethose that were recovered from the skin but not found at other bodysites (Seinost et al, 1999). However, here it is demonstrated that someisolates expressing OspC types C, D, and N were recovered from blood(LDP84, LDP63, LDP116, and LDP120) or cerebrospinal fluid (LDC83) andhence are invasive. This observation suggests that the correlation ofspecific OspC types with invasive infection may not be a strict one andthat the strength of the correlation requires re-evaluation.

Analysis of the Type Specificity of the Antibody Response to OspC DuringInfection in Mice.

To determine if the antibody response elicited to OspC during infectionis type specific, type A, B, C, D, H, K and N recombinant OspC proteinswere generated for use as test antigens.

The recombinant proteins were immunoblotted and screened with serumcollected from mice infected with B. burgdorferi isolates of the A, B,or D OspC type (as determined above) (FIG. 2). Expression of therecombinant proteins in E. coli and the equal loading of protein wasconfirmed by screening one immunoblot with HRP conjugated S-Proteinwhich recognizes the S-Tag in the N-terminal fusion. When screened withanti-B. burgdorferi B31 MI antiserum (type A OspC) collected at wk 2 ofinfection, strong reactivity was detected only with the type A protein.The strong and early IgG response to OspC is consistent with earlierreports (Theisen et al, 1995; Wilske et al, 1993). Sera collected at wk8 of infection also reacted predominantly with type A OspC but weakcross immunoreactivity with other OspC types was observed. The Abresponse to OspC in mice infected with LDP116 and LDP73 (OspC type D andβ isolates respectively) was also type specific. It can be concludedthat there is a significant degree of type specificity in the antibodyresponse to OspC and that this specificity implies that the in vivoimmunodominant epitopes are located within the type specific domains ofthe protein.

Localization of the OspC Linear Epitopes that Elicit an AntibodyResponse During Infection in Mice.

To identify the linear epitopes of type A OspC that elicit an antibodyresponse during infection, several recombinant OspC fragments weregenerated and screened with α-B. burgdorferi B31MI infection serum (wk8) (FIG. 3). B31MI is an OspC type A producing strain. The expression ofthe recombinant proteins was confirmed by immunoblotting with the HRPconjugated S-Protein. To localize the linear epitopes of OspC,immunoblots of the OspC fragments were screened with infection serum.Two domains containing one or more epitopes were localized, one withinthe C-terminal half of the protein between residues 168 and 203 of alphahelix 5 and the other between residues 136 and 150 of helix 3 and loop 5(henceforth, referred to as the alpha 5 and loop 5 epitopes,respectively). These epitopes have not been previously characterized inthe literature.

ospC Sequence Analyses and Computer Modeling of OspC Structure.

To determine where the loop 5 and alpha 5 epitopes spatially reside onthe OspC protein, the coordinates determined by X-ray crystallographicanalyses (Eicken et al., 2001; Kumaran et al, 2001) were accessed andribbon and space fill models were generated for monomeric and or dimericforms of type A OspC (data not shown). Monomeric forms of type I and EOspC proteins were also modeled. These analyses revealed that the loop 5epitope is surface exposed on both the monomeric and dimeric forms oftype A, E and I OspC proteins. In the original X-ray crystallographicanalyses, portions of both the N- and C-termini were either not part ofthe recombinant protein or could not be modeled. In any event, thedetermined structures indicate that both the N- and C-termini reside inclose proximity to one another and are proximal to the cell membrane.

To assess sequence variation within the loop 5 and alpha 5 epitopes atthe intra-type level, 227 OspC sequences were aligned. These analysesrevealed that both the loop 5 and alpha 5 epitopes are highly variableat the inter-type level but remarkably highly conserved within a type.FIG. 4 provides (in tabular form) the loop 5 and alpha 5 domainsequences for each OspC type and indicates the frequency with which eachspecific sequence was detected in the OspC sequences analyzed. Asevidence for the conservation of loop 5 at the intra-type level,comparison of 57 type A loop 5 epitopes sequences revealed that 53 wereidentical with the outlying sequences differing at only one or tworesidues. A similar observation was noted for the alpha 5 epitopes. Of43 type A OspC sequences, 42 were identical between residues 168 and203. Note that fewer alpha 5 epitope sequences were analyzed since inmany cases the sequences available in the databases were partial andlacked varying amounts of the C-terminus.

Demonstration that the Antibody Response to the Loop 5 Epitope is notUnique to an Individual Mouse.

In view of the intra-type conservation of loop 5 and its relativelyshort length, the loop 5 epitope might be an excellent candidate for usein the development of a chimeric OspC loop 5 based vaccinogen. To verifythat the antibody response to the loop 5 epitope occurs commonly duringinfection and was not unique to an individual mouse, immunoblots of theloop 5 containing 130-150 fragment were screened with serum from severaladditional mice infected with the type A OspC producing strains, B31MI,LDP56 and 5A4. In all cases, antibody was detected that recognized thisepitope (FIG. 5). While the response to loop 5 was weaker in theinfection serum from the LDP56 infected mouse 2, longer exposure clearlyrevealed that loop 5 was antigenic in this animal. This demonstratesthat the immune response mounted to these epitopes is not unique to anindividual animal and provides further support for its possible use invaccine development.

Discussion.

OspC is clearly established as an important contributor to Lyme diseasepathogenesis (Grimm et al, 2004; Pal et al, 2004; Schwan et al, 1995).There is strong evidence that it plays an important role during thetransit of the Lyme disease spirochetes from the midgut to the salivarygland (Pal et al, 2004). In addition, it is selectively expressed duringearly infection, is an immunodominant antigen (Fingerle et al, 1995;Schwan et al, 1998; Wilske et al, 1993) and has been hypothesized byothers to be a key determinant in the dissemination capability of Lymedisease isolates (Seinost et al., 1999). The goals of this study were totest the potential correlation between OspC type and invasive infection,determine if the antibody response to OspC is type specific and furtherdefine the antigenic structure of OspC by localizing the linear epitopesthat are presented during infection.

Sequence analyses of OspC have delineated 21 distinct OspC types(Seinost et al., 1999) and it has been postulated that only four ofthese (types A, B, I and K) are associated with invasive infections inhumans (Seinost et al., 1999). However, a recent study has called intoquestion this putative correlation (Alghaferi et al., 2005). To addressthis further, the OspC type of invasive and non-invasive Lyme diseaseisolates recovered from human patients in Maryland was determined. Toaccomplish this the full length ospC gene was PCR amplified, sequencedand comparative sequence analyses were performed. These analysesrevealed that the OspC types associated with invasive human infectionsin this patient population also includes types C, D, and N. While type IOspC producing strains have been suggested to be a dominant typeassociated with invasive human infections (Seinost et al., 1999), noneof the invasive isolates identified in the Maryland patient populationcarried a type I ospC. Similarly, Alghaferi et al. also did not detecttype I OspC producing strains (Alghaferi et al., 2005). Collectively,these two studies have identified 18 invasive isolates in the greaterBaltimore area with the following breakdown: A, n=5; B, n=2; C, n=1; D,n=1; H, n=1; K, n=3 and N, n=7. Hence, in this geographic area itappears that OspC type A and N producing invasive isolates predominate.These data argue against the hypothesis that only 4 OspC types areassociated with invasive infections in humans. Additional analyses ofisolates recovered from larger patient populations from differentgeographic regions will be required to further assess the validity ofOspC type—invasive infection correlation and to determine if differencesexist in the prevalence of specific OspC types in defined geographicregions.

The variable protection offered by vaccination with OspC in conjunctionwith the delineation of distinct OspC types (Seinost et al., 1999),raises the possibility that the antibody response could be typespecific. This hypothesis is supported by the fact that vaccination withOspC has been found to provide protection only against the same strain(Bockenstadt et al., 1997; Gilmore et al, 1999a; Probert and LeFebvre,1994). Until this report, the type specificity of the antibody responseto OspC during infection had not been directly assessed. To addressthis, a series of full length recombinant OspC proteins of types A, B,C, D, H, K and N were screened with infection serum generated in micewith clonal populations expressing known OspC types. The use ofinfection serum is important as it allows for a focused assessment ofthe antibody response to epitopes that are specifically presented by thebacterium in vivo. These analyses revealed that in spite of strongsequence conservation within the N and C-terminal domains of OspC, theantibody response to the OspC types analyzed was type specific. Forexample, serum from mice infected with type A or D strains wasimmunoreactive in a type specific manner with little or nocross-immunoreactivity with other OspC types. Although the antibodyresponse to all 21 OspC types was not analyzed, the data presented abovesuggest that the conserved domains are not immunodominant and that thelinear epitopes of OspC presented by the bacterium during infection arecontained within the variable domains (i.e., type specific domains) ofthe protein.

Only a few studies have been published to date that have sought tolocalize or identify the epitopes of OspC. Both linear andconformational epitopes have been identified. Gilmore and Mbowdemonstrated that independent N terminal deletions beyond the leaderpeptide as short as 6 residues and C-terminal truncations of 13 residuesabolish the binding of the monoclonal antibody B5 (Gilmore et al, 1999a;Gilmore, 1998). From this it was concluded that the B5 monoclonalantibody recognizes a conformationally defined epitope (Gilmore et al,1999b). The precise residues that comprise the antibody recognition sitewithin this conformationally defined epitope were not identified. Incontrast to that observed with monoclonal antibody B5, this analysis ofthe polyclonal antibody response to cell associated, native OspCrevealed that deletion of the last 10 C-terminal residues of OspC or ofextended regions of the N-terminus did not abolish recognition of OspCby IgG elicited during infection. This difference in results ispresumably a reflection of the focus on polyclonal versus monclonalantibodies. This data, which certainly do not preclude the existence ofconformational epitopes, clearly demonstrate that there are linearepitopes in OspC as well. In an earlier study, Mathieson et al. alsoreported on a linear epitope in OspC (Mathieson et al, 1998). They foundthat the C-terminal 7 residues of OspC constitute a linear epitope thatis recognized by IgM in serum collected from European neuroborreliosispatients. While IgM binding was not assessed in this report, deletion ofthe C-terminal 10 residues of OspC did not abolish IgG binding. Epitopesthat are recognized by infection induced IgG appear to be localized atseveral sites in the protein. However, this does not suggest that aC-terminal epitope does not exist or is not recognized by antibodyelicited during infection but rather that there are additional epitopeslocated elsewhere in OspC.

Immunoblot analysis of shorter OspC fragments allowed for more preciselocalization of OspC epitopes. The antigenic regions of OspC werelocalized to two regions. One spans residues 136-150 and the other spansresidues 168 to 210. Structural models generated using coordinates fromX-ray diffraction analyses place residues 136-150 largely within asurface exposed loop, termed loop 5 (Kumaran et al., 2001). Loop 5 issurface exposed in both the mono- and dimeric models of OspC and islocated within a prominent bend. While it has been demonstrated thatrecombinant OspC does in fact form dimers, it has not yet beendetermined if native OspC forms dimer or larger oligomers in vivo. Thedimeric model for OspC indicates a significant buried interface thatcomprises greater than >30% of the protein. A buried interface of thisextent suggests a tight interaction between the monomers and isconsidered to be an indication that the dimeric form of the protein isthe biologically active form [Kumaran et al., 2001; Eicken et al., 2001;Zuckert et al., 2001]. In the OspC dimer, residues within loop 5 arepredicted to be a part of a putative conformationally defined ligandbinding pocket that may be of biological significance. This chargedpocket is lined by amino acids containing carbonyl groups such asglutamate and aspartate residues. Crystal structures have beendetermined for three OspC proteins of types A, I (Kumaran et al., 2001)and E (Eicken et al., 2001). In all of these proteins the solventstructures of this putative binding pocket are remarkably wellconserved. The accessibility of loop 5 to antibody in infection serumsupports the postulate that this domain may be surface exposed andpotentially available for ligand binding. In spite of strong inter-typestructural conservation of loop 5 and the putative ligand bindingpocket, the sequence of this domain is highly variable at the inter-typelevel. The sequence of the alpha 5 domain spanning residues 168 to 210is also variable at the inter-type level with the exception of the last20 residues which are highly conserved. To determine if sufficientconservation exists at the intra-type level to allow for theconstruction of a chimeric OspC vaccine consisting of a series of typespecific epitopes, OspC sequences were aligned and a dendogram wasconstructed. Through these analyses the OspC type was determined for 227sequences (data not shown). Both the loop 5 and alpha 5 epitopes werefound to be well conserved at the intra-type level. For example, theloop 5 epitope of type A OspC proteins were identical in 54 of 57sequences while the alpha 5 epitope was conserved in 42 of 43 type Asequences. Significant conservation of these domains in the other OspCtypes was noted as well with types C through I, M, N and O exhibitingabsolute intra-type conservation within the loop 5 and alpha 5 epitopes.

This study demonstrates that there is greater OspC diversity amonginvasive isolates than previously recognized. This study alsodemonstrates that the antibody response to OspC in mice is largely typespecific and is defined by previously uncharacterized loop 5 and alphaepitopes. Earlier studies and the data presented here clearlydemonstrate that a single OspC protein will not convey protectionagainst diverse strains (Bockenstedt et al., 1997). One possiblevaccination approach is to exploit the epitopes identified in thisreport in the development of a recombinant chimeric OspC vaccinogen. Theloop 5 epitope or a combination of loop 5 and alpha 5 epitopes may offerthe most promise if they also prove to be consistently antigenic inhumans. These epitopes are relatively short in length, linear, andhighly conserved at the intra-type level. In light of these features itshould prove technically feasible to construct a loop 5-alpha 5 chimericvaccinogen that can convey protection against highly diverse Lymedisease isolates.

Example 2 Analysis of Antibody Response in Humans to the Type A OspCLoop 5 Domain and Assessment of the Potential Utility of the Loop 5Epitope in Lyme Disease Vaccine Development

Outer surface protein C (OspC) of the Lyme disease spirochetes is a22-kDa immunodominant (Fuchs et al, 1992) antigen that is expressed upontick feeding and during early stages of infection (Schwan et al, 1995).Although a strong antibody response to OspC is mounted during naturalinfection, the response does not lead to bacterial clearance becauseOspC production is turned off shortly after the establishment ofinfection (Schwan et al, 1995). OspC has emerged as an importantvirulence factor and a potential candidate for Lyme disease vaccinedevelopment. However, efforts to develop an OspC-based vaccine have beenhampered by its heterogeneity among strains (Theisen et al, 1993; Wilskeet al, 1996; Wilske et al, 1993). Although vaccination with OspC elicitsa highly protective response, most studies have reported onlystrain-specific protection (Bockenstedt et al, 1997; Gilmore et al,1996; Mbow et al, 1999; Probert et al, 1997; Rousselle et al, 1998;Scheiblhofer et al., 2003). Recent analyses have provided significantinsight into our understanding of the antigenic structure of OspC andthe basis of strain-specific protection. Twenty-one OspC types,designated A through U, have been defined (Lagal et al, 2003; Seinost etal, 1999; Wang et al, 1999). By infecting mice with clonal populationsof Borrelia burgdorferi that produce specific OspC types, is has beendemonstrated that the antibody response during early infection islargely OspC type specific (see Example 1). This suggests that thedominant epitopes presented during early infection are likely to residewithin the type-specific domains of OspC. While earlier studiessuggested that only 4 of the 21 OspC types are associated with invasiveinfection (Seinost et al, 1999), recent studies have demonstrated thatisolates producing additional OspC types can also establish invasiveinfection (Alghaferi et al, 2005; Example 1). However, type A OspCappears to predominate in strains that cause invasive infections inhumans. Epitope-mapping analyses of type A OspC revealed that one of thedominant linear epitopes that elicits a response in mice resides withinthe loop 5 domain (see Example 1). The loop 5 domain is highly variableat the intertype level but conserved within sequences of a given type(see Example 1). In the present study, we refine the location of theepitope, demonstrate its surface exposure on intact bacteria, anddemonstrate that it elicits bactericidal antibody.

Most studies that have sought to define the immunodominant epitopes ofOspC have been conducted with mice (Bockenstedt et al, 1997; Gilmore etal, 1996; Mbow et al, 1999; Probert et al, 1994). However, it has beendemonstrated that the antibody responses to some epitopes differ forhumans versus mice and other mammals (Lovrich et al, 2005). The firstobjective of the present study was to determine whether the loop 5domain of OspC is recognized by antibody elicited during infection inhumans. Ideally, these analyses would be conducted with serum collectedfrom individuals infected with a clonal population of a type A-producingstrain. Since one cannot determine with absolute certainty whether anindividual is infected with a heterogenous or a homogenous population,we sought to identify patient sera that exhibit a response to typeA-specific sequences. To accomplish this, a panel of serum samplescollected from patients with erythema migrans (early-stage Lyme disease)were screened by enzyme-linked immunosorbent assay (ELISA). Recombinanttype (r-type) A OspC and an r-type A OspC subfragment containing loop 5residues 130 to 150 were used to coat 96-well plates (250 ng ofr-protein/well; 0.1 M Na₂HPO₄; 4° C. overnight). The plates were blocked(10% nonfat dry milk in phosphate-buffered saline, 0.5% Tween 20; 37° C.for 2 h) and washed, and human Lyme disease patient serum (diluted1:400) was added to each well (37° C.; 1 h). Horseradishperoxidase-conjugated goat anti-human immunoglobulin G (IgG; Sigma) (50μl of a 1:40,000 dilution) was added (1 h; 37° C.), followed by TMBsubstrate (3,3,5,5-tetramethylbenzidine) as instructed by the supplier(Sigma). The optical density values at 450 nm were determined by using aplate reader. Additional wells were coated with bovine serum albumin toserve as negative controls. All assays were performed in triplicate. Themean A450 value is presented with standard deviations. As shown in FIG.6, several serum samples were found to have a strong IgG response toboth the full-length type A OspC and the loop 5 fragment. Serum samples8 and 44 displayed the strongest immunoreactivity with the loop 5fragment and hence were selected for further analysis.

To more accurately define the residues within the loop 5 domain that arerecognized by infection-induced antibody, PepSpot arrays were screenedwith the sera from patients 8 and 44 and with serum from mice infectedwith a clonal population of the type A OspC-producing strain B31MI (seeExample 1). The PepSpot arrays consisted of 12- to 13-residueoverlapping peptides (two-amino-acid step) spanning the loop 5 domain oftype A OspC spotted onto Whatman 50 cellulose membrane (150 nmol/cm²;JPT Peptide Technologies GmbH, Berlin, Germany). The PepSpot membraneswere blocked (5% nonfat dry milk in Tris-buffered saline-0.5% Tween 20),washed, and screened with mouse and human serum samples (diluted 1:1,000and 1:400 in blocking solution, respectively), and antibody binding wasdetected with species-specific anti-IgG antiserum. Although the specificresidues that make up the immunoreactive domain differed slightly inmice and humans, the major epitopes localized within residues 130 to 146(FIG. 7). In type A OspC sequences, this region encompasses theC-terminal region of alpha helix 3 and the N-terminal portion of loop 5.

The crystal structures of OspC spatially place loop 5 on a prominentbend of the protein (Eicken et al, 2005; Kumaran et al, 2001; FIG. 24).This loop has been postulated to be part of a potential ligand-bindingpocket (Kumaran et al, 2001). To determine whether loop 5 is displayedat the cell surface and is accessible to antibody in in vitro grownspirochetes, immunofluorescence assays (IFAs) were performed by usinganti-loop 5 antiserum. Immunoblot analyses with whole-cell lysates of B.burgdorferi B31 MI (type A OspC), B. parkeri, and S-tagged r-type A loop5 demonstrated that the loop 5 antiserum is specific, establishing thesuitability of this antiserum for IFAs. The strains analyzed by IFAconsisted of B. burgdorferi B31MI (type A OspC) and LDP74 (type K OspC).The spirochetes were grown at 33° C. and transferred to 37° C. for 3days to stimulate OspC expression. IFAs were conducted withpermeabilized cells (acetone fixed), nonpermeabilized cells (air dried),and standard methods as previously described (Roberts et al, 2002). Theslides were screened with a 1:1,000 dilution of mouse-loop 5 antiserum,mouse preimmune serum, or rabbit-flagellin antiserum. Detection wasachieved by using Alexa Fluor 568-conjugated goat α-mouse IgG or AlexaFluor 488-conjugated goat α-rabbit IgG (10 μml⁻¹ in blocking buffer).Slides were visualized on an Olympus BX51 fluorescence scope using arhodamine or fluorescein filter set, as appropriate, or by dark-fieldmicroscopy, and photographed by using an Olympus MagnaFIRE camera. Thelabeling observed by IFA was highly specific and consistent with theimmunoblot analyses; the type A-producing isolate was surface labeled,while the B. burgdorferi LDP74 type K OspC was not (data not shown). Inaddition, consistent with the upregulation of OspC at elevatedtemperature, IFAs revealed markedly greater surface labeling ofspirochetes grown at 37° C. than cells grown at 33° C. The α-FlaBantiserum, which recognizes an inner-membrane anchored, periplasmicprotein, did not label nonpermeabilized cells but readily labeled cellspermeabilized with acetone (data not shown). This control demonstratesthat the loop 5 epitope is in fact surface exposed and that theexperimental conditions used in the IFA did not disrupt cell integrityand thereby artificially expose epitopes that are not naturallypresented on the surface of the bacteria.

The ability of the loop 5 antiserum to efficiently bind to OspC at thecell surface raised the possibility that the interaction could bebactericidal, as has been demonstrated for antibody to full-length OspC(Bockenstedt et al, 1997; Ikushima et al, 2000; Jobe et al, 2003;Lovrich et al, 2005; Rousselle et al, 1998). To determine whetherantibody targeting loop 5 also exhibits bactericidal activity, killingassays were conducted with B. burgdorferi isolates B31MI and LDP74cultivated at 33° C. or temperature shifted to 37° C. The spirocheteswere harvested by centrifugation, washed, and adjusted to 5×10⁵ cellsper 500 l (in BSK-H medium), and 12.5 μl was transferred into a sterile0.65-ml microcentrifuge tube. Then, 10 μl of heat-inactivated (56° C.;30 min) loop 5 serum was added with or without guinea pig complement(7.5 μl; Sigma Chemical, St. Louis, Mo.), the components were mixed andincubated at 33 or 37° C. for 8 h. A total of 70 μl of H₂O was added,and spirochetes were stained with the Live/Dead BacLight stain(Molecular Probes, Eugene, Oreg.) according to the manufacturer'sinstructions. In brief, two stains are added to the cells; SYTO 9 andpropidium iodide. These dyes can distinguish live bacteria (i.e., withintact membranes) from bacteria with compromised membranes. Livebacteria fluoresce green due to staining with SYTO 9, whereas dead ordamaged bacteria fluoresce red due to staining with propidium iodide.The baseline level of cells with disrupted membranes observed upontreatment with preimmune heat inactivated serum (with or withoutcomplement) was 25%. In contrast, ˜70% of the cells exposed to theα-loop 5 antiserum displayed membrane disruption. The bactericidalactivity was determined to be complement dependent. The blebbing effectseen here upon treatment with anti-loop 5 antibody is consistent withthat reported with other anti-OspC antibodies (Bockenstedt et al, 1997;Escudero et al, 1997). It is also important to note that, consistentwith the upregulation of OspC at elevated temperature, the percentage ofdead cells was consistently higher in spirochetes grown at 37° C. thanthat in bacteria grown at 33° C. (data not shown). It is clear from thedata presented that anti-loop 5 antibody is bactericidal.

Several reports have outlined the clear and strong justification for thedevelopment of Lyme disease vaccines (reviewed in Hanson and Edelman,2004). However, at the present time, no vaccine is commerciallyavailable. In an effort to develop a broadly protective Lyme diseasevaccine, Baxter pursued a strategy of generating a vaccine cocktail of14 different full-length r-OspC proteins (Hanson and Edelman, 2004).However, the cocktail was deemed unacceptably reactigenic. Thereactigenicity may have resulted from the large amount of protein thatwas required to elicit a sufficient response to the unique protectiveepitopes of each OspC type protein in the cocktail. A potential problemwith cocktail vaccines that use multiple full-length proteins is thepotential for misdirection of the antibody response to conserved,irrelevant, nonprotective epitopes. It may be possible to overcome thisproblem through the development of a chimeric, r-vaccinogen composed ofthe naturally presented immunodominant linear epitopes of each of thedominant OspC types. This general concept has its origins in efforts todevelop malarial vaccines using epitopes from proteins expressed atdifferent stages of infection (Hanson and Edelman, 2004). The sameconcept has been applied in the development of a hexavalent M proteinvaccine for group A streptococci (Dale, 1999) and in the development ofvaccines against several other pathogens with excellent success (Apta etal, 2006; Caro-Aguilar et al, 2005; Fan et al, 2005; Horvath et al,2005; Kotloff et al, 2005; McNeil et al, 2005; Wang et al, 2005). Withnew insights into the physical and antigenic structure of OspC, it maynow be possible to develop an effective, r-polyvalent, chimeric, OspCvaccine. The newly identified loop 5 domain is ideally suited forinclusion in such a vaccine.

Example 3 Development of an OspC-Based Tetravalent, Recombinant,Chimeric Vacinogen

Lyme disease is the most common arthropod-borne disease in North Americaand Europe. At present, there is no commercially available vaccine foruse in humans. Outer surface protein C (OspC) has antigenic andexpression characteristics that make it an attractive vaccine candidate;however, sequence heterogeneity has impeded its use as a vaccinogen.Sequence analyses have identified 21 well defined OspC phyletic groupsor “types” (designated A through U). This study reports mapping of thelinear epitopes presented by OspC types B, K and D during human andmurine infection and exploitation of these epitopes (along with thepreviously identified type A OspC linear epitopes) in the development ofa recombinant, tetravalent, chimeric vaccinogen. The construct was foundto be highly immunogenic in mice and the induced antibodies surfacelabeled in vitro cultivated spirochetes. Importantly, vaccinationinduced complement-dependent bactericidal antibodies against strainsexpressing each of the OspC types that were incorporated into theconstruct. These results suggest that an effective and broadlyprotective polyvalent OspC-based Lyme disease vaccine can be produced asa recombinant, chimeric protein.

Materials and Methods Borrelia Burgdorferi Isolates and Cultivation.

Clonal populations of Borrelia burgdorferi isolates B31MI (type A OspC),LDP73 (type B), LDP116 (type D) and LDP74 (type K) [see Example 1] wereobtained by subsurface plating as previously described [Sung et al,2000]. The OspC type of individual clones was determined by PCRamplification (Taq Polymerase, Promega) and DNA sequencing of ospC, withassignment to type by phylogenetic analysis [see Example 1]. Spirocheteswere cultivated at 33 or 37° C., as indicated, in complete BSK-H medium(Sigma).

Ligase Independent Cloning and Production of Recombinant (r) OspCProteins.

Full length type B, K and D OspC and a series of truncations andfragments were generated by PCR amplification of the corresponding genefrom each isolate. The primers were designed with 5′ overhangs to allowligase-independent cloning (LIC) in the pET-32 Ek/LIC vector (Table 3)[Example 1]. All LIC methods were performed essentially as directed bythe manufacturer (Novagen). In brief, after amplification andregeneration of single stranded tails, the amplicons were annealed withthe pET-32 Ek/LIC vector, which was transformed into and propagated inNovaBlue (DE3) E. coli cells. The plasmids were recovered and the insertsequences confirmed by DNA sequencing. For protein purification,purified plasmid was used to transform E. coli BL21 (DE3) cells andprotein expression was induced by addition of IPTG (1 mM) to thecultures during the logarithmic growth phase followed by a three hourincubation. The N-terminal fusion added by expression from the pET-32Ek/LIC vector contains a Trx-tag, S-tag, and a hexahistidine (His-tag)motif. The His-tag was exploited to allow purification of the r-proteinsby nickel affinity chromatography. Briefly, cells were lysed and nucleicacid and cell wall peptidoglycan were degraded by benzonase nuclease andr-lysozyme, respectively. The soluble proteins were clarified bycentrifugation (16000×g for 15 min), passed over an immobilized nickelcolumn, washed, and eluted as per the manufacturer's protocol (Novagen).The eluted proteins were dialyzed extensively against phosphate bufferedsaline (PBS; pH 7.4) across a 10 kDa molecular weight cut-off membrane(Slid-a-lyzer, Pierce), the final protein concentration was quantifiedby the BCA assay (Pierce), and the purity of the preparation assessed bySDS-PAGE.

TABLE 3 PCR primers used in the generation of various OspC type fragments.Primer Sequence Description SEQ ID NO: ospC20(+)LIC GACGACGACAAGATTAATAmplifies OspC 180 AATTCAGGGAAAGATGGG from aa 20 and adds LIC tailospC210(+)LIC GACGACAAGCCCGGTTT Amplifies OspC up 181AAGGTTTTTTTGGACTTTC to aa 210 and adds TGC LIC tail OCB110LIC(−)GAGGAGAAGCCCGGTTT Amplifies type B 182 ATTGTGTTATTAAGGTTGAup to aa 110 and TATTG adds LIC tail OCB131LIC(+) GACGACGACAAGATCTTCAmplifies type B 183 TGAAGAGTTTAGTACTAAA from aa 131 and CTAAAAadds LIC tail OCB140LIC(−) GAGGAGAAGCCCGGTTT Amplifies type B 184ATTTTAGTTTAGTACTAAA up to aa 140 and CTCTTCAG adds LIC tail OCB140LIC(+)GACGACGACAAGATAGAT Amplifies type B 185 AATCATGCACAGCTTGGTAfrom aa 140 and TACAG adds LIC tail OCB148LIC(+) GACGACGACAAGATTATAAmplifies type B 186 CAGGGCGTTACTGATGAA from aa 148 and AATGCadds LIC tail OCB153LIC(+) GACGACGACAAGATTGA Amplifies type B 187AAATGCAAAAAAAGCTAT from aa 153 and TTTAAAA adds LIC tail OCB155LIC(−)GAGGAGAAGCCCGGTTT Amplifies type B 188 ATGCATTTTCATCAGTAACup to aa 155 and GCCCTG adds LIC tail OCB164LIC(+) GACGACGACAAGATTGCAAmplifies type B 189 GCGGGTAAAGATAAGGGC from aa 164 and GTTGAAGadds LIC tail OCB169LIC(−) GAGGAGAAGCCCGGTTT Amplifies type B 190ACTTATCTTTACCCGCTGC up to aa 169 and adds LIC tail OCB175LIC(+)GACGACGACAAGATTGA Amplifies type B 191 AAAGTTGTCCGGATCATTAfrom aa 175 and GAAAGC adds LIC tail OCB180LIC(−) GAGGAGAAGCCCGGTTTAmplifies type B 192 ATGATCCGGACAACTTTTC up to aa 180 and AAGTTCTTCadds LIC tail OCB181LIC(+) GACGACGACAAGATCTTA Amplifies type B 193GAAAGCTTATCGAAAGCA from aa 181 and GCTAAAGAG adds LIC tail OCB185LIC(−)GAGGAGAAGCCCGGTTT Amplifies type B 194 ATGATTAAGCTTTCTAATGup to aa 185 and ATCCGGAC adds LIC tail OCB190LIC(−) GAGGAGAAGCCCGGTTTAmplifies type B 195 ACTCTTTAGCTGCTTTTGA up to aa 190 and TAAGCTTCadds LIC tail OCB200LIC(−) GAGGAGAAGCCCGGTTT Amplifies type B 196ATGTAAGCTCTTTAACTGA and K up to aa 200 ATTAGCAAG and adds LIC tailOCB49LIC(−) GAGGAGAAGCCCGGTTT Amplifies type B 197 AAATTTTTTTACTTATTTCTand D up to aa 49 GTAAG and adds LIC tail OCB80LIC(−) GAGGAGAAGCCCGGTTTAmplifies type B 198 ATTTTTTACCAATAGCTTT up to aa 80 and AGCAAGCTCadds LIC tail OCD112LIC(−) GAGGAGAAGCCCGGTTT Amplifies type D 199ATAATTTTTCTGTTATTAG up to aa 112 and AGCTG adds LIC tail OCD130LIC(+)GACGACGACAAGATTAA Amplifies type D 200 ATGTTCTGAAAGCTTTACfrom aa 130 and adds LIC tail OCD135LIC(−) GAGGAGAAGCCCGGTTTAmplifies type D 201 AAAAGCTTTCAGAAACATT up to aa 135 and TCTTAGCadds LIC tail OCD135LIC(+) GACGACGACAAGATTACT Amplifies type D 202AAAAAACTATCAGATAAT from aa 135 and CAAGCAG adds LIC tail OCD144LIC(+)GACGACGACAAGATTGA Amplifies type D 203 GCTTGGTATAGAGAATGCTfrom aa 144 and ACTGATG adds LIC tail OCD151LIC(+) GACGACGACAAGATTGCTAmplifies type D 204 ACTGATGATAATGCAAAA from aa 151 and AAGGCadds LIC tail OCD155LIC(−) GAGGAGAAGCCCGGTTT Amplifies type D 205AATTATCATCAGTAGCATT up to aa 155 and CTCTATACC adds LIC tailOCD166LIC(−) GAGGAGAAGCCCGGTTT Amplifies type D 206 AAGCATTATGTGTTTTTAAup to aa 166 and AATAGCC adds LIC tail OCD167LIC(+) GACGACGACAAGATTAAAmplifies type D 207 AGACAAGGGTGCTGAAGA from aa 167 and ACTTGadds LIC tail OCD180LIC(−) GAGGAGAAGCCCGGTTT Amplifies type D 208ATGATTCAGATAACTTTAC up to aa 180 and AAGTTC adds LIC tail OCD180LIC(−)GACGACGACAAGATTTCA Amplifies type D 209 GTAGCAGGCTTATTAAAAGfrom aa 180 and CAGCTC adds LIC tail OCD195LIC(−) GAGGAGAAGCCCGGTTTAmplifies type D 210 ATGAATTAGCCAGTATGGC up to aa 195 and TTGAGCTGCadds LIC tail OCD195LIC(+) GACGACGACAAGATTTCA Amplifies type D 211GTTAAAGAGCTTACAAGTC from aa 195 and CTG adds LIC tail OCD80LIC(−)GAGGAGAAGCCCGGTTT Amplifies type D 212 AATCTATTTTTTTACCAATup to aa 80 and A adds LIC tail OCK110LIC(−) GAGGAGAAGCCCGGTTTAmplifies type K 213 ATTGTGTTATTAGTTTTGA up to aa 110 and TATTGadds LIC tail OCK130LICH GATGACGACGACAAGAT Amplifies type K 214TAAATGTTCTGAAGATTTT from aa 130 and AC adds LIC tail OCK135LIC(−)GAGGAGAAGCCCGGTTT Amplifies type K 215 AAAAATCTTCAGAACATTTup to aa 135 and CTTAGC adds LIC tail OCK148LIC(+) GATGACGACGACAAGATAmplifies type K 216 AATTGAAAATGTTACTGAT from aa 148 and GAGAATGCadds LIC tail OCK150LIC(−) GAGGAGAAGCCCGGTTT Amplifies type K 217AATTTTCAATTCCAAGTTG up to aa 150 and CGCATGTTC adds LIC tailOCK160LIC(−) GATGACGACGACAAGAT Amplifies type K 218 TATTTTAATAACAGATGCAfrom aa 160 and GCTAAAG adds LIC tail OCK166LIC(−) GAGGAGAAGCCCGGTTTAmplifies type K 219 AAGCTGCATCTGTTATTAA up to aa 166 and AATAGCadds LIC tail OCK175LIC(−) GAGGAGAAGCCCGGTTT Amplifies type K 220ATTCAAGCTCTGCAGCGCC up to aa 175 and CTTATC adds LIC tail OCK180LIC(−)GAGGAGAAGCCCGGTTT Amplifies type K 221 ATGCTTTAAATAGCTTTTCup to aa 180 and AAGCTCTGC adds LIC tail OCK180LIC(+) GATGACGACGACAAGATAmplifies type K 222 TGCAGTAGAAACTTGGCA from aa 180 and AAAGCAGCadds LIC tail OCK190LIC(−) GAGGAGAAGCCCGGTTT Amplifies type K 223ACTCTTTAGCTGCMTGC up to aa 190 and CTTGTTTTC adds LIC tail OCK191LIC(−)GAGGAGAAGCCCGGTTT Amplifies type K 224 ACATCTCTTTAGCTGCTTTup to aa 191 and TGCCAAG adds LIC tail OCK80LIC(−) GAGGAGAAGCCCGGTTTAmplifies type K 225 ATTTTTTACCAATAGCTTT up to aa 80 and AGTAGCadds LIC tail LIC tails are in bold.

Immunoblot Analyses: Epitope Mapping of OspC Types B, D, and K

To allow for the mapping of epitopes relevant during infection, C3H/HeJmice were infected with 104 spirochetes of clonal populations expressingOspC types B, K, or D and blood was collected at weeks 2, 4, 6, 8 and 12by tail bleed. These sera were used to screen purified OspC proteins andtruncations as described in Example 1. The r-proteins were subjected toSDS-PAGE, transferred to PVDF, and screened with a 1:1000 dilution ofthe type-specific murine infection sera (collected at wk 6). Similarly,the r-proteins were screened with serum (1:400) from patients known tohave been infected with a B. burgdorferi strain expressing OspC types B,K, or D (kindly provided by Dr. Allen Steere). The appropriateIgG-specific, horseradish peroxidase (HRP)-conjugated secondaryantibodies were utilized, and the results were visualized bychemiluminescence.

Construction and Expression of a Tetravalent Chimeric Vaccinogen.

The loop 5 region (aa 131 to 149) of type A and the alpha helix 5 regionof types B (aa 160-201), K (aa 161-201), and D (aa 161-201) were chosenfor inclusion in the tetravalent test vaccinogen. Eachepitope-containing region was PCR amplified from the r-plasmidsdescribed above and primers listed in Table 4. PCR conditions werestandard with an initial 2 min 94° C. denaturation step, followed by 35cycles of denaturation at 94° C. for 15 sec, primer annealing at 50° C.for 30 sec, and extension at 72° C. for 60 sec, with a final 72° C.extension for 7 min. The primers were designed with vector-specific LICtails or with unstructured, protease-resistant linker sequences as 5′overhangs (FIG. 9A) [Crasto and Feng, 2000]. All amplicons were analyzedby electrophoresis in agarose gels using TAE buffer and were gelpurified (QiaQuick Gel Extraction, Qiagen). The purified products werethen used as templates in subsequent rounds of PCR. In the second round,the amplicons of type A loop 5 and type B alpha helix 5 were combined astemplates. After denaturation, the amplicons annealed via theircomplementary linker sequences allowing for overlap extension andsubsequent amplification using the forward type A loop 5 and reversetype B alpha helix 5 primers. The types K and D alpha helix 5 sequenceswere added to the construct in a similar manner, except that theannealing temperature was increased to 60° C. after the first 10 cyclesto increase the annealing specificity. The final product was annealed tothe pET-46 Ek/LIC expression vector, which encodes an N-terminalhexahistidine tag fusion (Novagen), and NovaBlue (DE3) E. coli cellswere transformed. The vaccinogen sequence was confirmed by DNAsequencing of purified plasmid. Protein expression and purification werecompleted as described above.

TABLE 4 PCR primers used in the generation of the ABKD chimeric vaccinogen. Primer Sequence Description SEQ ID NO: OCAL5LIC(+) GACGACGACAAGATTTCTGAmplifies type A 226 AAACATTTACTAATAAATTA from aa 131 and AAAGAAAAACadds LIC tail OCAL5L1(−) TAACATACCCATGCTACCTT Amplifies type A up 227CTTTACCAAGATCTGTGTG to aa 149 and adds linker 1 (GSMGML; SEQ ID 76)OCBH5L1(+) GGTAGCATGGGTATGTTAAA Amplifies type B 228 AGCAAATGCAGCGGGfrom aa 160 and adds linker 1 (GSMGML; SEQ ID 76) OCBH5L2(−)TAAGTTACCGTTTGTGCTTG Amplifies type B up 229 TAAGCTCTTTAACTGAATTAto aa 201 and adds G linker 2 (STNGNL; SEQ ID 77) OCKH5L2(+)AGCACAAACGGTAACTTAAT Amplifies type K 230 AACAGATGCAGCTAAAGATfrom aa 161 and AAGG adds linker 2 (STNGNL; SEQ ID 77) OCKH5L3(−)TAAAACGCTCATGCTACTTG Amplifies type K up 231 TAAGCTCTTTAACTGAATTAto aa 201 and adds GC linker 3 (SSMSVL; SEQ ID 78) OCDH5L3(+)AGTAGCATGAGCGTTTTAAA Amplifies type D 232 AACACATAATGCTAAAGACfrom aa 161 and AAG adds linker 3 (SSMSVL; SEQ ID 78) OCDH5LIC(−)GAGGAGAAGCCCGGTTTAA Amplifies type D up 233 CTTGTAAGCTCTTTAACTGAto aa 201 and adds ATTAG an LIC tail LIC tails are in bold, and linkersequences are underlined.Immunization of Mice with the Tetravalent ABKD Chimeric Vaccinogen.

Twelve six-week-old, male, C3H/HeJ strain mice were immunized with 50 μgof the chimeric vaccinogen emulsified in a 1:1 ratio with completeFreund's adjuvant (CFA). The vaccinogen was administered in a totalvolume of 200 μL, in divided intraperitoneal and subcutaneous depots.Three control mice were administered sham vaccinations of PBS in CFA. Atweeks 2 and 4, mice were boosted with 50 μg protein in Freund'sincomplete adjuvant. Sham immunized mice received PBS in adjuvant. Allmice were bled by tail nick prior to the first injection, and at week 6.

Assessment of the Immunogenicity of the ABKD Chimeric Vaccinogen.

The immunogenicity of the vaccinogen was assessed by immunoblot analysesand ELISA. Immunoblots were generated and screened as described above.One μg of each purified r-protein (OspC types A, B, K, D, and thechimeric vaccinogen) was analyzed by immunoblot. r-BBN39, an unrelated,His-tagged protein, derived from B. burgdorferi (paralogous proteinfamily 163) served as the negative control. To verify equal proteinloading, one blot was screened with anti-His tag monoclonal Ab (mAb)(1:2000; Novagen). To assess the response to vaccination, identicalblots were screened with a 1:500 dilution of the mouse anti-ABKDantiserum. HRP-conjugated goat-anti-mouse IgG (1:40000 dilution) servedas the secondary antibody and binding was visualized bychemiluminescence. ELISA analyses were conducted using 96 well plates(Costar 3590; Corning) coated with 100 ng per well of the vaccineconstruct or r-OspC (types A, B, K, or D) in carbonate buffer (pH 9.6;16 hr at 4° C.). The plates were blocked (1% BSA in PBS with 0.2%Tween-20 (PBS-T); 2 hr), washed 3 times with PBS-T, and serially dilutedanti-ABKD antiserum (100 μL; 1:50 to 1:109350) was added to the wells ofduplicate plates (1 hr). HRP-conjugated goat-anti-mouse IgG (1:20000)served as the secondary antibody and ABTS as the chromogenic substrate.The absorbance was read at 405 nm in an ELISA plate reader (ELx 808;Biotek) while the reaction rate was linear. Titers were calculated byfitting a sigmoidal curve by a four parameter logistic equation(SigmaPlot) to the absorbance curve and calculating the inverse dilutioncorresponding to 50% of the maximum absorbance plateau.

Immunoglobulin Isotype Profiling of the Anti-ABKD Antibody Response.

The isotype profile of the anti-ABKD antibody response was assessed bycoating duplicate ELISA plates with 100 ng per well of the chimericconstruct. The plates were washed and blocked as described above.Anti-ABKD antisera collected from the 12 vaccinated mice were analyzedin duplicate (100 μL; 1:10000; 1 hr). Bound vaccinogen-specific Ig wasdetected by incubation with isotype specific, biotinylated secondaryantibodies (1 hr; Mouse isotyping kit; Zymed). Bound biotinylatedantibody was detected by HRP-conjugated streptavidin (30 min) and thechromogenic substrate, ABTS. All incubations were completed at roomtemperature.

Indirect Immunofluorescence Assays (IFA).

To determine if epitopes included in the ABKD chimeric vaccinogen arepresented on the surface of in vitro cultivated B. burgdorferi, IFAanalyses were conducted. To maximize OspC production, cultures of clonalpopulations producing type A, B, K, or D OspC were temperature shiftedfrom 33 to 37° C. The spirochetes from 5 mL of dense culture (˜10⁷-10⁸cells mL⁻¹) were collected by centrifugation (7000×g for 15 min), washed3 times with PBS, resuspended in 5 mL of PBS, and 100 μL spread over a 2cm² area on charged slides (Superfrost Plus, Fisher Scientific). One setof slides was air dried and a second was acetone fixed. The slides wereblocked (1 hr; 3% BSA in PBS-T) and then screened with a 1:100 dilutionof anti-ABKD antiserum, pre-immune serum, or a 1:1000 dilution ofrabbit-anti-flagellin antiserum (1 hr). Bound antibody was detected byAlexafluor 568-conjugated goat-anti-mouse IgG or Alexafluor488-conjugated goat-anti-rabbit IgG (10 μg mL⁻¹ blocking buffer). Slideswere washed three times in PBS-T between each step, and all incubationswere for one hour at room temperature in a darkened, humidified chamber.Slides were mounted with Fluoromount-G (Electron Microscopy Sciences),visualized on an Olympus BX51 fluorescence scope using a rhodamine orfluorescein filter set, as appropriate, or by darkfield microscopy, andphotographed using an Olympus MagnaFire digital camera.

Assessment of Bactericidal Activity.

The ability of the anti-ABKD antisera to kill B. burgdorferi wasassessed in vitro. Spirochetes that had been temperature shifted from 33to 37° C., as described above, were washed 3 times with BSK-H medium andthe cell density adjusted to ˜10⁶ cells mL⁻¹. Eight μL of cells werecombined with 8 μL of guinea pig complement (Sigma) and 4 μL of eachtest serum (heat inactivated at 56° C.; 30 min). Controls included heatinactivated anti-ABKD antisera without complement, complement only, andpooled heat-inactivated preimmune sera with complement. The totalreaction volume was brought to 20 μL by the addition of BSK-H medium, asneeded, and the samples were incubated at 37° C. for 18 hr. Killing wasassessed using the BacLight LIVE/DEAD assay (Molecular Probes) andmanual counts of live and dead/damaged cells in five high power fieldsusing an Olympus BX51 fluorescence microscope with fluorescein andrhodamine filter sets.

Results

Identification of the Epitopes of OspC Types B, D, and K that arePresented During Infection in Mice and Humans.

To date, OspC types A, B, C, D, H, I, K and N have been recovered frompatients determined to have invasive infections [Seinost et al, 1999;Example 1; Alghaferi et al, 2005]. Four of these OspC types (A, B, K,and D) were selected to establish proof of principle of the utility of apolyvalent chimeric OspC vaccine. Since the epitopes presented duringinfection had only been identified for type A OspC, the first step inthis study was to identify the infection-relevant epitopes of OspC typesB, K and D. To accomplish this, immunoblots of truncations and fragmentsof each type were screened with sera from mice infected with clonalpopulations of B. burgdorferi (OspC types B, K or D) or with sera fromhuman Lyme disease patients determined to have been infected, at leastin part, with B. burgdorferi strains producing OspC of types B, K, or D(personal communication, Dr. Allen Steere and Kathryn Jones). Theantibody response in mice at week 6 was type-specific; however, some ofthe human sera displayed cross-immunoreactivity between types (data notshown) suggesting that these patients were possibly infected with mixedspirochete populations. For OspC type B, the epitopes localized in alphahelix 5 (between aa 175 and 200) for mouse infection sera. Humaninfection sera reacted with a similarly located fragment (aa 164-185),indicating that the alpha helix 5 region of type B is antigenic. In typeK OspC, epitopes were mapped between aa 148 and 160 in the mouse, and tothe alpha helix 5 region (between aa 160 and 175) in the human. OspCtype D epitopes were mapped to the alpha helix 5 region (between aa 167and 180) in the mouse and in the human, though there were multipleadditional epitopes recognized by the human serum. These data indicatethat the alpha helix 5 region of OspC types B, K, and D are appropriateselections for inclusion in the tetravalent ABKD vaccinogen construct.

Construction, Expression and Purification of a Tetravalent Chimeric OspCVaccinogen.

Using the alpha helix 5 epitopes defined above for types B, K and D andthe type A loop 5 epitope defined in an earlier study [Example 1] apolyvalent, chimeric r-vaccinogen was produced that is composed of thefour epitope-containing regions. The epitopes were joined by short,unstructured, protease-resistant linker sequences (FIG. 9B). Therecombinant vaccinogen is 169 aa in length with a molecular mass of 18.0kDa and an isoelectric point of 6.49. Its structure is predicted to bepredominantly helical [Gasteiger et al, 2005; Kneller et al, 1990] andto have a high stability index [Guruprasad et al, 1990]. Followingdialysis with PBS, there was some precipitation of recombinantvaccinogen; however, approximately 500 μg mL⁻¹ remained soluble, andthis soluble protein was used for all experiments. Analysis of thepurified vaccinogen protein by SDS-PAGE demonstrated a single band of 18kDa molecular mass and no contaminating proteins.

Immunogenicity of the ABKD Chimeric Vaccinogen in Mice.

To assess the antibody response to the ABKD chimeric vaccinogen and itsindividual component epitopes, C3H/HeJ mice were administered thevaccinogen in Freund's adjuvants. Serum was collected from thevaccinated (n=12) and sham (PBS+adjuvant) immunized mice (n=3) andassessed for reactivity with the ABKD chimeric vaccinogen and fulllength r-OspC proteins of types A, B, K, and D. Western blot analysisdemonstrated that the anti-ABKD antisera reacted strongly with thevaccinogen protein and with r-OspC of types A, B, and K. In contrast,reactivity with the C-terminal OspC type D epitope of the chimericconstruct was considerably weaker (FIG. 10). There was no reactivity ofany of the sera with the negative control protein (r-BBN39) and serafrom sham-vaccinated mice did not react with any of the proteins.Quantitative ELISA-based titration of serum reactivity demonstrated ahigh-titered IgG response against the ABKD chimeric vaccinogen protein,with a mean titer of 27,800 (FIG. 11A). Titration of reactivity againsttype-specific epitopes was accomplished by assessing binding withimmobilized full length r-OspC proteins. Significant differences in theantibody titer to the individual epitopes were observed (FIG. 11B). Itis notable that the epitope-specific titer decreases with its proximityto the C-terminus of the vaccinogen.

Immunoglobulin Isotype Profile of the Anti-ABKD Antisera.

The immunoglobulin isotype profile is critical for the assessment ofpotential effector functions of vaccine-specific antibodies. To assessimmunoglobulin heavy chain class switching induced by the ABKD chimericvaccinogen, the isotype profile was determined by ELISA. The predominantisotype was IgG1, with marginally lower levels of IgG2a and IgG2b. Thesix-week sera showed only limited levels of IgM, IgG3, or IgA (FIG. 12).

Indirect Immunofluorescence Assays.

The ability of antibody elicited to each epitope of the ABKD chimericvaccinogen to bind OspC on the Borrelia cell surface was assessed byindirect immunofluorescent microscopy. Specific surface labeling wasobserved with cells producing OspC of types A, B, K, and D (data notshown). The intensity of the fluorescent signal was consistent with thetype-specific titer, with the most intense fluorescence seen with cellsbearing OspC types A or B. Fluorescence of cells of bearing types K or Dwas less intense, and the staining was patchy, giving the cells astippled appearance. No reactivity was noted in cells probed withmatched preimmune sera. The lack of surface labeling by anti-flagellinantibody to air fixed cells served to verify that the outer membrane ofthe cells was intact and that the epitopes detected are naturallypresented at the cell surface. As expected, cells permeabilized withacetone were labeled by anti-flagellin antibody (data not shown).

Demonstration that Vaccination with the ABKD Chimeric Vaccinogen InducesBactericidal Antibody.

The bactericidal activity of the anti-ABKD antisera was assessed usingthe LIVE/DEAD BacLight assay [Tily et al, 2001; Ledin et al, 2005; Eliaset al, 2000; Montgomaery et al, 2006; Elias et al, 2002; Shin et al,2004]. Bactericidal activity was detected against strains bearing OspCof all types included in the chimeric vaccine construct. Incubation withthe anti-ABKD antiserum induced significant cell aggregation. Both liveand dead cells were present within the aggregates. Due to the inherentdifficulty of counting cells within aggregates, the percentage of liveand dead cells were determined by counting only non-aggregated, freecells. For all four OspC types, the background level of dead cells inthe cultures used for the bactericidal assay was approximately 20-30%.This background level of dead cells has been consistently observed inour laboratory following transfer of the cultures from 33 to 37° C. toupregulate OspC expression. In the bactericidal assay, killing occurredin a complement dependent fashion, with the percentage of dead cellsincreasing significantly above background to 56 to 90%. The number ofdead cells was in all cases at least twice that of the number of deadcells seen in any of the controls. Complement alone did not elicitkilling. There was no bactericidal activity elicited by pooled preimmuneserum, indicating that the specific immune response to the vaccinogenwas necessary for bactericidal activity.

Discussion

Several studies have explored the potential utility of OspC of the Lymedisease spirochetes as a potential vaccinogen. Although vaccination withOspC elicits a protective antibody response, protection has beenreported to be largely strain specific [Gilmore et al, 1996;Scheiblhofer et al, 2003; Wallich et al, 2001; Brown et al, 2005;Probert and LeFebvre, 1994; Gilmore 3t al, 2003]. Attempts to elicitbroader protection using cocktails of multiple OspC proteins have notproven successful. Baxter tested an OspC cocktail consisting of 14different full length OspC variants; however, they were not able toelicit sufficient antibody titers directed against the unique domains ofeach variant—a requirement if broad protection is to be conveyed. Inaddition, unacceptable reactigenicity was reported [Hanson et al, 2004].A general concern with cocktail vaccines is the potential misdirectionof the antibody response to epitopes that are not naturally presentedduring infection and that do not elicit protective antibody. Thegeneration of chimeric vaccines offers an alternative approach that cancircumvent the problems encountered using simple cocktails ofr-proteins. Chimeric vaccines consisting of a series of immunodominantepitopes have been explored in the development of vaccines againstmalaria [Hanson et al, 2004; Caro-Aguilar et al, 2005;], group Astreptococci [McNeil et al, 2005; Dale et al, 2005; Hu et al, 2002;Dale, 1999; Kotloff et al, 2005; Horvath et al, 2005], and severalviruses [Apt et al, 2006; Fan and Mei, 2005; Wang et al, 2005; Bouche etal, 2005]. If a polyvalent OspC vaccine is to be broadly protective itwill be necessary to incorporate into the vaccinogen a sufficient arrayof epitopes to elicit a protective response against diverse strains. Theability to move forward with the construction of such a vaccinogen hasbeen greatly facilitated by phylogenetic analyses which have delineated21 distinct OspC types designated A through U [Seinost et al, 1999], ofwhich only a subset have been correlated with invasive infection inhumans [Seinost et al, 1999; Example 1; Alghaferi et al, n 2005].

A detailed understanding of the epitope structure of OspC is requiredfor the development of a chimeric vaccinogen. There have been severalprevious descriptions of OspC epitope locations [Gilmore et al, 1996;Jobe et al, 2003; Lovrich et al, 2005]. Two studies have reported thatthe epitope responsible for eliciting bactericidal antibodies resideswithin the C-terminal domain of OspC [Jobe et al, 2003; Lovrich et al,2005]; however, since this domain is relatively conserved it is notclear why antibodies against the C-terminus are not broadly protective.Matheisen et al. also suggested that the C-terminus was the predominanttarget of the antibody response, noting greater reactivity of sera fromEuropean neuroborreliosis patients with full length OspC than with a 10amino acid C-terminal truncated form [Mathiesen et al, 1998]. From thisthey concluded that there must be a C-terminal epitope; however, sincethe test antigen consisted of a single OspC variant of unknown type, themore widespread recognition of the C-terminus may be due to the greaterconservation of this domain and not necessarily indicate that theC-terminus is immunodominant. Gilmore et al. demonstrated thatimmunization of mice with a non-denatured, but not with a denatured,r-OspC conferred protection to challenge with the homologous isolate[Gilmore et al, 1996; Gilmore and Mbow, 1999], indicating thatprotective epitopes may be conformationally defined. In a separateanalysis, Gilmore et al. analyzed the immunoreactivity of a limitednumber of OspC truncations derived from a single OspC type (type A) withan anti-OspC monoclonal antibody that confers passive immunity [Gilmoreand Mbow, 1999]. Deletion of either the N- or C-terminus eliminateddetection of the r-proteins by the mAb, further suggesting the existenceof a conformational or discontinuous epitope. It is not clear if theepitope recognized by the mAb is immunodominant, relevant during naturalinfection or conserved among the different OspC types. Linearimmunodominant epitopes of type A OspC have recently been mapped andfound to reside within the loop 5 and alpha helix 5 regions [Example 1].A r-protein containing the type A loop 5 epitope elicited bactericidalantibodies in mice, raising the possibility that individualtype-specific epitopes can be exploited in vaccine development [seeExample 2]. In this report, the epitopes of OspC types B, K, and D thatare presented during early infection are mapped, and a tetravalentchimeric vaccinogen based on these epitopes has been constructed. ThisABKD chimeric vaccinogen was highly immunogenic in mice and elicitedantibodies that bind OspC at the cell surface and effectively killstrains producing types A, B, K, and D OspC in a complement-dependentmanner.

The first step in our efforts to develop a tetravalent chimeric testvaccinogen was to identify the linear epitopes of OspC types B, K and Dpresented during infection in mice and humans. These analyses wereconducted essentially as described in Example 1 that identified the loop5 and alpha helix 5 epitopes of type A OspC. In brief, extensive panelsof type B, K and D OspC truncations and fragments were screened withserum from mice infected with clonal isolates and from humans infectedwith, at least in part, a strain expressing the corresponding OspC type.Precise epitope mapping was possible using sera from the experimentallyinfected mice; however, in naturally infected humans the antibodyresponse was to a broader epitope array. This is not surprising andpresumably reflects the expansion of the antibody response to OspCepitopes that are not normally presented at the bacterial cell surfaceduring early infection. New epitopes, some of which may be fromconserved domains of OspC (e.g. alpha helix 1), may become accessibleupon bacterial cell death and release of OspC from the membrane. Thisillustrates the caveats that accompany the use of human serum samples inepitope mapping; namely that the exact duration of infection istypically not known and the clonality of the infecting population isdoubtful [Wang et al, 1999; Ruzic-Sabljic et al, 2006; Hofmeister et al,1999; Guttman et al, 1996; Rijpkema et al, 1997]. In any event, it isclear from the analyses of the human serum samples that epitopes withinthe alpha helix 5 region are recognized during infection by strainsproducing OspC types A, B, K or D. In addition, the consistency of theresponse to alpha helix 5 among several different OspC type producingstrains may be an indication of functional relevance of this OspCdomain.

Although the alpha helix 5 and loop 5 region sequences are variablebetween OspC types, these regions are highly conserved within each type[see Examples 1]. This suggests that, in the context of a chimericvaccine, only a limited number of OspC epitopes will be required toeffect broad protection. As a first step in the development of a broadlyprotective vaccinogen, the type A loop 5 epitope and the alpha helix 5epitopes from OspC types B, K and D were employed in the development ofa test vaccinogen. The region containing these epitopes was PCRamplified with primers designed to encode linker sequences. This allowedthe use of PCR overlap extension in the creation of the chimericconstruct, and provided a means to separate the epitopes with short,unstructured, protease-resistant amino acid sequences [Crasto and Feng,2000]. The experimental OspC-based, tetravalent, ABKD chimericvaccinogen developed in this study elicited a consistent, high titeredIgG antibody response in all mice tested (n=12). Furthermore, thevaccinogen elicited antibody to each incorporated epitope.Interestingly, the epitope-specific titer appears to be influenced bythe epitope position within the construct. There was a progressivedecrease in titer from the N-terminal epitope (loop 5 of type A) throughthe C-terminal epitope (alpha helix 5 of type D). The phenomenon ofdecreased titer to C-terminal epitopes was also reported in earlystudies of a streptococcal M-protein based chimeric vaccine [Dale et al,1993; Dale et al, 1996]. The basis for the location-specific effect ontiter is not clear, but may be due to in vivo degradation or alterationof the structure of the C-terminus [Dale et al, 1999].

Although the Th cytokine response and related immunoglobulin isotypepattern necessary for protection against Borrelia infection have notbeen completely resolved [Kraiczy et al, n 2000; Widhe et al, 2004;Keane-Myers et al, 1995; Keane-Myers et al, 1996; Keane-Myers andNickell, 1995], determination of this pattern is an important step invaccinogen development and may provide important information regardingthe potential protective capability of different constructions of thevaccinogen. The isotype profile of the response was determined by ELISA,and heavy chain Ig isotypes associated with a mixed Th1 and Th2 cytokineresponse were observed. The class switching noted in this study impliesadequate T-cell help, even in the absence of a defined T-cell epitopeincorporated into the vaccinogen. Analysis of the vaccinogen sequenceusing predictive peptide binding algorithms for a subset of the murine(H2Ak/H2Ek) and human (HLA-DRB1) type II MHC, revealed potential T-cellepitopes in the vaccinogen predicted to bind all available alleles[Rammensee et al, 1999; Zhang et al, 2005]. One of the predicted bindingpeptides, LANSVKELT is repeated three times within the construct, andthis repetition may be important in eliciting a Th response [Jiang etal, 1999; Ahlborg et al, 1998; Kjerrulf et al, 1997; Theisen et al,2000]. While the analysis of potential T-cell epitopes was notexhaustive, the predictions support our data that indicate the chimericvaccinogen can elicit T-lymphocyte help in the mouse. Further, itimplies that this construct would likely do so in humans without theneed to incorporate a promiscuous T-cell epitope sequence. Theimportance of Freund's adjuvants in the generation of this isotypeprofile is not known, but the responses and isotype profiles will needto be assessed in the context of alum or other adjuvants appropriate foruse in humans [ten Hagen et al, 1993; Lindblad, 2004; Petrovsky andAguilar, 2004; Brewer et al, 1999; McNeela and Mills, 2001].Additionally, alteration of the epitope order or structure of thechimeric vaccinogen may provide a mechanism by which the immune responsecan be tailored to maximize in vivo protection [Tongren et al, 2005; Caiet al, 2004].

For the response to the vaccinogen to be productive in terms of vaccinedevelopment, the elicited antibody must be able to bind to the surfaceof intact B. burgdorferi cells and cause bacterial killing. IFA analysesrevealed strong labeling of the cell surface of strains producing OspCtypes A, B, K and D. Even though the antibody titer to the type Depitope was of significantly lower titer than that elicited to the moreN-terminal epitopes, surface labeling of type D producing strains wasreadily apparent. A subset of cells in each of the OspC type cultureswere observed not to label with the anti-ABKD antisera, implying thatthose cells were not expressing OspC. However, in vivo, it has beendemonstrated that most if not all cells are expressing OspC duringtransmission from the tick to mammal and during early mammalianinfection [Gilmore et al, 2001; Zhong et al, 1997]. The ability ofanti-ABKD antibody to effect cell killing was also assessed. Serum fromvaccinated mice efficiently killed spirochetes expressing types A, B, Kand D OspC proteins in a complement dependent manner. While there wasless than 100% killing for all of the OspC types, this is likely afunction of the heterogeneity of in vitro OspC expression among cells ofa population, a phenomenon that has been well documented in vivo [Schwanet al., 1995; Schwan and Piesman, 2000; Hu et al., 1996].

This Example describes the construction and proof of principle of anovel r-chimeric polyvalent OspC-based Lyme disease vaccinogen. The useof an epitope-based r-chimeric protein allows coverage of multiple OspCtypes in the same construct, and circumvents the potential problem ofimmune responses misdirected against irrelevant protein domains. Themapping of linear epitopes recognized during active infection is acrucial component of chimeric vaccine development, and this has beensuccessfully completed for four OspC types associated with invasiveinfection in humans. The epitopes included in the vaccinogen haveelicited type-specific IgG antibodies capable of binding OspC at theBorrelia cell surface, and effecting complement-mediated bacterialkilling.

Example 4 Immune Responses to Variants of a Chimeric Polyvalent LymeDisease Vaccine Intended to Improve Immunogenicity

In this study, we sought to improve the solubility of the construct andassess the potential impact of epitope placement, epitope reiteration,and the inclusion of putative C-terminal stabilizing tags on the immuneresponse. These analyses provide new insight into design strategies fora broadly protective OspC vaccine, and for construction of chimericvaccines in general.

Materials and Methods Expression and Purification of Recombinant OspC

Recombinant full length OspC proteins of types A, B, K and D weregenerated as previously described [see Examples 1 and 2]. Briefly, theospC gene from clonal populations of B. burgdorferi isolates B31MI (typeA OspC), LDP73 (type B), LDP74 (type K), and LDP116 (type D) wereamplified by PCR using primers with 5′ overhangs to allowligase-independent cloning (LIC) in the pET-32 Ek/LIC vector (Novagen)[Example 1]. After amplification and regeneration of single strandedtails, the amplicons were annealed with the pET-32 Ek/LIC vector, whichwas transformed into and propagated in NovaBlue (DE3) E. coli cells.Following confirmation of the insert sequence by DNA sequencing(MWG-Biotech), protein expression was induced with IPTG (1 mM). Proteinswere purified by nickel affinity chromatography using the pET-32 Ek/LICexpression tag-encoded hexahistidine motif (Novagen). Theimidazole-eluted proteins were dialyzed extensively against phosphatebuffered saline (PBS; pH 7.4) across a 10 kDa molecular weight cut-offmembrane (Slid-a-lyzer, Pierce), the protein concentration wasquantified by the BCA assay (Pierce), and the purity of the preparationwas assessed by SDS-PAGE.

Construction, Expression, and Purification of ABKD Vaccine Variants

In order to investigate potential mechanisms of, and solutions to, thedecreasing IgG titer to specific epitopes across the vaccine construct,multiple variants of the original vaccine were constructed. All vaccinevariants were based on the sequence of the ABKD vaccinogen previouslydescribed [Example 3] and contain the same epitope-containing sequences.These include the loop 5 region of type A (amino acids (aa) 131 to 149)and the alpha helix 5 regions of types B (aa 160-201), K (aa 161-201),and D (aa 161-201) (FIG. 13 inset). The ABKDppa and ABKDgg added aPro-Pro-Ala or Gly-Gly motif, respectively, to the C-terminus of theoriginal ABKD construct. Both of these constructs were made byamplifying the original ABKD construct using reverse primers (Table 5)that added the motif via a 5′ overhang encoding the appropriate aminoacids (FIG. 13A). The other vaccine variants were made by overlapannealing and extension techniques similar to those used in constructionof the original ABKD vaccinogen [Example 3]. The ABKDD construct wasmade by re-amplifying the ABKD construct using a reverse primer bearinga 3′ tail sequencing encoding an unstructured, protease-resistantlinker. This allowed the PCR product to anneal to the type D OspCepitope-containing sequence that had been amplified with thecomplementary linker-encoding sequence at the 5′ end, with subsequentoverlap extension and amplification of the annealed construct (FIG.13B). The ADBK construct was made by annealing separately amplified typeA and D epitope-containing regions with each other and subsequently withthe type B and K helix 5 epitope regions amplified from the originalABKD construct (FIG. 13C). The ADBKD construct was made by annealingamplicons from the ABKD and ADBK sequences (FIG. 13D). In all cases, thePCR amplification was completed with GoTaq Green (Promega) using aninitial 2 min 94° C. denaturation step, followed by 35 cycles ofdenaturation at 94° C. for 15 sec, primer annealing at 50° C. for 30sec, and extension at 72° C. for 60 sec, with a final 72° C. extensionfor 7 min. All primers use in construction of these vaccinogens arelisted in Table 5. All PCR products were gel purified (Qiagen) prior touse as templates in subsequent PCR reactions. Final amplicons wereannealed to the pET-46 Ek/LIC vector by ligase independent cloning, andtransformed into Novablue (DE3) E. coli cells. Colonies were screenedfor inserts using T7 primers, and plasmids were recovered (QiafilterMidi, Qiagen) for confirmation of the insert by DNA sequencing.Recombinant proteins were expressed and purified as described above.Following purification, the vaccine proteins were dialyzed across a 10kDa molecular weight cutoff membrane (Slide-a-Lyzer, Pierce) againstthree changes of either PBS (pH 7.4) or a pH 8 buffer containing 100 mMphosphate, 100 mM NaCl, 50 mM arginine, 50 mM glutamic acid (Arg/Glubuffer) [Golovanov et al, 2004]. The purity of the constructs wasassessed by SDS-PAGE.

TABLE 5  Primers used in construction of the chimeric vaccinogens. Primer Sequence Description SEQ ID NO: OCAL5LIC(+) GACGACGACAAGATTTAmplifies type A from 234 CTGAAACATTTACTAA aa 131 and adds LICTAAATTAAAAGAAAA tail AC OCAL5L5(−) TAAAGCTGACATAGCAAmplifies type A up to 235 CCTTCTTTACCAAGAT aa 149 and adds linkerCTGTGTG 5 (GAMSAL; SEQ ID 80) OCBH5L1(+) GGTAGCATGGGTATGTAmplifies type B from 236 TAAAAGCAAATGCAGC aa 160 and adds linker GGG1 (GSMGML; SEQ ID 76) OCKH5L3(−) TAAAACGCTCATGCTA Amplifies type K up to237 CTTGTAAGCTCTTTAA aa 201 and adds linker CTGAATTAGC3 (SSMSVL; SEQ ID 78) OCKH5LIC(−) GAGGAGAAGCCCGGT Amplifies type K up to238 TTAACTTGTAAGCTCT aa 201 and adds an TTAACTGAATTAGC LIC tailOCDHSLIC(−) GAGGAGAAGCCCGGT Amplifies type D up to 239 TTAACTTGTAAGCTCTaa 201 and adds an TTAACTGAATTAG LIC tail OCDH5ppaLIC(−) GAGGAGAAGCCCGGTAmplifies type D up to 240 TTATGCAGGAGGACTT aa 201 and adds TPA′GTAAGCTCTTTAACTG and an LIC tail AATTAG OCDH5ggLIC(−) GAGGAGAAGCCCGGTAmplifies type D up to 241 TTATCCTCCACTTGTA aa 201 and adds ‘GG’AGCTCTTTAACTGAAT and an LIC tail TAG OCDH5L1(−) TAACATACCCATGCTAAmplifies type D up to 242 CCACTTGTAAGCTCTT aa 201 and adds linkerTAACTGAATTAG 1 (GSMGML; SEQ ID 76) OCDH5L4(+) AGTTCAAGCCAAGGCTAmplifies type D from 243 TAAAAACACATAATGC aa 161 and adds linkerTAAAGACAAG 4 (SSSQGL; SEQ ID 79) OCDH5L4(−) TAAGCCTTGGCTTGAAAmplifies type D up to 244 CTTGTAAGCTCTTTAA aa 201 and adds linkerCTGAATTAGC 4 (SSSQGL; SEQ ID 79) OCDH5L5(+) GGTGCTATGTCAGCTTAmplifies type D from 245 TAAAAACACATAATGC aa 161 and adds linkerTAAAGACAAG 5 (GAMSAL; SEQ ID 80) 3′REVLIC(−) GAGGAGAAGCCCGGTAmplifies up to the 3′ 246 LIC tail pET46 T7(+) CGAAATTAATACGACTAmplifies from 247 CACTATAGGGG pET46, 123 bases upstream of cloning sitepET46 T7(−) GCTAGTTATTGCTCAG Amplifies up to 248 CGG pET46, 117 basesdownstream of the cloning site LIC tails are in bold, and linkersequences are underlined.Immunization of Mice with Vaccine Variants

Six week old male C3H/HeJ mice were immunized (3 mice per construct)with each of the six vaccinogen variants. Since the immunogenicity ofthe variants were to be compared with each other, it was desirable toadminister the protein on a molar basis, to compensate for differencesin the number of epitopes per unit of vaccinogen mass. Each mousereceived approximately 2.8 nanomoles of protein per immunization, whichis 50 μg of constructs ABKD, ABKDppa, ABKDgg, and ADBK or 62.5 μg ofconstructs ABKDD and ADBKD. Mice were immunized with vaccine in completeFreund's adjuvant, then boosted with Freund's incomplete adjuvant onweeks 2 and 4. Serum was collected from all mice by tail nick prior tothe first immunization and at week 6. To determine the effect ofadjuvant on the total and epitope-specific antibody titers, as well ason isotype profiles, mice (6 per adjuvant) were immunized with the ABKDvaccinogen emulsified in Freund's adjuvants as described above, oradsorbed onto alum (Imject Alum, Pierce), and serum was collected bytail nick at week 6.

Assessment of Epitope-Specific IgG Titer Induced by Vaccine Variants

The immunogenicity of each vaccinogen was assessed both by Western blotand ELISA. For the western blots, r-OspC of types A, B, K, D were loadedat 500 ng per lane in reducing sample buffer, electrophoresed in a 12.5%SDS-PAGE gel (Criterion, Biorad), and electroblotted to PVDF(Immobilon-P, Millipore). The blots were blocked with 1% BSA inphosphate buffered saline with 0.2% Tween-20 (PBS-T). The blots wereprobed with a 1:2500 dilution of each antiserum in PBS-T for one hour,and then washed three times. To verify equal protein loading, one blotwas screened with anti-His tag monoclonal antibody (1:2000; Novagen).Secondary detection was by a 1:40000 dilution of peroxidase-conjugatedgoat-a-mouse IgG and chemiluminescence (Super Signal Pico, Pierce). Forquantitative analysis, OspC type-specific IgG titers were determined byELISA analyses. r-OspC of types A, B, K, or D were coated onto 96 wellplates (Costar 3590; Corning) at 100 ng well-1 for 16 hr at 4° C. incarbonate buffer (pH 9.6). The plates were blocked (1% BSA in PBS with0.2% Tween-20 (PBS-T); 2 hr), washed 3 times with PBS-T, and seriallydiluted anti-vaccinogen antiserum (100 μL) was added to the wells ofduplicate plates (1 hr). HRP-conjugated goat-a-mouse IgG (1:20000)served as the secondary antibody and ABTS as the chromogenic substrate.The absorbance was read at 405 nm in an ELISA plate reader (ELx 808;Biotek) while the reaction rate was linear, and titers were calculatedby fitting a sigmoidal curve to the absorbance curve by a four parameterlogistic equation (SigmaPlot). The titer is reported as the inversedilution corresponding to 50% of the maximum absorbance plateau.

Determination of Epitope-Specific Immunoglobulin Isotype Profiles

The isotype profiles of the antibody response to the ABKD, ABKDD, andADBKD vaccine variant constructs were assessed by ELISA. 96 well plateswere coated with 100 ng well-1 of r-OspC of type A, B, K, and D. Theplates were blocked and washed as described above. Anti-vaccinogenantisera were added to the plate and analyzed in duplicate (100 μL;1:10000; 1 hr). Bound epitope-specific Ig was detected by incubationwith isotype specific, biotinylated secondary antibodies (1 hr; Mouseisotyping kit; Zymed). The secondary antibodies were detected byperoxidase-conjugated streptavidin (30 min) and the chromogenicsubstrate, ABTS. All incubations were completed at room temperature.

Determination of IFN-γ and IL-4 Production by Vaccine-SpecificT-Lymphocytes

The cytokine response of splenocytes from immunized mice was assessed byin vitro restimulation with vaccinogen using modifications of themethods of Abuodeh et al. [1999]. Vaccinated mice were euthanized by CO₂narcosis, and spleens were aseptically removed and placed into RPMImedia (Sigma). Spleens from the three mice immunized with each vaccineconstruct were pooled, and the cells were harvested by repeatedinjection of RPMI into the splenic capsule using 22 gauge needles. Thecell suspensions were transferred to 50 mL centrifuge tubes and thecells harvested at 200×g for 5 minutes. Erythrocytes were lysed byexposure to 3 mL of 8.3 mg/mL ammonium chloride (R-7757, Sigma) for 1minute. The ammonium chloride was then diluted with 20 mL of RPMI(Sigma), and the cells were centrifuged and washed three times. Thecells were resuspended in 10 mL RPMI containing 10% FCS, 100 μg mL⁻¹streptomycin, 100 U mL⁻¹ penicillin, 2.5 μg mL⁻¹ amphotericin B. Thecells were stained with trypan blue to assess viability, enumerated witha hemacytometer, and all cell suspensions adjusted to 107 cells mL⁻¹.Cells were aliquoted into 24 well plates (Costar 3526) at 10⁷ cells perwell (12 wells per vaccinogen type). Triplicate wells were stimulatedwith the immunizing vaccinogen at 5 or 10 μg mL⁻¹. Controls includedtriplicate wells stimulated with an irrelevant protein, bovine serumalbumin at 10 μg mL⁻¹, and unstimulated wells (no protein). All plateswere incubated at 37° C., 5% CO₂ for 96 hours, then supernatants wereharvested and frozen at −80° C. pending ELISA quantification ofcytokines.

To quantify the levels of the Th1/Th2 cytokines IFN-γ and IL-4, anELISA-based assay (ELISA-Max; Biolegend) was used according to themanufacturer's instructions. Briefly, a capture antibody was coated onto96-well ELISA plates, the plates were blocked, and 100 uL of eachculture supernatant, in duplicate, was incubated for 2 hr in the plates.For IL-4 detection, undiluted culture supernatant was used, whereas forIFN-γ, the supernatant was tested undiluted and diluted 1:20 in PBS. Astandard curve was generated using samples containing knownconcentrations of each of the cytokines. Detection of bound cytokineswas by a biotinylated secondary antibody followed by HRP-conjugatedstreptavidin and colorimetric detection using TMB substrate.

Results Construction, Expression and Purification of Variant VaccineConstructs

Using primers with 5′ overhangs and overlap annealing and extension PCRtechniques, five variants of the original ABKD vaccine were produced(FIG. 13). The DNA sequences of all of the constructs were confirmed.Select physicochemical properties of the vaccinogens are presented inTable 6 [Gasteiger et al, 2005]. Following purification of therecombinant vaccinogens by nickel chromatography, it was noted that asignificant proportion of the r-protein precipitated during dialysisagainst PBS. This was also noted in the initial report of the ABKDvaccinogen [Example 3]. While the higher molecular weight constructs,ABKDD and ADBKD, had higher solubility in PBS, r-protein precipitationwas still significant. For that reason, a modified dialysis buffer(Arg/Glu buffer) was developed based on the work of Golovanov et al.[2004]. The pH of the buffer was increased from that of PBS (pH 7.4) topH 8.0 to increase the difference between the buffer pH and the pI ofthe r-proteins (pI 6.49 or 6.85). In addition, the salt concentrationwas decreased from 150 mM to 100 mM and 50 mM arginine and 50 mMglutamic acid was added. Using this buffer, no precipitation of any ofthe r-proteins was noted, and there was a marked increase in theconcentrations of soluble protein. As visualized by SDS-PAGE, ther-proteins were pure and free of degradation products (FIG. 14).

TABLE 6 Physicochemical properties of the vaccinogens. Amino MolecularIsoelectric Instability Construct acids mass (Da) point index ABKD 16918014.4 6.49 10.14 ABKDppa 172 18279.7 6.49 14.93 ABKDgg 171 18128.56.49 10.86 ABKDD 214 22632.7 6.85 15.49 ADBK 170 18027.4 6.49 8.51 ADBKD215 22645.7 6.85 14.18

Immunogenicity of Vaccine Variants

To assess the relative immunogenicity of the ABKD vaccine variants, micewere immunized with each of the variants in Freund's adjuvants.Epitope-specific reactivity of the sera was assessed by western blot, inwhich the sera were used to probe PVDF-immobilized r-OspC of each of thefour types. The proteins were confirmed to be equally loaded on theblot, as assessed by reactivity with the tag-specific mouse-a-His tagmonoclonal antibody. The sera from immunized mice demonstratedvaccinogen-dependent differences in the levels of reactivity with eachof the r-OspC proteins (FIG. 15A). Notably, there was diminishedreactivity with the type D helix 5 epitope in mice vaccinated with theABKDppa and ABKDgg variants, and most markedly with the ADBK variant. Inorder to assess these variations in a quantitative way, titration of IgGreactivity with each of the OspC type-specific epitopes included in theconstructs was accomplished by ELISA, again by using full length r-OspCof each of the four types as the immobilized antigens. The titerslargely mimicked the qualitative western blot findings, demonstratingvaccine-specific differences in the reactivity of immune serum toindividual epitopes (FIG. 15B). The most marked differences were seen inreactivity with the type D epitope, with particularly low titers seenfor the ABKDppa, ABKDgg and ADBK variants.

Isotype Profiles of Vaccine Variant-Specific Immunoglobulins

To understand in greater detail the immune response induced by thevariant vaccinogens, epitope-specific immunoglobulin isotype profileswere completed for the three variants with the best vaccine potential(ABKD, ABKDD, ADBKD), as determined by epitope-specific titers. Ingeneral, there was a preponderance of IgG1 in the antigen-specificimmunoglobulins, smaller amounts of IgG2a and IgG2b, and very littleIgG3 or IgM, a pattern which has been previously noted [Example 3] (FIG.16). For all epitopes and all vaccine variants, the pattern of Igisotype was similar, with one exception. There was a greater reactivityof type K and D epitope-specific IgG2a and IgG2b in mice immunized withthe ABKDD than with the ABKD or the ADBKD variants.

Th1/Th2 Cytokine Production by Vaccine-Specific T-Lymphocytes

To assess the potential impact of the cytokine environment and Th1/Th2balance induced by the variations in the ABKD vaccinogen, mousesplenocytes were re-stimulated in vitro with the vaccinogen with whichthe mice had been immunized. Marked differences in the induced levels ofIFN-γ were noted between the differently immunized mice. All vaccinevariants were associated with increased levels of IFN-γ in the culturesupernatant, though ADBK and ADBKD had levels two to three times higherthan that induced by the other vaccinogens (FIG. 17). In all cases, boththe 5 μg mL⁻¹ and 10 μg mL⁻¹ concentrations of antigen induced IFN-γ,with levels ranging from 0.5 to 8.6 ng/mL. Cell culture supernatantsfrom unstimulated splenocytes or from splenocytes stimulated with bovineserum albumin all had IFN-γ levels that were below the 15.6 pg/mLdetection limit of the assay. In neither the vaccine-stimulated nor thecontrol culture supernatants was IL-4 detected, indicating that theconcentration was below the 2.0 pg/mL detection limit of the assay.

Effect of Adjuvant Type on Antibody Titer and Isotype Profile

To determine the effect of adjuvant type on the response to thevaccinogen, mice were immunized with the ABKD protein emulsified inFreund's adjuvants or adsorbed to alum. The IgG titer against the wholevaccinogen, as well as against each component epitope was slightly lowerin mice immunized with alum adjuvant, though the general pattern of theresponse was similar between the two adjuvants (FIG. 18A). Despitesimilar levels of IgG1, mice immunized with alum had reducedvaccinogen-specific IgG3, IgG2a, and IgG2b (FIG. 18B). Theepitope-specific isotype profiles were very similar to the profile seenusing the whole vaccinogen (data not shown).

Discussion

The use of chimeric proteins containing multiple B-cell epitopes haspotential advantages over whole-protein polyvalent vaccinogens andpeptide conjugates in vaccine development. The inclusion of onlyprotective epitope sequences reduces the potential for misdirection ofthe response against irrelevant epitopes either in the parent moleculeor on a peptide carrier. This is important if, as with OspC, there arelarge conserved domains that are immunodominant in the recombinantvaccinogen, but are not presented by the bacteria during infection[Example 1; Kumaran et al, 2001; Eicken et al, 2001]. Such epitopes areirrelevant to the generation of a protective immune response. Thecreation of novel proteins, however, requires consideration of inter-and intramolecular interactions that can occlude epitopes or impactprotein stability and solubility. In this Example, we have extended theinvestigation of a recombinant, polyvalent chimeric Lyme diseasevaccinogen based on OspC. The original ABKD vaccine was highlyimmunogenic in mice, and the induced IgG bound native OspC at thebacterial cell surface and elicited complement-dependent killing[Example 3]. Despite this success, the ABKD construct had two factorsthat required improvement, its poor solubility in PBS, which interferedwith production of r-protein and could impact storage stability, anddifferences in the IgG titer against individual epitopes in the protein.Specifically, titer decreased in relation to the proximity of theepitope to the vaccine C-terminus. The goals of this study were toimprove vaccinogen solubility, and use modified vaccinogens thatdiffered in epitope placement, epitope reiteration, and the inclusion ofstabilizing motifs to improve the total and the epitope-specific immuneresponse.

In an earlier study, it was noted that there was significantprecipitation of recombinant vaccinogen following dialysis against PBS[Example 3]. This poor solubility not only limited vaccinogen productionbut may also have impacted vaccine immunogenicity. The maximumconcentration of the ABKD construct achieved following dialysis againstPBS was 0.5 mg/mL, and was frequently much less. The OspC crystalstructure suggests that the helix 5 epitope regions participate inintramonomeric 4-helical bundles in the native OspC proteins [Kumaran etal, 2001; Eicken et al, 2001]. This may lead to interactions betweenexposed hydrophobic helical faces within and between vaccinogenproteins, in turn leading to precipitation. The addition of Arg and Gluto the dialysis buffer was found to increase the solubility of all ofthe recombinant vaccinogen proteins by 4 to 100-fold (Table 7). Thebasis for this increased solubility may be an interaction of Arg and Gluwith both with exposed residues of opposite charge, and with hydrophobicresidues by interaction with the aliphatic portion of the Arg and Gluside chains [Golovanov et al, 2004]. Mice immunized with the ABKDconstruct dialyzed in the Arg/Glu buffer had markedly higher titers thanthose immunized with the ABKD vaccinogen dialyzed against PBS [Example3]. The Arg/Glu buffer may cause a more advantageous folding pattern orfewer inter- or intramolecular interactions, thereby providing betteraccess of epitopes to B-cell receptors. Adsorption of Arg or Glu to ther-protein apparently did not interfere with epitope recognition. TheArg/Glu buffer has been reported to protect against the activity ofproteases in vitro [Golovanov et al, 2004]. While there is no apparentproteolytic degradation in either the PBS- or Arg/Glu-dialyzed samples,in vivo protection against proteolytic cleavage cannot be excluded.Dialysis against buffers containing Arg and Glu may be a useful toolthat can be applied to other novel chimeric proteins that havesignificant intermolecular interactions.

TABLE 7 Concentration of soluble protein for vaccinogens dialyzedagainst PBS or Arg/Glu buffer. Protein concentration (mg mL⁻¹) ConstructPBSArg/Glu buffer ABKD 0.15 3.04 ABKDppa 0.20 3.78 ABKDgg 0.22 5.99ABKDD 0.80 4.66 ADBK 0.04 4.37 ADBKD 1.12 4.66

The association of poor immune response with the C-terminal epitopelocation has been previously reported in a chimeric streptococcalM-protein vaccinogen, potentially due to structural issues associatedwith the C-terminus, or proteolytic degradation by carboxypeptidases[Dale et al, 1993; Dale et al, 1996; Dale et al, 1999]. Numerous methodshave been proposed for protection of peptides and recombinant proteinsfrom protease activity, including amidation or PEGylation of theC-terminus, acetylation of the amino (N)-terminus, and addition ofprotective amino acid motifs [Brickerhoff et al, 1999; Powell et al,1992; Lee et al, 2005; Alvarez et al, 2004; Kawarasaki et al, 2003;Walker et al, 2003]. Amino acid motifs have also been reported tostabilize the C-terminus of proteins by inhibiting the action ofcarboxypeptidases; however, their ability to protect has only beenassessed with a few proteins. Two stabilizing motifs were assessed fortheir ability to enhance antibody responses to the ABKD vaccinogen. Theaddition of two neutral, hydrophilic Gly residues may reduce theactivity of carboxypeptidases C and D, which have specificity forhydrophobic and basic C-terminal amino acids, respectively [Alvarez etal, 2004; Kawarasaki et al, 2003; Remington and bredam, 1994]. Additionof a Pro-Pro-Ala motif may sterically hinder carboxypeptidaseprogression through the juxtaposed, bulky proline residues [Walker etal, 2003].

To assess the impact of addition of these motifs on the antibodyresponse to the ABKD chimeric vaccinogen, mice were immunized with theABKDgg or ABKDppa constructs. In both cases, the sera had lower mean IgGtiters against one of more epitopes, compared with those immunized withthe unmodified ABKD construct. The ABKDppa construct had a reduction inthe titer of type D specific IgG, though this was primarily due to asingle outlier. The ABKDgg construct had reduced titers against thetypes K and D epitopes. On the basis of IgG titers, there was noadvantage to the use of either of these motifs. The reduction in thetiter to the C-terminal epitopes does not appear to be mediated by theaction of those carboxypeptidases to which these motifs should conferresistance, though it is possible that any advantage due to proteaseprotection may have been masked by similar protection provided by theArg/Glu buffer [Golovanov et al, 2004].

To investigate possible structural factors involved in the poor immuneresponse to the C-terminal epitope, several additional constructs werecreated. In the chimeric streptococcal vaccine, reiterating theN-terminal epitope at the C-terminus ‘protected’ the former C-terminalepitope by an unknown mechanism [Dale et al, 1999; Dale et al, 2005; Huet al, 2002; McNeil et al, 2005]. Based on that success, similarvariants of the ABKD vaccinogen were developed. The ABKDD construct wascreated to assess whether the response to the type D epitope could beprotected by a second C-terminal type D epitope. To assess whether thedecreased titer was due primarily to the C-terminal epitope location,the type D epitope was moved to the second-most N-terminal location(ADBK). Finally, the ADBKD construct was used to assess protection by areiterated C-terminal epitope and, with ABKDD, the effect of a repeatedepitope on the specific immune response. Epitope reiteration in theABKDD vaccinogen doubled the type D-specific IgG titer, butsimultaneously caused a decrease in the titer against the adjacent typeK epitope. When the type D epitope was placed in a more N-terminallocation in the ADBK construct, the type-D specific IgG titer wassignificantly reduced. Furthermore, the reactivity against theC-terminal type K epitope in the ADBK construct was improved over thatin the ABKD. Adding a C-terminal type D epitope (ADBKD) did not improvethe type K-specific titer; however, it yielded a significantly improved,though not doubled, titer against the type D epitope. These resultsindicate that the C-terminal location of the type D epitope ispreferable to an internal location, and that there is no apparentprotection of a C-terminal epitope by an additional ‘protective’C-terminal epitope. The primary determinant of epitope-specific titer inthis vaccinogen is not its proximity to the C-terminus, but is morelikely the tertiary structure of the chimeric protein.

Vaccinogen-induced Ig isotypes may have consequences on in vivoprotective efficacy. By altering the epitopes or their order, it may bepossible to alter the isotype profile [Tongren et al, 2005], and thusantibody effector functions. To measure epitope-specific isotypeprofiles, antisera against the most promising vaccinogens (ABKD, ABKDD,ADBKD) were bound to immobilized rOspC of types A, B, K or D, and thebound antibody detected with isotype-specific antisera. As previouslyreported for the ABKD vaccinogen [Example 3], the predominant isotypewas IgG1, with somewhat lower levels of IgG2a and IgG2b, dependent onthe construct, and low levels of IgM and IgG3. The epitope specific Igisotype profiles were similar between the ABKD and ADBKD antisera, witha decrease in the levels of IgG2a and IgG2b from the N- to theC-terminal epitope, mimicking the total IgG titer. The ABKDD had aconsistent level of IgG2a and IgG2b across all of the epitopes, despitethe lower type K-specific total IgG titer.

The ABKD vaccinogen elicits complement-dependent bactericidal antibodies[Example 3]. In the mouse, IgG1 does not activate complement [Dangl etal, 1988; Miletic and Frank, 1995], indicating that the major inducedisotype may not be protective. While it has been reported thatOspA-specific IgG1 can be borreliacidal by a complement-independentmechanism [Munson et al, 2000], bacterial killing by ABKDvaccinogen-induced antibodies is complement dependent [Example 3]. Theelicited isotype profile may be influenced by the use of C3H/HeJ mice, astandard animal model for Lyme disease research. Humoral immunedifferences between C3H/HeJ and BALB/c strain mice have been notedduring B. burgdorferi infection, especially in the levels of total IgGand especially in the levels of IgG2a, both of which are higher inC3H/HeJ mice [Yang et al, 1992; Keane-Myers and Nickell, 1995].Additionally, the C3H/HeJ mouse line is deficient in TLR-4, though thisis not expected to be critical for protection against Lyme disease byvaccination or during infection, as Borrelia do not makelipopolysaccharide [Takayama et al, 1987; Barthold et al, 1990].

Since it is generally accepted that humoral borreliacidal activity iscomplement-dependent, the elicitation of a Th1 cytokine response may beadvantageous, as it is in many bacterial diseases (reviewed in[Spellberg and Edwards, 2001]). During active infection, Th cytokineshave been implicated in the development and resolution of Lyme diseaseand its sequelae. Several studies have found that IL-4 is not a criticalcytokine for the development of a borreliacidal antibody response[Munson et al, 2000; Potter et al, 2000; Christie et al, 2000; Satoskaret al, 2000-64], implying that a Th1-type response may be associatedwith protection. Additionally, IFN-γsecreting Th1 cells promote theresolution of carditis associated with Lyme disease [Bockenstedt et al,2001; Kelleher et al, 1998]. Conversely, arthritis severity and the skinspirochete load are reduced by administration of r-IL-4, and increasedby administration of an α-IL-4 antibody during infection [Keane-Myersand Nickell, 1995; Keane-Myers et al, 1996]. The production of IFN-γ hasbeen associated with the development of chronic Lyme disease duringnatural infection [Widhe et al, 2004], as well as with the degree ofjoint swelling in Lyme arthritis [Gross et al, 1998]. IFN-γ has alsobeen associated with inhibited production of borreliacidal anti-OspAantibodies induced from in vitro lymph node cultures [Munson et al,2002]. To investigate the Th cytokine environment induced byvaccination, mouse splenocytes were re-stimulated with vaccinogen invitro, and Th1 (IFN-γ) and Th2 (IL-4) cytokines and were quantified byELISA. IFN-γ was detected in the supernatants of cells re-stimulatedwith vaccinogen, though in differing concentrations depending on theconstruct. In contrast, IL-4 was not detected in any of the splenocytesupernatants. The ABKD, ABKDppa, and ABKDD constructs all had similarconcentrations of IFN-γ. The ADBKD had approximately double theconcentration of IFN-γ, and the ADBK had an even higher level. There wasno apparent correlation between the level of IFN-γ in the supernatant ofre-stimulated cells and the total epitope-specific serum IgG titers orisotype profiles.

The cytokine and associated Ig isotype profiles could be altered by thechoice of immunological adjuvant. Freund's complete adjuvant has beenassociated with a Th1 cytokine response [Cribbs et al, 2003; Shibaki andKatz, 2002], which may increase the level of IgG2a. The only adjuvantcurrently approved for human use is alum, which is known to increasesecretion of Th2 cytokines [Cribbs et al, 2003; Brewer et al, 1999;Lindblad, 2004; Petrovsky and Aguilar, 2004]. In mice immunized withalum, the expected moderate decrease in IgG titer to the vaccinogen andits component epitopes was noted, in comparison with Freund's adjuvant.Additionally, there was a proportionally greater decrease in the IgG3,IgG2a, and IgG2b isotypes, as compared with IgG1. This conforms with theexpectation of lower Th1 cytokine response with this adjuvant. Thevaccinogen does, however, continue to elicit antibodies capable ofcomplement fixation, indicating that significant changes to theconstruct or modifications of the adjuvant may not be necessary for aneffective response.

In this Example, we have investigated alterations to a potentialchimeric polyvalent Lyme disease vaccinogen that were intended tooptimize the induced humoral immune response. A significant improvementto the immunogenicity of the construct was effected by increasing itssolubility by dialysis against Arg/Glu buffer. This may have reducedprotein interactions, allowing greater epitope exposure in vivo [Theisenet al, 2000]. Neither the addition of protease-protective C-terminalmotifs nor addition of ‘protective’ C-terminal epitopes improved theimmune response to the vaccinogen. Reordering of epitopes caused asubstantial decline in the immune response to the epitope that wasmoved. Differences in the immune response toward component epitopes inthis vaccine construct appear to be primarily dependent on the structureof the protein, rather than on the resistance of the protein to proteasedigestion. Furthermore, there is evidence that Th cytokines and IgGisotypes elicited by a vaccinogen can be altered by the structure of thechimeric construct and by the adjuvant formulation. This study providesimportant information regarding the basis for suboptimal immuneresponses to chimeric vaccinogens, as well as methods by which thoseresponses can be improved.

Example 5 Analyses of Available OspC Sequences Demonstrate theFeasibility of a Broadly Protective Polyvalent Chimeric Lyme DiseaseVaccine

To facilitate the further development of a broadly protective chimericconstruct we have conducted phylogenetic analyses of OspC sequencesavailable in the databases. The segment of OspC analyzed spannedresidues 20 through 200 (using numbering for the B31MI sequence).Shorter sequences in the databases were excluded from these analyses,leaving sequences from 280 Borrelia strains available for analysis. TheOspC type designation of each sequence was determined through alignment(PAM40 scoring matrix) and pairwise identity matrix analysis. Consistentwith earlier studies, sequences that exhibited 95% or greater sequenceidentity were considered to belong to the same OspC type (Attie et al,2006; Wang et al, 1999) (FIG. 19). A clear bimodal distribution ofsequence comparisons, with a mean sequence identity of 65% betweendiffering OspC type sequences, and >97% identity within types wasobserved. In addition to the 21 types described by Wang et al (1999), 17additional clusters were defined. We did not assign OspC typedesignation to clusters that included less than 3 sequences. In namingnew OspC types, we chose to maintain the existing OspC type designationsA through U (Wang et al, 1999), with additional types named based on aprototype strain contained within each cluster. Of 280 analyzedsequences, 202 were assigned to OspC types, all of which were from Lymedisease-causing species. The 78 sequences not assigned to an OspC typeincluded both Lyme disease-causing spirochetes (51 isolates) and otherBorrelia species (27 isolates). The geographic and biological origin ofthe isolate from which each OspC sequence was obtained is indicated inFIG. 20 in tabular form. The majority of B. burgdorferi isolates werefrom North America (80%) with lesser numbers from Europe (16%) and Asia(4%). Fifty three percent of the B. burgdorferi, 48% of the B. afzeliiand 79% of the B. garinii OspC sequences originated from isolatescollected from humans. It is noteworthy that B. garinii OspC sequencesfrom human isolates were predominantly of cerebrospinal fluid (CSF)origin (68%) whereas B. afzelii isolates were predominantly from theskin (83%). In contrast, B. burgdorferi derived OspC sequences were fromisolates recovered from human skin (51%), plasma (30%), and CSF (19%).These findings are in agreement with the known patterns of diseasecaused by these organisms and indicate that the sample of OspC sequencesassessed in this report is representative of the true population of Lymedisease spirochetes.

To facilitate further phylogenetic analyses, the set of sequencesanalyzed was reduced to 74 by eliminating identical sequences. Thesesequences were then aligned and analyzed using the Phylip (v. 3.66)phylogenetics package with bootstrapping (n=1000). Distances werecalculated for the regions spanning 20 to 200, 20 to 130 and 131 to 200using the Dayhoff PAM matrix, and trees were created by neighborjoining. The B. hermsii OspC ortholog (Vmp33) sequence served as anoutgroup (Margolis et al, 1994). A consensus tree was generated bymajority rule (50% cutoff for group inclusion). Distances werere-calculated for the consensus tree by the maximum likelihood methodunder the Dayhoff PAM model (FIG. 21).

The consensus trees generated with the 20-200 aa segment of OspC werewell supported at the terminal nodes, with all determined OspC typesclustering as expected. While several of the deeper branches were lesssupported by the bootstrap analyses (FIG. 21A) this is not unexpectedsince the extended regions of identity among the sequences makes theirphylogenetic differentiation subtle. Consensus trees generated using the20-200 and 20-130 amino acid segments of OspC exhibited similarphylogenetic clustering (FIG. 21A, 21B), based largely on speciesidentity. However, the consensus tree generated using amino acids131-200 (FIG. 21C) yielded significantly different clustering patternsthat were not strongly supported by bootstrap analyses. This observationis consistent with the hypothesis that recombination between shortsegments of the ospC gene has occurred between strains of differing OspCtypes. Evidence for recombination of short segments of OspC between OspCtypes can be seen in specific sequences. For example, sequences of theB. afzelii OspC type, PLj7, have regions within the amino acid 20-130domain that are identical to that seen in B. garinii OspC sequences thatform the Pki cluster. In the 131-200 region of PLj7, the hypervariableloop 5 and loop 6 regions have motifs identical to those seen in B.burgdorferi OspC types F and M, respectively. Further evidence forrecombination came from bootscanning using SimPlot (v. 3.5.1) (Lole etal, 1999). In bootscanning, potential recombination is assessed bygeneration of phlylogenetic trees (Kimura model, Ts/Tv ratio=2.0,Neighbor joining) of sequence segments within a sliding window (40 basewindow, 10 base step interval). The trees are bootstrapped (n=100) andthe number of permuted trees supporting sequence grouping within thatwindow is reported. Evidence of recombination is typically considered tobe supported when >70% of permuted trees cluster the sequences togetherwithin a window. Evidence was found of possible recombination in thetypes described above (FIG. 22), as well as in numerous other OspC types(data not shown).

The evidence that OspC variability occurs by exchange between existingOspC types rather than by hypermutation provides evidence that there isa limit to the absolute number of OspC type-specific epitopes requiredfor inclusion in a broadly protective vaccinogen. Since currently mappedlinear epitopes are all contained in the C-terminal region of OspC (aa131-200), it is possible to define a theoretical number of epitopesrequired for a chimeric vaccinogen. By inspecting this region in the 74representative sequences described above, the number of uniqueepitope-containing regions can be reduced to 34 by elimination ofsequences that are either identical or have only a single amino acidchange (FIG. 22). It is likely that this number can be furtherrestricted by epitope mapping since some epitopes may convey protectionagainst two or more OspC types. Further reduction in the required numberof epitopes could also come from consideration of only those OspC typesassociated with human disease or, more specifically, with invasive humandisease (see Example 1). One theoretical concern with vaccinationagainst a subset of OspC epitopes is the potential to drive selectiontoward types not included in the vaccinogen, thus increasing thefraction of the population bearing those rare alleles. However, ashumans are only incidental hosts, it is unlikely that vaccination willsignificantly alter the population distribution of strains expressingspecific OspC types in the tick vector or mammalian reservoirs.

In summary, the extensive nature of the OspC database has allowedthorough analyses to be conducted which have defined new OspC types andprovided information regarding their frequency of isolation andassociation with human disease. The data suggest that the number of OspCepitope-containing sequences required for inclusion in a broadlyprotective chimeric vaccinogen is limited and that the development of achimeric vaccinogen is feasible.

Example 6 Construction of an Octavalent Chimera

The ENICABKD octavalent construct (also referred to as construct A8.1herein, e.g. in Example 7) is shown below, and several properties of theconstruct are presented as calculated by the PROTPARAM program. In thisrepresentation, “TAG” represents a histidine tag on the amino terminusof the protein. “RS” indicates an amino acid sequence that is encoded bya DNA sequence bearing a restriction site; such sequences basicallyfunction as linkers in the protein. “L” (e.g. L1, L2, L3, L6, L7, L8,etc.) indicates a linker sequence, e.g. an unstructured linker sequence)used to join the type specific sequences together.

A8.1 (SEQ ID NO: 249)<----TAG----->RS<----------------------Type E--------------- 1AHHHHHHVDDDDKITGLKSEHAVLGLDNLTDDNAQRAILKKHANKDKGAAELEKLFKAVE-------------<L9>-----------------Type N-----------------><L 61NLSKAAQDTLKNAPGVGATTDEEAKKAILRTNAIKDKGADELEKLFKSVESLAKAAQDAT6><----------------Type I----------------><L7><------------- 121QMLKTNNDKTKGADELEKLFESVKNLSKAAKEMLTNSVKELTSTEPSEEFTKKLKEKHTD------Type C---------------------><L8RS<------Type A-----><- 181LGKKDATDVHAKEAILKTNGTKDKGAAELEKLFESGEDVSETFTNKLKEKHTDLGKEGSML1><----------------Type B-----------------><L2><----------- 241GMLKANAAGKDKGVEELEKLSGSLESLSKAAKEMLANSVKELTSTNGNLITDAAKDKGAA----Type K------------------><L3><---------------Type D----- 301ELEKLFKAVENLAKAAKEMLANSVKELTSSMSVLKTHNAKDKGAEELVKLSESVAGLLKA-----------------------> 361 AQAILANSVKELTSPVVAESPKKPNumber of amino acids: 384Molecular weight: 41263.7Theoretical isoelectric point: 6.52

Amino Acid Composition:

Ala (A) 51 13.3% Arg (R) 2 0.5% Asn (N) 20 5.2% Asp (D) 25 6.5% Cys (C)0 0.0% Gln (Q) 5 1.3% Glu (E) 42 10.9% Gly (G) 21 5.5% His (H) 12 3.1%Ile (I) 7 1.8% Leu (L) 46 12.0% Lys (K) 62 16.1% Met (M) 7 1.8% Phe (F)7 1.8% Pro (P) 5 1.3% Ser (S) 27 7.0% Thr (T) 26 6.8% Trp (W) 0 0.0% Tyr(Y) 0 0.0% Val (V) 19 4.9% Total number of negatively charged residues(Asp + Glu): 67 Total number of positively charged residues (Arg + Lys):64

Atomic Composition:

Carbon C 1787 Hydrogen H 2983 Nitrogen N 501 Oxygen O 597 Sulfur S 7Formula: C1787H2983N501O597S7 Total number of atoms: 5875

Estimated Half-Life:

The N-terminal of the sequence considered is A (Ala).The estimated half-life is: 4.4 hours (mammalian reticulocytes, invitro).

-   -   >20 hours (yeast, in vivo).    -   >10 hours (Escherichia coli, in vivo).

Instability Index:

The instability index (II) is computed to be 12.58This classifies the protein as stable.Aliphatic index: 81.46Grand average of hydropathicity (GRAVY): −0.668

When administered to test mammals, this chimeric protein construct isfound to elicit a robust immune response, and to provide protection fromthe development of Lyme disease.

Example 7 Constructs for Use as Early Diagnostic Agents and VaccineAntigens

Several chimeric proteins have shown promise for the development ofearly diagnostic assays, as well as vaccine candidates, for Lymedisease. Early detection (e.g. within about 3 weeks) is importantbecause disease symptoms may be more treatable then and irreversible,chronic damage might not yet have occurred, and can be prevented.However, the diagnostics can be used at later times, e.g. within 6weeks, or even longer, if necessary. As for vaccines, they can beadministered prophylactically or therapeutically. Generally, theproteins are chimeric constructs formed by linking full length and/orantigenic subfragments of outer surface protein C (OspC) or outersurface protein A (OspA) from several different Borrelia phylogenetictypes.

Exemplary data generated using the A8.1 construct are presented in FIG.27. The data presented in this figure demonstrate that in anexperimentally infected canine model, seroconversion can be detectedspecifically and at early time points following infection. The dogs wereinfected by wild-caught ticks that were confirmed to contain spirochetesexpressing, in aggregate, a majority of described OspC types. This assaydemonstrates that the chimeric protein is capable of detecting a broadarray of OspC serotype-specific IgG antibodies, which is critical forthe sensitivity of an OspC-based Lyme diagnostic. It also demonstratesdetection of OspC seroconversion at early time points followinginfection. Since OspC is the dominant protein expressed at the Borreliacell surface during early infection, it has definite advantages in earlydetection of seroconversion as compared with other potential diagnosticantigens. For these same reasons, it also has significant potential as avaccine antigen.

The A9 series of proteins may also be used as the basis for diagnosticassays, or alternatively, as vaccines. The A9 proteins contain antigenicfragments from the OspC phylogenetic types predominantly found in NorthAmerican strains of Borrelia burgdorferi. The A9.1, A9.2, and A9.3vaccine proteins each contain sequences from the same OspC types, butdiffer in the precise subfragment and/or order in which the subfragmentsare assembled in the protein. A9.1 includes sequences from loop 5through helix 5 plus the native intervening sequences for each indicatedtype. FIG. 28A depicts the general location of epitopes of the OspCprotein and the arrangement or pattern of epitopes in construct A9.1.FIG. 28 B shows the precise patterns in A9.1. In A9.1, the N- andC-termini are truncated to eliminate redundant sequences; the epitopesof various types are linked without linker sequences; and the conservedC-terminal motif is present at the end. For all of the “A” constructs,including the A10, A11 and A12 series described in this Example, theepitopes include those of B. burgdorferi types A, B, C, D, E, F, H, I,K, M, N, T, and U.

Construct A9.1 (SEQ ID NO: 250)SETFTNKLKEKHTDLGKEGVTDADAKEAILKTNGTKTKGAEELGKLFESVEVLSKAAKEM<----------------------------Type A-------------------------LANSVKELTSSEEFSTKLKDNHAQLGIQGVTDENAKKAILKANAAGKDKGVEELEKLSGS---------<>---------------------Type B----------------------LESLSSEDFTKKLEGEHAQLGIENVTDENAKKAILITDAAKDKGAAELEKLFKAVENLAA----><---------------------Type K-------------------------><KLKGEHTDLGKEGVTDDNAKKAILKTNNDKTKGADELEKLFESVKNLSKAAKEMLTNSSE---------------------Type I------------------------------><-KFAGKLKNEHASLGKKDATDDDAKKAILKTHGNTDKGAKELKDLSDSVESLVSDDFTKKL  -------------------Type H------------------------><-------QSSHAQLGVAGGATTDEEAKKAILRTNAIKDKGADELEKLFKSVESLAKAAQDALANSVN---------------------Type N---------------------------------ELTSKKLKEKHTDLGKKDATDVHAKEAILKTNGTKDKGAAELEKLFESVENLAKAAKEML---><-----------------------Type C--------------------------SNSNKAFTDKLKSSHAELGIANGAATDANAKAAILKTNGTKDKGAQELEKLFESVKNLSK--><--------------------------Type M------------------------AAQETLNNSSESFTKKLSDNQAELGIENATDDNAKKAILKTHNAKDKGAEELVKLSESVA--------><-------------------------------Type D-------------GLLKAAQAILANSVKELTSPVVAESPKKP ---------------------------->For construct A9.1, the number of amino acids is 569, the molecularweight is 60657.2, and the theoretical pI is 6.35.

The sequence of the A9.2 construct is provided below (where “Lp”indicates “loop” and “Hx” indicates “helix”) and depicted schematicallyin FIG. 29A. In this construct, the N- and C-termini are truncated toeliminate redundant sequences; the epitopes of various types are linkedwithout linker sequences; intervening sequences (helix 4 and loop 6) arenot present, and the conserved C-terminal motif is present. For thisconstruct, the epitope order is the same as that of A9.1 (above).

Construct A9.2 (SEQ ID NO: 251)SETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSKAAKEMLANSVKELTSSEEFST<-----Lp A-----------><--------------Hx A--------------><---KLKDNHAQLGIQGVTKGVEELEKLSGSLESLSSEDFTKKLEGEHAQLGIENVTAAELEKL---Lp B--------><------Hx B------><--------Lp K--------><---FKAVENLAKAAKEMAKLKGEHTDLGKEGVTKGADELEKLFESVKNLSKAAKEMLTNSKES--Hx K--------><------Lp I-----><-----------Hx I----------><EKFAGKLKNEHASLGKKDATKGAKELKDLSDSVESLVKASDDFTKKLQSSHAQLGVAGGA-------Lp H--------><-------Hx H-------><--------Lp N-------TTADELEKLFKSVESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDATAAELEKLFESV-><------------Hx N-------------><-----Lp C------><---------ENLAKAAKEMLSNSNKAFTDKLKSSHAELGIANGAATKGAQELEKLFESVKNLSKAAQET-Hx C---------><---------Lp M---------><-----------Hx M-----LNNSVKESESFTKKLSDNQAELGIENATKGAEELVKLSESVAGLLKAAQAILANSVKELT------><--------Lp D--------><-----------------Hx D---------SPVVAESPKKP  ---------->For construct A9.2, the number of amino acids is 431, the molecularweight is 46088.0, and the theoretical pI: 5.85.

The sequence of the A9.3 construct is provided below (where “Lp”indicates “loop” and “Hx” indicates “helix”) and depicted schematicallyin FIG. 30A. In this construct, the N- and C-termini are truncated toeliminate redundant sequences; the epitopes of various types are linkedwithout linker sequences; intervening sequences (helix 4 and loop 6) arenot present, and the conserved C-terminal motif is present. For thisconstruct, the epitope order differs from that of A9.1 and A9.2 and,instead, epitopes are ordered as “helix-helix-loop-loop”. The protein isdesigned to orient hydrophobic faces of the helices toward one anotherand between linked helices. Without being bound by theory, it isbelieved that this arrangement may promote orientation of the helix 5epitopes in a manner similar to that found in native OspC.

Construct A9.3 (SEQ ID NO: 252)SETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSKAAKEMLANSVKELTSKGVEEL<--------Lp A-------><-------------Hx A--------------><-----EKLSGSLESLSNKAFTDKLKSSHAELGIANGAATKKLKEKHTDLGKKDATKGADELEKLF--Hx B----><---------Lp M---------><-----Lp C------><-------ESVKNLSKAAKEMLTNSKEIAAELEKLFKAVENLAKAAKEMAKLKGEHTDLGKEGVTSEE----Hx I------------><--------Hx K--------><------Lp I----->FSTKLKDNHAQLGIQGVTKGAKELKDLSDSVESLVKAAAELEKLFESVENLAKAAKEMLS<------Lp B-------><-------Hx H-------><---------Hx C-------NSSEKFAGKLKNEHASLGKKDATSEDFTKKLEGEHAQLGIENVTKGAQELEKLFESVKNL-><--------Lp H--------><--------Lp K--------><--------Hx M-SKAAQETLNNSVKEADELEKLFKSVESLAKAAQDALANSVNELTSSESFTKKLSDNQAEL-------------><------------Hx N-------------><-------Lp D---GIENATSDDFTKKLQSSHAQLGVAGGATTKGAEELVKLSESVAGLLKAAQAILANSVKEL-----><--------Lp N---------><--------------------Hx D------TSPVVAESPKKP  ----------->For construct A9.3, the number of amino acids is 432, the molecularweight is 46201.2, and the theoretical pI is 5.85.

In addition to the A9 series, similarly constructed proteins have beendeveloped which cover Borrelia OspC types that are not commonly found inNorth America, but which are more prevalent in Europe and Asia. Many ofthese OspC types are found in Borrelia garinii or Borrelia afzelii.These proteins are designated as the B9 and C9 series. For the B9series, epitopes from B. garinii types Pwa, Pli, Pbes, Pki, PfiM, H13,Smar and HT22 are included (with some exceptions described below). Forthe C9 series, epitopes from B. afzellii types Pko, PLj7, pHez, Pmit,Szid, VS461, HT25 and DK15 are present (with some exceptions describedbelow).

B9.1 and C9.1 contain loop 5 and helix 5 plus intervening sequences fromthe indicated type (as described above for A9.1, and as depicted inFIGS. 28C and D).

Constructs B9.2 and C9.2 contain epitopes (as described for A9.2 above,and as depicted in FIGS. 29B an C), except that the H13 helix 5 isidentical to Pki helix 5, so it is excluded (i.e. the sequence ispresent only once) and the Dk15 helix 5 is identical to VS461 helix 5,so that sequence is also present only once. In addition, the C-terminusmotif is not present.

Constructs B9.3 and C9.3 contain epitopes (as described for A9.3 aboveand as depicted in FIGS. 30B and C), except that the H13 helix isidentical to that of Pki, so it is excluded (i.e. the sequence ispresent only once) and the Dk15 helix is identical to the VS461 helix,so that sequence is also present only once. In addition, the C-terminusmotif is not present.

Construct B9.1 (SEQ ID NO: 253)SEKFTTKLKDSHAELGIQSVQDDNAKKAILKTHGTKDKGAKELEELFKSLESLSKAAQAA<------------------------------------PWa--------------------LTNSVKELTNSDKFTKKLTDSHAQLGAVGGAINDDRAKEAILKTHGTNDKGAKELKELSE---------><------------------------PLi----------------------SVESLAKAAQAALANSSEAFTKKLKDSNAQLGMQNGAATDAHAKAAILKTDATKDKGATE---------------><-------------------------PBes--------------LGELFKSVESLSKAAQEASVAFTSKLKSSNAQLGVANGNATDDDAKKAILKTNTPNDKGA-----------------><---------------------------Pki-----------KELKELFESVESLAKAAQAALVNSVQELTNSEAFTNRLKGSHAQLGVAAATDDHAKEAIL-----------------------------><-----------------PFiM--------KSNPTKDKGAKELKDLSESVESLAKAAQEALANSVKELTNSEAFTKKLKDNNAQLGIQNV---------------------------------------><----------H13------QDVEAKKAILKTNGDISKSEAFTNKLKEKHAELGVNGGDTTDDNAKAAIFKTHPTKDKGV-----------------><------------------Smar-------------------EDLEKLSESVKSLLKAAQAALSNSAAFTKKLQDGHVDLGKTDVTDDNAKEAILKTNPTKT----------------------><-------------------------HT22-------KGATELEELFKSVEGLVKAAKEA ---------------------->For construct B9.1, the number of amino acids is 503, the molecularweight is 53102.4, and the theoretical pI is 7.16.

Construct B9.2 (SEQ ID NO: 254)SEKFTTKLKDSHAELGIQSVQDKGAKELEELFKSLESLSKAAQAALTNSVKELTNSDKFT<-----Lp PWa-----><--------------Hx PWa---------------><----KKLTDSHAQLGAVGGAINDKGAKELKELSESVESLAKAAQAALANSSEAFTKKLKDSNAQ-----Lp Pli------><-----------Hx Pli---------><------Lp PBesLGMQNGAATDKGATELGELFKSVESLSKAAQEASVAFTSKLKSSNAQLGVANGNATDKGA--------><--------Hx PBes-------><--------Lp Pki-------><---KELKELFESVESLAKAAQAALVNSVQELTNSEAFTNRLKGSHAQLGVAAATDKGAKELKD-------Hx Pki----------------><------Lp PFim------><--------LSESVESLAKAAQEALANSVKELTNSEAFTKKLKDNNAQLGIQNVQSEAFTNKLKEKHAE---Hx PFim--------------><-----Lp H13--------><----Lp Smar---LGVNGGDTTDKGVEDLEKLSESVKSLLKAAQAALSNSAAFTKKLQDGHVDLGKTDVTTKG--------><---------Hx Smar---------><------Lp HT22------><--ATELEELFKSVEGLVKAAKEA  ------Hx HT22------->For construct B9.2, the number of amino acids is 381, the molecularweight is 39928.6, and the theoretical pI is 5.79.

Construct B9.3 (SEQ ID NO: 255)SEAFTKKLKDSNAQLGMQNGAATDKGAKELEELFKSLESLSKAAQAALTNSVKELTNKDK<----------Lp PBes----><-------------Hx PWa-------------><--GAKELKELFESVESLAKAAQAALVNSVQELTNSEKFTTKLKDSHAELGIQSVQSDKFTKK--------Hx PKi-----------------><------Lp PWa-------><------LTDSHAQLGAVGGAINDKGAKELKELSESVESLAKAAQAALANSDKGAKELKDLSESVES-Lp Pli--------><----------Hx Pli----------><-------------HxLAKAAQEALANSVKELTNSVAFTSKLKSSNAQLGVANGNATSEAFTKKLKDNNAQLGIQNPFim-------------><------Lp PKi---------><------Lp H13------VQTKGATELEELFKSVEGLVKAAKEADKGVEDLEKLSESVKSLLKAAQAALSNSAAFTKK-><--------Hx HT22-------><----------Hx Smar--------><------LQDGHVDLGKTDVTSEAFTNRLKGSHAQLGVAAATDKGATELGELFKSVESLSKAAQEASLp HT22------><-----Lp PFim-------><-------Hx PBes--------><EAFTNKLKEKHAELGVNGGDTT -------Lp Smar------->For construct B9.3, the number of amino acids is 382, the molecularweight is 40056.8, and the theoretical pI is 5.93.

Construct C9.1 (SEQ ID NO: 256)SEEFTNKLKSGHADLGKQDATDDHAKAAILKTHATTDKGAKEFKDLFESVEGLLKAAQVA<-------------------------------------Pko-------------------LTNSVKELTSKLKGGHAELGLAAATDENAKKAILKTNGTKDKGAEELEKLFKSVESLAKA---------><------------------------------PLj7---------------AKESLTNSVKELTNTKLRDSHAELGIQNVQDDNAKRAILKTHGNKDKGAKELKELSESLE-------------><------------------PHez-----------------------KLSKAAQAALANSVQELTSSEAFTNKLKEKTQELAVAAGAATDIDAKKAILKTNRDKDLG------------------><--------------PMit----------------------ADERGKLFKSVESLSKAAQEASANSVKELTSSEAFTDKLKNEHASLGKKDATDDDAKKAI------------------------------><-----------------Szid-------LKTNVDKTKGADELIKLSGSLESLSKAAQAILANSEAFTKKLQDSNADLGKHNATDADSK---------------------------------><--------------VS461------EAILKTNGTKTKGAKELEELFKSVESLSKAAKEALSNSVKELTSSQDFINKLKGGHAELG-------------------------------------------><---------------LVAATDANAKAAILKTNGDKTKGADEFEKLFKSVEGLLKAAQEALTNSVKELTSSEAFTK-------HT25------------------------------------------><-----KLQDSNADLGKHDATDADAKKAILKTDATKDK -----------DK15---------------->For construct C9.1, the number of amino acids is 512; the molecularweight is 54372.0; and the theoretical pI is 8.14.

Construct C9.2 (SEQ ID NO: 257)SEEFTNKLKSGHADLGKQDATKGAKEFKDLFESVEGLLKAAQVALTNSVKELTSKLKGGH<-----Lp PKo--------><---------Hx PKo----------------><---LpAELGLAAATKGAEELEKLFKSVESLAKAAKESLTNSVKELTNTKLRDSHAELGIQNVQKGPLj7----><-------------Hx PLj7-----------><----Lp PHez---><-AKELKELSESLEKLSKAAQAALANSVQELTSSEAFTNKLKEKTQELAVAAGAATLGADER---------Hx PHez--------------><-------Lp PMit-------><-----GKLFKSVESLSKAAQEASANSVKELTSSEAFTDKLKNEHASLGKKDATKGADELIKLSGS------Hx PMit-------------><------Lp Szid------><-----------LESLSKAAQAILANSEAFTKKLQDSNADLGKHNATKGAKELEELFKSVESLSKAAKEALSHx Szid------><------Lp VS461-----><-------------Hx VS461---NSVKELTSSQDFINKLKGGHAELGLVAATKGADEFEKLFKSVEGLLKAAQEALTNSVKEL-------><------Lp HT25------><------------Hx HT25-----------TSSEAFTKKLQDSNADLGKHDAT -><------Lp DK15------>For construct C9.2, the number of amino acids is 383, the molecularweight is 40492.5, and the theoretical pI: 6.45.

Construct C9.3 (SEQ ID NO: 258)SEEFTNKLKSGHADLGKQDATKGAKEFKDLFESVEGLLKAAQVALTNSVKELTSKEKGAE<------Lp PKo-------><-------------Hx PKo-------------><-----ELEKLFKSVESLAKAAKESLTNSVKELTNSEAFTDKLKNEHASLGKKDATTKLRDSHAEL----Hx PLj7-----------------><-----Lp Szid-------><-------LpGIQNVQLGADERGKLFKSVESLSKAAQEASANSVKELTSKEKGAKELEELFKSVESLSKAPHez-><------------Hx PMit-------------><----------Hx VS461-AKEALSNSVKELTSSEAFTKKLQDSNADLGKHNATSEAFTKKLQDSNADLGKHDATKGAD-------------><------Lp VS461-----><-------Lp DK15-----><---EFEKLFKSVEGLLKAAQEALTNSVKELTSELKELSESLEKLSKAAQAALANSVQELTSSE-------Hx HT25--------------><-----------Hx PHez---------><-AFTNKLKEKTQELAVAAGAATKLKGGHAELGLAAATKGADELIKLSGSLESLSKAAQAIL-----Lp PMit--------><---Lp PLj7---><---------Hx Szid-------ANSQDFINKLKGGHAELGLVAAT -><-----Lp HT25------->For construct C9.3, the number of amino acids is 383, the molecularweight is 40622.6; and the theoretical pI is 6.10

The A10, A11, and A12 series proteins were also developed as proteinsfor vaccines and/or as diagnostic antigens, as follows:

A10CF (SEQ ID NO: 259)SEDFTNKLKNGNAQLGLAAATKGAKELKDLSDSVESLVKAAQVMLTNSSTGFTNKLKSGH<-------lpF---------><-----------hxF-----------><------lpT-AELGPVGGNATKGAKELKDLSESVEALAKAAQAMLTNSSEKFTKKLSESHADIGIQAATK----------><----------hxT------------><--------lpU--------><GAEELDKLFKAVENLSKSTEFTNKLKSEHAVLGLDNLTKGAAELEKLFKAVENLSKAAQD------hxU-------><--------lpE--------><----------------hxE--TLKNAVKELTSPIVAESPKKPSETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSK--------------------><-------lpA---------><----------hxA----AAKEMLANSVKELTSSEEFSTKLKDNHAQLGIQGVTKGVEELEKLSGSLESLSSEDFTKK--------------><------lpB----------><------hxB------><------LEGEHAQLGIENVTAAELEKLFKAVENLAKAAKEMAKLKGEHTDLGKEGVTKGADELEKL--lpK--------><--------hxK--------><-----lpI------><--------FESVKNLSKAAKEMLTNSVKESEKFAGKLKNEHASLGKKDATKGAKELKDLSDSVESLVK---hxI--------------><--------lpH--------><-------hxH-------ASDDFTKKLQSSHAQLGVAGGATTADELEKLFKSVESLAKAAQDALANSVNELTSKKLKE ><---------lpN---------><-------------hxN-------------><----KHTDLGKKDATAAELEKLFESVENLAKAAKEMLSNSNKAFTDKLKSSHAELGIANGAATK--lpC-----><----------hxC----------><--------lpM----------><GAQELEKLFESVKNLSKAAQETLNNSVKESESFTKKLSDNQAELGIENATKGAEELVKLS------------hxM-------------><--------lpD--------><---------ESVAGLLKAAQAILANSVKELTSPVVAESPKKPNNSGKDGNTSANSADESVKGPNLTEIS----------hxD-------------------><--------------------------KKITESNAVVLAVKEIETLLSSIDELATKAIGQKIDANGLGVQANQNGSLLAGAYAISTL------------------------------OsPc Type F-------------------ITQKLSALNSEDLKEKVAKVKKCSEDFTNKLKNGNAQLGLAAATDDNAKAAILKTNGTND------------------------------------------------------------KGAKELKDLSDSVESLVKAAQVMLTNSVKELTSPVVAESPKKP------------------------------------------>For construct A10CF, the number of amino acids is 823, the molecularweight is 87013.4 and the theoretical pI is 6.28. The estimatedhalf-life (the N-terminal of the sequence considered is S (Ser)) is: 1.9hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo);and >10 hours (Escherichia coli, in vivo).The instability index (II) iscomputed to be 17.53. This classifies the protein as stable. Thealiphatic index is 86.18. The grand average of hydropathicity (GRAVY) is−0.487.

A11 (SEQ ID NO: 260)SEDFTNKLKNGNAQLGLAAATKGAKELKDLSDSVESLVKAAQVMLTNSSTGFTNKLKSGH<-------lpF---------><-----------hxF-----------><------lpT--AELGPVGGNATKGAKELKDLSESVEALAKAAQAMLTNSSEKFTKKLSESHADIGIQAATK----------><----------hxT------------><--------lpU--------><GAEELDKLFKAVENLSKSTEFTNKLKSEHAVLGLDNLTKGAAELEKLFKAVENLSKAAQD------hxU-------><--------lpE--------><----------------hxE--TLKNAVKELTSPIVAESPKKPSETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSK--------------------><-------lpA---------><----------hxA----AAKEMLANSVKELTSSEEFSTKLKDNHAQLGIQGVTKGVEELEKLSGSLESLSSEDFTKK--------------><------lpB----------><------hxB------><------LEGEHAQLGIENVTAAELEKLFKAVENLAKAAKEM --lpK--------><--------hxK-------->For construct A11, the number of amino acids: 335; the molecular weightis 35688.4; and the theoretical pI is 5.87. The estimated half-life (theN-terminal of the sequence considered is S (Ser)) is: 1.9 hours(mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo); and >10hours (Escherichia coli, in vivo). The instability index (II) iscomputed to be 17.08. This classifies the protein as stable. Thealiphatic index: is 84.57. The grand average of hydropathicity (GRAVY)is −0.478

A12 (SEQ ID NO: 261)AKLKGEHTDLGKEGVTKGADELEKLFESVKNLSKAAKEMLTNSVKESEKFAGKLKNEHAS<-----lpI------><-----------hxI--------------><--------lpH--LGKKDATKGAKELKDLSDSVESLVKASDDFTKKLQSSHAQLGVAGGATTADELEKLFKSV------><-------hxH-------><---------lpN---------><----------ESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDATAAELEKLFESVENLAKAAKEMLSN---hxN-------------><------lpC-----><----------hxC----------SNKAFTDKLKSSHAELGIANGAATKGAQELEKLFESVKNLSKAAQETLNNSVKESESFTK ><--------lpM----------><------------hxM-------------><-----KLSDNQAELGIENATKGAEELVKLSESVAGLLKAAQAILANSVKELTSPVVAESPKKP---lpD--------><-------------------hxD------------------->For construct A12, the number of ammo acids is 298; the molecular weightis 31637.7; and the theoretical p1 is 7.19 Estimated half-life (theN-terminal of the sequence considered is A (Ala) is: 4.4 hours(mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo); and >10hours (Escherichia coli, in vivo). The instability index (II) iscomputed to be 17.79; this classifies the protein as stable. Thealiphatic index is 82.99 and the grand average of hydropathicity (GRAVY)is −0.573

A12A (SEQ ID NO: 262)AKLKGEHTDLGKEGVTKGADELEKLFESVKNLSKAAKEMLTNSVKESEKFAGKLKNEHAS<-----lpI------><-----------hxI--------------><--------lpH--LGKKDATKGAKELKDLSDSVESLVKASDDFTKKLQSSHAQLGVAGGATTADELEKLFKSV------><-------hxH-------><---------lpN---------><----------ESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDATAAELEKLFESVENLAKAAKEMLSN---hxN-------------><------lpC-----><----------hxC----------SNKAFTDKLKSSHAELGIANGAATKGAQELEKLFESVKNLSKAAQETLNNSVKESESFTK ><--------lpM----------><------------hxM-------------><-----KLSDNQAELGIENATKGAEELVKLSESVAGLLKAAQAILANSVKELTSPVVAESPKKPST---lpD--------><-------------------hxD-------------------><-EEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYVLEGTLTAEKTTLVVKE--------------------------------------OspA121273------------GTVTLSKNISKSGEVSVELNDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENT------------------------------------------------------------ITVQQYDSNGTKLEGSAVEITKLDEIKNALK ------------------------------>For construct A12A, the number of amino acids is 451; the molecularweight is 48061.1; and the theoretical pI is 7.19 The estimatedhalf-life (the N-terminal of the sequence considered is A (Ala) is: 4.4hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo);and >10 hours (Escherichia coli, in vivo). The instability index (II) iscomputed to be 16.121; this classifies the protein as stable. Thealiphatic index is 81.84. The grand average of hydropathicity (GRAVY) is−0.579.

A12CF (SEQ ID NO: 263)AKLKGEHTDLGKEGVTKGADELEKLFESVKNLSKAAKEMLTNSVKESEKFAGKLKNEHAS<-----lpI------><-----------hxI--------------><--------lpH--LGKKDATKGAKELKDLSDSVESLVKASDDFTKKLQSSHAQLGVAGGATTADELEKLFKSV------><-------hxH-------><---------lpN---------><----------ESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDATAAELEKLFESVENLAKAAKEMLSN---hxN-------------><------lpC-----><----------hxC----------SNKAFTDKLKSSHAELGIANGAATKGAQELEKLFESVKNLSKAAQETLNNSVKESESFTK ><--------lpM----------><------------hxM-------------><-----KLSDNQAELGIENATKGAEELVKLSESVAGLLKAAQAILANSVKELTSPVVAESPKKPNN---lpD--------><-------------------hxD-------------------><-SGKDGNTSANSADESVKGPNLTEISKKITESNAVVLAVKEIETLLSSIDELATKAIGQKI------------------------------------------------------------DANGLGVQANQNGSLLAGAYAISTLITQKLSALNSEDLKEKVAKVKKCSEDFTNKLKNGN------------------------OspC Type F-------------------------AQLGLAAATDDNAKAAILKTNGTNDKGAKELKDLSDSVESLVKAAQVMLTNSVKELTSPV------------------------------------------------------------ VAESPKKP------->For construct A12CF, the number of amino acids is 488; the molecularweight is 51342.9; and the theoretical pI is 7.18. The estimatedhalf-life (the N-terminal of the sequence considered is A (Ala)) is: 4.4hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo);and >10 hours (Escherichia coli, in vivo). The instability index (II) iscomputed to be 17.56; this classifies the protein as stable. Thealiphatic index is 87.30. The grand average of hydropathicity (GRAVY) is−0.492.

Further exemplary chimeric proteins which may be used as diagnosticantigens, designated as LDX1, LDX2, LDX3, and LDX4, are presented below.These sequences may also be used in vaccine compositions. In thesesequences, “ECR” represents “epitope containing regions.” The ECRscontain the regions from (and including) loop 5 to (and including) helix5, as well as the C-terminal motif from the indicated type.

LDX1 (SEQ ID NO: 264)NNSGKDGNTSANSADESVKGPNLTEISKKITDSNAVLLAVKEVEALLSSIDEIAAKAIGK<-----------------------------------------------------------KIHQNNGLDTENNHNGSLLAGAYAISTLIKQKLDGLKNEGLKEKIDAAKKCSETFTNKLK------------------------Type A full length------------------EKHTDLGKEGVTDADAKEAILKTNGTKTKGAEELGKLFESVEVLSKAAKEMLANSVKELT------------------------------------------------------------SPVVAESPKKPSEDFTKKLEGEHAQLGIENVTDENAKKAILITDAAKDKGAAELEKLFKA----------><---------------------Type K ECR-----------------VENLAAKLKGEHTDLGKEGVTDDNAKKAILKTNNDKTKGADELEKLFESVKNLSKAAKEM----><---------------------------Type I ECR-----------------LTNSSEEFSTKLKDNHAQLGIQGVTDENAKKAILKANAAGKDKGVEELEKLSGSLESLSS---><----------------------------Type B ECR---------------><DDFTKKLQSSHAQLGVAGGATTDEEAKKAILRTNAIKDKGADELEKLFKSVESLAKAAQD---------------------------------Type N ECR-----------------ALANSVNELTSSESFTKKLSDNQAELGIENATDDNAKKAILKTHNAKDKGAEELVKLSES----------><---------------------Type D ECR-----------------VAGLLKAAQAILANSVKELTSPVVAESPKKP ------------------------------> LDX2(SEQ ID NO: 265)SETFTNKLKEKHTDLGKEGVTDADAKEAILKTNGTKTKGAEELGKLFESVEVLSKAAKEM<-------------------------------Type A ECR------------------LANSVKELTSSEDFTKKLEGEHAQLGIENVTDENAKKAILITDAAKDKGAAELEKLFKAV---------><---------------------Type K ECR------------------ENLAAKLKGEHTDLGKEGVTDDNAKKAILKTNNDKTKGADELEKLFESVKNLSKAAKEML---><---------------------------Type I ECR------------------TNSSEEFSTKLKDNHAQLGIQGVTDENAKKAILKANAAGKDKGVEELEKLSGSLESLSSD--><----------------------------Type B ECR---------------><-DFTKKLQSSHAQLGVAGGATTDEEAKKAILRTNAIKDKGADELEKLFKSVESLAKAAQDA--------------------------------Type N ECR------------------LANSVNELTSSESFTKKLSDNQAELGIENATDDNAKKAILKTHNAKDKGAEELVKLSESV---------><---------------------Type D ECR------------------AGLLKAAQAILANSVKELTSPVVAESPKKP -----------------------------> LDX3(SEQ ID NO: 266)NNSGKDGNTSANSADESVKGPNLTEISKKITESNAVVLAVKEIETLLSSIDELATKAIGQ<-----------------------------------------------------------KIDANGLGVQANQNGSLLAGAYAISTLITQKLSALNSEDLKEKVAKVKKCSEDFTNKLKN------------------------Type F full length------------------GNAQLGLAAATDDNAKAAILKTNGTNDKGAKELKDLSDSVESLVKAAQVMLTNSVKELTS------------------------------------------------------------PVVAESPKKPSEKFAGKLKNEHASLGKKDATDDDAKKAILKTHGNTDKGAKELKDLSDSV---------><---------------------Type H ECR------------------ESLVSTGFTNKLKSGHAELGPVGGNATDENAKQAILKTHGNVTKGAKELKDLSESVEALA---><---------------------------Type T ECR------------------KAAQAMSEKFTKKLSESHADIGIQAATDANAKDAILKTNPTKTKGAEELDKLFKAVENLS-----><-------------------------Type U ECR------------------KAAKKLKEKHTDLGKKDATDVHAKEAILKTNGTKDKGAAELEKLFESVENLAKAAKEMLS--><----------------------------Type C ECR------------------NSNKAFTDKLKSSHAELGIANGAATDANAKAAILKTNGTKDKGAQELEKLFESVKNLSKA-><-----------------------------Type M ECR------------------AQETLNNSSTEFTNKLKSEHAVLGLDNLTDDNAQRAILKKHANKDKGAAELEKLFKAVEN-------><-----------------------Type E ECR------------------LSKAAQDTLKNAVKELTSPIVAESPKKP ---------------------------> LDX4(SEQ ID NO: 267)NKLKNGNAQLGLAAATDDNAKAAILKTNGTNDKGAKELKDLSDSVESLVKAAQVMLTNSS<-------------------------Type F ECR----------------------><EKFAGKLKNEHASLGKKDATDDDAKKAILKTHGNTDKGAKELKDLSDSVESLVSTGFTNK--------------------------Type H ECR----------------><------LKSGHAELGPVGGNATDENAKQAILKTHGNVTKGAKELKDLSESVEALAKAAQAMSEKFT--------------------------Type T ECR------------------><----KKLSESHADIGIQAATDANAKDAILKTNPTKTKGAEELDKLFKAVENLSKAAKKLKEKHT--------------------------Type U ECR---------------><-------DLGKKDATDVHAKEAILKTNGTKDKGAAELEKLFESVENLAKAAKEMLSNSNKAFTDKLK--------------------------Type C ECR--------------><--------SSHAELGIANGAATDANAKAAILKTNGTKDKGAQELEKLFESVKNLSKAAQETLNNSSTE--------------------------Type M ECR--------------------><--FTNKLKSEHAVLGLDNLTDDNAQRAILKKHANKDKGAAELEKLFKAVENLSKAAQDTLKN--------------------------Type E ECR------------------------AVKELTSPIVAESPKKP ---------------->

Example 8 Evaluation of Immune Response to Chimeric A12CF Protein inDogs

Ten dogs, approximately two months old, in good health, and notpreviously vaccinated against Lyme disease, were used in the study. Onegroup (5 dogs) was administered subcutaneously (SC), at the nape of thecervical region/dorsal shoulders, a 1 ml dose of 0.063% PBS on both day0 and 21. The second group (5 dogs) was similarly administered a 1 mldose of chimeric A12CF protein adjuvanted with Rehydragel LV, also onday 0 and 21. Serum was collected on days 0, 21, 42 and 63, and analyzedby ELISA and/or Western blots for antibodies to the A12CF chimericprotein.

Dogs receiving the saline administrations remained serologicallynegative for antibodies to OspC throughout the study, having titers of41.0 (day 0), 54.1 (day 21), 58.7 (day 42), and 71.4 (day 63). Dogsreceiving the A12CF protein adjuvanted with Rehydragel LV, however,mounted a robust serological response to the protein, having titers of77.6 (day 0), 540.6 (day 21), 16333.0 (day 42), and 8650.2 (day 63).

While the invention has been described in terms of its preferredembodiments, those skilled in the art will recognize that the inventioncan be practiced with modification within the spirit and scope of theappended claims. Accordingly, the present invention should not belimited to the embodiments as described above, but should furtherinclude all modifications and equivalents thereof within the spirit andscope of the description provided herein.

REFERENCES

-   Abuodeh R O, Shubitz L F, Siegel E, Snyder S, Peng T, Orsborn K I,    et al. Resistance to Coccidioides immitis in mice after immunization    with recombinant protein or a DNA vaccine of a proline-rich antigen.    Infect Immun 1999 June; 67(6):2935-40.-   Ahlborg N, Nardin E H, Perlmann P, Berzins K, Andersson R.    Immunogenicity of chimeric multiple antigen peptides based on    Plasmodium falciparum antigens: impact of epitope orientation.    Vaccine 1998; 16(1):38-44.-   Alghaferi, M. Y., J. M. Anderson, J. Park, P. G. Auwaerter, J. N.    Aucott, D. E. Norris, and J. S. Dumler. 2005. Borrelia burgdorferi    ospC heterogeneity among human and murine isolates from a defined    region of Northern Maryland and Southern Pennsylvania: Lack of    correlation with invasive and non-invasive genotypes. J. Clin.    Microbiol. 43:1879-1884.-   Alvarez P, Buscaglia C A, Campetella O. Improving protein    pharmacokinetics by genetic fusion to simple amino acid sequences. J    Biol Chem 2004 Jan. 30; 279(5):3375-81.-   Alverson, J., S. F. Bundle, C. D. Sohaskey, M. C. Lybecker,    and D. S. Samuels. 2003. Transcriptional regulation of the ospA B    and ospC promoters from Borrelia burgdorferi. Mol. Microbiol.    48:1665-1677.-   Apta, D., K. Raviprakashb, A. Brinkman, A. Semyonov, S. Yang, C.    Skinnera, L. Diehl, R. Lyons, K. Porter, and J. Punnonen. 2006.    Tetravalent neutralizing antibody response against four dengue    serotypes by a single chimeric dengue envelope antigen. Vaccine    24:335-344.-   Asch E S, Bujak D I, Weiss M, Peterson M G, Weinstein A. Lyme    disease: an infectious and postinfectious syndrome. J Rheumatol    1994; 21(3):454-61.-   Attie, O., J. F. Bruno, Y. Xu, D. Qiu, B. J. Luft, and W. G.    Qiu. 2006. Co-evolution of the outer surface protein C gene (ospC)    and intraspecific lineages of Borrelia burgdorferi sensu stricto in    the northeastern United States. Infect Genet Evol E-pub.-   Barthold S W, Beck D S, Hansen G M, Terwilliger G A, Moody K D. Lyme    borreliosis in selected strains and ages of laboratory mice. J    Infect Dis 1990 July; 162(1):133-8.-   Barthold S W, Persing D H, Armstrong A L, Peeples R A. Kinetics of    Borrelia burgdorferi dissemination and evolution of disease after    intradermal inoculation of mice. Am J Pathol 1991; 139(2):263-73.-   Benach J L, Bosler E M, Hanrahan J P, Coleman J L, Bast T F, Habicht    G S, et al. Spirochetes isolated from the blood of two patients with    Lyme disease. N Engl J Med 1983; 308:740-2.-   Bockenstedt, L. K., E. Hodzic, S. Feng, K. W. Bourrel, A. de    Silva, R. R. Montgomery, E. Fikrig, J. D. Radolf, and S. W.    Barthold. 1997. Borrelia burgdorferi strain-specific OspC mediated    immunity in mice. Infect. Immun. 65:4661-4667.-   Bockenstedt L K, Kang I, Chang C, Persing D, Hayday A, Barthold S W.    CD4+ T helper 1 cells facilitate regression of murine Lyme carditis.    Infect Immun 2001 September; 69(9):5264-9.-   Bouche F B, Steinmetz A, Yanagi Y, Muller C P. Induction of broadly    neutralizing antibodies against measles virus mutants using a    polyepitope vaccine strategy. Vaccine 2005; 23(17-18):2074-7.-   Brewer J M, Conacher M, Hunter C A, Mohrs M, Brombacher F,    Alexander J. Aluminium hydroxide adjuvant initiates strong    antigen-specific Th2 responses in the absence of I L-4- or    IL-13-mediated signaling. J Immunol 1999; 163(12):6448-54.-   Brinckerhoff L H, Kalashnikov V V, Thompson L W, Yamshchikov G V,    Pierce R A, Galavotti H S, et al. Terminal modifications inhibit    proteolytic degradation of an immunogenic MART-1 (27-35) peptide:    implications for peptide vaccines. Int J Cancer 1999 Oct. 29;    83(3):326-34.-   Brisson D, Dykhuizen D E. ospC diversity in Borrelia burgdorferi:    Different hosts are different niches. Genetics 2004; 168:713-22.-   Brown E L, Kim J H, Reisenbichler E S, Hook M. Multicomponent Lyme    vaccine: three is not a crowd. Vaccine 2005; 23(28):3687-96.-   Burgdorfer W, Barbour A G, Hayes S F, Benach J L, Grunwaldt E, Davis    J P. Lyme disease—a tick-borne spirochetosis? Science 1982;    216:1317-9.-   Cai Q L, Wei F, Lin Y H, Shao D D, Wang H. Immunogenicity of    polyepitope libraries assembled by epitope shuffling: an approach to    the development of chimeric gene vaccination against malaria.    Vaccine 2004; 23(2):267-77.-   Caro-Aguilar, I., S. Lapp, J. Pohl, M. R. Galinski, and A.    Moreno. 2005. Chimeric epitopes delivered by polymeric synthetic    linear peptides induce protective immunity to malaria. Microbes    Infect. 7:1324-1337.-   Christe M, Rutti B, Brossard M. Cytokines (IL-4 and IFN-gamma) and    antibodies (IgE and IgG2a) produced in mice infected with Borrelia    burgdorferi sensu stricto via nymphs of Ixodes ricinus ticks or    syringe inoculations. Parasitol Res 2000 June; 86(6):491-6.-   Coyle P K, Schutzer S E. Neurologic aspects of Lyme disease. Med    Clin North Am 2002; 86(2):261-84.-   Crasto C J, Feng J A. LINKER: a program to generate linker sequences    for fusion proteins. Protein Eng 2000; 13(5):309-12.-   Cribbs D H, Ghochikyan A, Vasilevko V, Tran M, Petrushina I,    Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2    responses to immunization with beta-amyloid. Int Immunol 2003 April;    15(4):505-14.-   Dale J B, Simmons M, Chiang E C, Chiang E Y. Recombinant, octavalent    group A streptococcal M protein vaccine. Vaccine 1996; 14(10):944-8.-   Dale J B, Penfound T, Chiang E Y, Long V, Shulman S T, Beall B.    Multivalent group A streptococcal vaccine elicits bactericidal    antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005;    12(7):833-6.-   Dale J B, Chiang E Y, Lederer J W. Recombinant tetravalent group A    streptococcal M protein vaccine. J Immunol 1993; 151(4):2188-94.-   Dale, J. B. 1999. Mutlivalent group A streptococcal vaccine designed    to optimize the immunogenicity of six tandem M protein fragments.    Vaccine 17:193-200.-   de Silva A M, Zeidner N S, Zhang Y, Dolan M C, Piesman J, Fikrig E.    Influence of outer surface protein A antibody on Borrelia    burgdorferi within feeding ticks. Infect Immun 1999; 67(1):30-5.-   Dangl J L, Wensel T G, Morrison S L, Stryer L, Herzenberg L A, Oi    V T. Segmental flexibility and complement fixation of genetically    engineered chimeric human, rabbit and mouse antibodies. EMBO J. 1988    July; 7(7):1989-94.-   Eicken, C., C. Sharma, T. Klabunde, R. T. Owens, D. S. Pikas, M.    Hook, and J. C. Sacchettini. 2001. Crystal structure of Lyme disease    antigen outer surface protein C from Borrelia burgdorferi. J. Biol.    Chem. 276:10010-10015.-   Eiffert H, Karsten A, Thomssen R, Christen H-J. Characterization of    Borrelia burgdorferi strains in Lyme arthritis. Scand J Infect Dis    1998; 24:437-9.-   Elias A F, Stewart P E, Grimm D, Caimano M J, Eggers C H, Tilly K,    et al. Clonal polymorphism of Borrelia burgdorferi strain B31 MI:    implications for mutagenesis in an infectious strain background.    Infect Immun 2002; 70(4):2139-50.-   Elias A F, Bono J L, Carroll J A, Stewart P, Tilly K, Rosa P.    Altered stationary-phase response in a Borrelia burgdorferi rpoS    mutant. J Bacteriol 2000; 182(10):2909-18.-   Escudero, R., M. Halluska, P. Backenson, J. Coleman, and J.    Benach. 1997. Characterization of the physiological requirements for    the bactericidal effects of a monoclonal antibody to OspB of    Borrelia burgdorferi by confocal microscopy. Infect. Immun.    65:1908-1915.-   Fahrer H, van der Linden S M, Sauvian M J, Gem L, Zhioua E,    Aeschlimann A. The prevalence and incidence of clinical and    asymptomatic Lyme borreliosis in a population at risk. J Infect Dis    1991; 163:305-10.-   Fan, C. F., and X. G. Mei. 2005. Co-immunization of BALB/c mice with    recombinant immunogens containing G protein fragment and chimeric    CTL epitope of respiratory syncytial virus induces enhanced cellular    immunity and high level of antibody response. Vaccine 23:4453-4461.-   Fingerle, V., U. Hauser, G. Liegl, B. Petko, V. Preac-Mursic, and B.    Wilske. 1995. Expression of outer surface proteins A and C of    Borrelia burgdorferi in Ixodes ricinus. J. Clin. Microbiol.    33:1867-1869.-   Fraser, C., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R.    Lathigra, O. White, K. A. Ketchum, R. Dodson, E. K. Hickey, M.    Gwinn, B. Dougherty, J. F. Tomb, R. D. Fleischman, D. Richardson, J.    Peterson, A. R. Kerlavage, J. Quackenbush, S. Salzberg, M.    Hanson, R. Vugt, N. Palmer, M. D. Adams, J. Gocayne, J. Weidman, T.    Utterback, L. Watthey, L. McDonald, P. Artiach, C. Bowman, S.    Garland, C. Fujii, M. D. Cotton, K. Horst, K. Roberts, B. Hatch, H.    O, Smith, and J. C. Venter. 1997. Genomic sequence of a Lyme disease    spirochaete, Borrelia burgdorferi. Nature 390:580-586.-   Fuchs, R., S. Jauris, F. Lottspeich, V. Preac-Mursic, B. Wilske,    and E. Soutschek. 1992. Molecular analysis and expression of a    Borrelia burgdorferi gene encoding a 22-kDa protein (pC) in    Escherichia coli. Mol. Microbiol. 6:503-509.-   Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins M R, Appel R    D, et al. Protein Identification and Analysis Tools on the ExPASy    Server. In: Walker J M, editor. The Proteomics Protocols Handbook.    Totowa, N.J.: Humana Press, 2005: 571-608.-   Gilmore, R. D., and M. L. Mbow. 1999. Conformational nature of the    Borrelia burgdorferi B31 outer surface protein C protective epitope.    Infect. Immun. 67:5463-5469.-   Gilmore R D, Jr., Mbow M L, Stevenson B. Analysis of Borrelia    burgdorferi gene expression during life cycle phases of the tick    vector Ixodes scapularis. Microbes Infect 2001; 3(10):799-808.-   Gilmore, R. D., R. M. Bacon, A. M. Carpio, J. Piesman, M. C. Dolan,    and M. L. Mbow. 2003. Inability of outer-surface protein C    (OspC)-primed mice to elicit a protective anamnestic immune response    to a tick-transmitted challenge of Borrelia burgdorferi. J. Med.    Microbiol. 52:551-556.-   Gilmore, R. D. J. 1998. A monoclonal antibody generated by antigen    inoculation via tick bite is reactive to the Borrelia burgdorferi    Rev protein, a member of the 2.9 gene family locus. Infect. Immun.    66:980-986.-   Gilmore, R. D., K. J. Kappel, M. C. Dolan, T. R. Burkot,    and B. J. B. Johnson. 1996. Outer surface protein C (OspC) but not    P39 is a protection immunogen against a tick-transmitted Borrelia    burgdorferi challenge: evidence for a conformational protective    epitope in OspC. Infect. Immun. 64:2234-2239.-   Golovanov A P, Hautbergue G M, Wilson S A, Lian L Y. A simple method    for improving protein solubility and long-term stability. J Am Chem    Soc 2004 Jul. 28; 126(29):8933-9.-   Grimm, D., K. Tilly, R. Byram, S. P. E, J. G. Krum, D. M.    Bueschel, T. G. Schwan, P. F. Policastro, A. F. Elias, and P. A.    Rosa. 2004. Outer surface protein C of the Lyme disease spirochetes:    A protein induced in ticks for infection in mammals. Proc. Natl.    Acad. Sci. USA 101:3142-3147.-   Gross D M, Steere A C, Huber B T. T helper 1 response is dominant    and localized to the synovial fluid in patients with Lyme arthritis.    J Immunol 1998 Jan. 15; 160(2):1022-8.-   Guruprasad K, Reddy B V, Pandit M W. Correlation between stability    of a protein and its dipeptide composition: a novel approach for    predicting in vivo stability of a protein from its primary sequence.    Protein Eng 1990; 4(2):155-61.-   Guttman D S, Wang P W, Wang I N, Bosler E M, Luft B J, Dykhuizen    D E. Multiple infections of Ixodes scapularis ticks by Borrelia    burgdorferi as revealed by single-strand conformation polymorphism    analysis. J Clin Microbiol 1996; 34(3):652-6.-   Hanson, M. S., and R. Edelman. 2004. Vaccines against Lyme    disease, p. 487-498. In M. Levine, J. B. Kaper, R. Rappuoli, M. A.    Liu, and M. F. Good (ed.), New generation vaccines, vol. 3. Marcel    Dekker A G, New York, N.Y.-   Hodzic E, Feng S, Barthold S W. Stability of Borrelia burgdorferi    outer surface protein C under immune selection pressure. J Infect    Dis 2000; 181(2):750-3.-   Hofineister E K, Glass G E, Childs J E, Persing D H. Population    dynamics of a naturally occurring heterogeneous mixture of Borrelia    burgdorferi clones. Infect Immun 1999; 67(11):5709-16.-   Horvath, A., L. Karpati, H. K. Sun, M. Good, and I. Toth. 2005.    Toward the development of a synthetic group a streptococcal vaccine    of high purity and broad protective coverage. J. Med. Chem.    47:4100-4104.-   Hovis, K., J. V. McDowell, L. Griffin, and R. T. Marconi. 2004.    Identification and characterization of a linear plasmid encoded    factor H-binding protein (FhbA) of the relapsing fever spirochete,    Borrelia hermsii. J. Bacteriol. 186:2612-2618.-   Hu C M, Simon M, Kramer M D, Gem L. Tick factors and in vitro    cultivation influence the protein profile, antigenicity and    pathogenicity of a cloned Borrelia garinii isolate from Ixodes    ricinus hemolymph. Infection 1996; 24(3):251-7.-   Hu M C, Walls M A, Stroop S D, Reddish M A, Beall B, Dale J B.    Immunogenicity of a 26-valent group A streptococcal vaccine. Infect    Immun 2002; 70(4):2171-7.-   Hubner, A., X. Yang, D. M. Nolen, T. G. Popova, F. C. Cabello,    and M. V. Norgard. 2001. Expression of Borrelia burgdorferi OspC and    DbpA is controlled by a RpoN-RpoS regulatory pathway. Proc Natl Acad    Sci USA 98:12724-12729.-   Ikushima, M., K. Matsui, F. Yamada, S. Kawahashi, and A.    Nishikawa. 2000. Specific immune response to a synthetic peptide    derived from outer surface protein C of Borrelia burgdorferi    predicts protective borreliacidal antibodies. FEMS Immunol. Med.    Microbiol. 29:15-21.-   Jiang Y, Lin C, Yin B, He X, Mao Y, Dong M, et al. Effects of the    configuration of a multi-epitope chimeric malaria DNA vaccine on its    antigenicity to mice. Chin Med J (Engl) 1999; 112(8):686-90.-   Jobe, D. A., S. D. Lovrich, R. F. Schell, and S. M. Callister. 2003.    C-terminal region of outer surface protein C binds borreliacidal    antibodies in sera from patients with Lyme disease. Clin. Diagn.    Lab. Immunol. 10:573-578.-   Kalish R A, Leong J M, Steere A C. Association of treatment    resistant chronic Lyme arthritis with HLA-DR4 and antibody    reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun    1993; 61:2774-9.-   Kawarasaki Y, Yamada Y, Ichimori M, Shinbata T, Kohda K, Nakano H,    et al. Stabilization of affinity-tagged recombinant protein    during/after its production in a cell-free system using wheat-germ    extract. J Biosci Bioeng 2003; 95(3):209-14.-   Keane-Myers A, Maliszewski C R, Finkelman F D, Nickell S P.    Recombinant IL-4 treatment augments resistance to Borrelia    burgdorferi infections in both normal susceptible and    antibody-deficient susceptible mice. J Immunol 1996; 156(7):2488-94.-   Keane-Myers A, Nickell S P. T cell subset-dependent modulation of    immunity to Borrelia burgdorferi in mice. J Immunol 1995;    154(4):1770-6.-   Keane-Myers A, Nickell S P. Role of IL-4 and IFN-gamma in modulation    of immunity to Borrelia burgdorferi in mice. J Immunol 1995;    155(4):2020-8.-   Kelleher Doyle M, Telford S R, 3rd, Criscione L, Lin S R, Spielman    A, Gravallese E M. Cytokines in murine Lyme carditis: Th1 cytokine    expression follows expression of proinflammatory cytokines in a    susceptible mouse strain. J Infect Dis 1998 January; 177(1):242-6.-   Kjerrulf M, Lowenadler B, Svanholm C, Lycke N. Tandem repeats of T    helper epitopes enhance immunogenicity of fusion proteins by    promoting processing and presentation. Mol Immunol 1997;    34(8-9):599-608.-   Kneller D G, Cohen F E, Langridge R. Improvements in protein    secondary structure prediction by an enhanced neural network. J Mol    Biol 1990; 214(1):171-82.-   Koide S, Yang X, Huang X, Dunn J J, Luft B J. Structure-based design    of a second-generation Lyme disease vaccine based on a C-terminal    fragment of Borrelia burgdorferi OspA. J Mol Biol 2005;    350(2):290-9.-   Kotloff, K. L., M. Coretti, K. Palmer, J. D. Campbell, M. A.    Reddish, M. C. Hu, S. S. Wasserman, and J. B. Dale. 2005. Safety and    immunogenicity of a recombinant multivalent group A streptococcal    vaccine in healthy adults: phase 1 trial. JAMA 292:738-739.-   Kraiczy P, Hunfeld K P, Peters S, Wurzner R, Ackert G, Wilske B, et    al. Borreliacidal activity of early Lyme disease sera against    complement-resistant Borrelia afzelii FEM1 wild-type and an    OspC-lacking FEM1 variant. J Med Microbiol 2000; 49(10):917-28.-   Kumaran, D., S. Eswaramoorthy, B. J. Luft, S. Koide, J. J.    Dunn, C. L. Lawson, and S.-   Swaminathan. 2001. Crystal structure of outer surface protein C    (OspC) from the Lyme disease spirochete, Borrelia burgdorferi.    EMBO J. 20:971-978.-   Lagal, V., D. Postic, E. Ruzic-Sabljic, and G. Baranton. 2003.    Genetic diversity among Borrelia strains determine by    single-stranded confromation polymorphism analysis of the ospC gene    and its association with invasiveness. J. Clin. Microbiol.    41:5059-5065.-   Ledin K E, Zeidner N S, Ribeiro J M, Biggerstaff B J, Dolan M C,    Dietrich G, et al. Borreliacidal activity of saliva of the tick    Amblyomma americanum. Med Vet Entomol 2005; 19(1):90-5.-   Lee E N, Kim Y M, Lee H J, Park S W, Jung H Y, Lee J M, et al.    Stabilizing peptide fusion for solving the stability and solubility    problems of therapeutic proteins. Pharm Res 2005 October;    22(10):1735-46.-   Lindblad E B. Aluminium compounds for use in vaccines. Immunol Cell    Biol 2004; 82(5):497-505.-   Lole, K. S., R. C. Bollinger, R. S. Paranjape, D. Gadkari, S. S.    Kulkarni, N. G. Novak, R. Ingersoll, H. W. Sheppard, and S.C.    Ray. 1999. Full-length human immunodeficiency virus type 1 genomes    from subtype C-infected seroconverters in India, with evidence of    intersubtype recombination. J. Virol. 73:152-160.-   Lovrich, S. D., D. A. Jobe, R. F. Schell, and S. M. Callister. 2005.    Borreliacidal OspC antibodies specific for a highly conserved    epitope are immunodominant in human Lyme disease and do not occur in    mice or hamsters. Clin. Diagn. Lab. Immunol. 12:746-751.-   Marconi R T, Samuels D S, Garon C F. Transcriptional analyses and    mapping of the ospC gene in Lyme disease spirochetes. J Bacteriol    1993; 175:926-32.-   Marconi, R. T., D. S. Samuels, T. G. Schwan, and C. F. Garon. 1993.    Identification of a protein in several Borrelia species which is    related to OspC of the Lyme disease spirochetes. J. Clin. Microbiol.    31:2577-2583.-   Marconi, R. T., D. S. Samuels, and C. F. Garon. 1993.    Transcriptional analyses and mapping of the ospC gene in Lyme    disease spirochetes. J. Bacteriol. 175:926-932.-   Margolis, N., D. Hogan, W. J. Cieplak, T. G. Schwan, and P. A.    Rosa. 1994. Homology between Borrelia burgdorferi OspC and members    of the family of Borrelia hermsii variable major proteins. Gene    143:105-110.-   Mathiesen, M. J., A. Holm, M. Christiansen, J. Blom, K. Hansen, S.    Ostergard, and M. Theisen. 1998. The dominant epitope of Borrelia    garinii outer surface protein C recognized by sera from patients    with neuroborreliosis has a surface exposed conserved structural    motif. Infect. Immun. 66:4073-4079.-   Mbow, M. L., R. D. Gilmore, Jr., and R. G. Titus. 1999. An    OspC-specific monoclonal antibody passively protects mice from    tick-transmitted infection by Borrelia burgdorferi B31. Infect.    Immun. 67:5470-5472.-   McDowell, J. V., S. Y. Sung, L. T. Hu, and R. T. Marconi. 2002.    Evidence that the variable regions of the central domain of V1sE are    antigenic during infection with the Lyme disease spirochetes.    Infect. Immun. 70:4196-4203.-   McNeela E A, Mills K H. Manipulating the immune system: humoral    versus cell-mediated immunity. Adv Drug Deliv Rev 2001;    51(1-3):43-54.-   McNeil, S. A., S. A. Halperin, J. M. Langley, B. Smith, A.    Warren, G. P. Sharratt, D. M. Baxendale, M. A. Reddish, M. C.    Hu, S. D. Stroop, J. Linden, L. F. Fries, P. E. Vink, and J. B.    Dale. 2005. Safety and immunogenicity of 26-valent group a    streptococcus vaccine in healthy adult volunteers. Clin. Infect.    Dis. 41:1114-1122.-   Meltzer M I, Dennis D T, Orloski K A. The cost effectiveness of    vaccinating against Lyme disease. Emerg Infect Dis 1999; 5:321-8.-   Metts, S., J. V. McDowell, M. Theisen, P. R. Hansen, and R. T.    Marconi. 2003. Analysis of the OspE determinants involved in the    binding of factor H and OspE targeting antibodies elicited during    infection in mice. Infect. Immun. 71:3587-3596.-   Miletic V D, Frank M M. Complement-immunoglobulin interactions. Curr    Opin Immunol 1995 February; 7(1):41-7.-   Montgomery R R, Schreck K, Wang X, Malawista S E. Human neutrophil    calprotectin reduces the susceptibility of Borrelia burgdorferi to    penicillin. Infect Immun 2006; 74(4):2468-72.-   Munson E L, Du Chateau B K, Jobe D A, Lovrich S D, Callister S M,    Schell R F. Production of borreliacidal antibody to outer surface    protein A in vitro and modulation by interleukin-4. Infect Immun    2000 October; 68(10):5496-501.-   Munson E L, Du Chateau B K, Jensen J R, Callister S M, DeCoster D J,    Schell R F. Gamma interferon inhibits production of Anti-OspA    borreliacidal antibody in vitro. Clin Diagn Lab Immunol 2002    September; 9(5):1095-101.-   Nachman S A, Pontrelli L. Central nervous system Lyme disease. Semin    Pediatr Infect Dis 2003; 14(2):123-30.-   Nagi K S, Joshi R, Thakur R K. Cardiac manifestations of Lyme    disease: a review. Can J Cardiol 1996; 12(5):503-6.-   Ohnishi, J., J. Piesman, and A. M. de Silva. 2001. Antigenic and    genetic heterogeneity of Borrelia burgdorferi populations    transmitted by ticks. Proc. Natl. Acad. Sci. USA, 98:670-675.-   Pal, U., X. Yang, M. Chen, L. K. Bockenstedt, J. F. Anderson, R. A.    Flavell, M. V. Norgard, and E. Fikrig. 2004. OspC faciliates    Borrelia burgdorferi invasion of Ixodes scapularis salivary glands.    The Journal of Clinical Investigation 113:220-230.-   Petrovsky N, Aguilar J C. Vaccine adjuvants: current state and    future trends. Immunol Cell Biol 2004; 82(5):488-96.-   Potter M R, Noben-Trauth N, Weis J H, Teuscher C, Weis J J.    Interleukin-4 (IL-4) and IL-13 signaling pathways do not regulate    Borrelia burgdorferi-induced arthritis in mice: IgG1 is not required    for host control of tissue spirochetes. Infect Immun 2000 October;    68(10):5603-9.-   Powell M F, Grey H, Gaeta F, Sette A, Colon S. Peptide stability in    drug development: a comparison of peptide reactivity in different    biological media. J Pharm Sci 1992 August; 81(8):731-5.-   Probert, W. S., M. Crawford, R. B. Cadiz, and R. B. LeFebre. 1997.    Immunization with outer surface protein (Osp) A but not OspC    provides crossprotection of mice challenged with North American    isolates of Borrelia burgdorferi. J. Infect. Dis. 175:400-405.-   Probert, W. S., and R. B. LeFebvre. 1994. Protection of C3H/HeN mice    from challenge with Borrelia burgdorferi through active immunization    with OspA, OspB, or OspC but not with OspD or the 83-kilodalton    antigen. Infect. Immun. 62:1920-1926.-   Rammensee H, Bachmann J, Emmerich N P, Bachor O A, Stevanovic S.    SYFPEITHI: database for MHC ligands and peptide motifs.    Immunogenetics 1999; 50(3-4):213-9.-   Remington S J, Breddam K. Carboxypeptidases C and D. Methods Enzymol    1994; 244:231-48.-   Rijpkema S G, Tazelaar D J, Molkenboer M J, Noordhoek G T, Planting    a G, Schouls L M, et al. Detection of Borrelia afzelii, Borrelia    burgdorferi sensu stricto, Borrelia garinii and group VS116 by PCR    in skin biopsies of patients with erythema migrans and    acrodermatitis chronica atrophicans. Clin Microbiol Infect 1997;    3(1):109-16.-   Roberts, D., M. Caimano, J. McDowell, M. Theisen, A. Holm, E.    Orff, D. Nelson, S. Wikel, J. Radolf, and R. Marconi. 2002.    Environmental regulation and differential expression of members of    the Bdr protein family of Borrelia burgdorferi. Infect. Immun.    70:7033-7041.-   Rousselle, J. C., S. M. Callister, R. F. Schell, S. D.    Lovrich, D. A. Jobe, J. A. Marks, and C. A. Wienke. 1998.    Borreliacidal antibody production against outer surface protein C of    Borrelia burgdorferi. J. Infect. Dis. 178:733-741.-   Ruzic-Sabljic E, Lotric-Furlan S, Maraspin V, Cimperman J, Logar M,    Jurca T, et al. Comparison of isolation rate of Borrelia burgdorferi    sensu lato in MKP and BSK-II medium. Int J Med Microbiol 2006;    296(Suppl 40):267-73.-   Sadziene, A., B. Wilske, M. S. Ferdows, and A. G. Barbour. 1993. The    cryptic ospC gene of Borrelia burgdorferi B31 is located on a    circular plasmid. Infect. Immun. 61:2192-2195.-   Satoskar A R, Elizondo J, Monteforte G M, Stamm L M, Bluethmann H,    Katavolos P, et al. Interleukin-4-deficient BALB/c mice develop an    enhanced Th1-like response but control cardiac inflammation    following Borrelia burgdorferi infection. FEMS Microbiol Lett 2000    Feb. 15; 183(2):319-25.-   Scheiblhofer, S., R. Weiss, H. Durnberger, S. MostBock, M.    Breitenbach, I. Livey, and J. Thalhamer. 2003. A DNA vaccine    encoding the outer surface protein C from Borrelia burgdorferi is    able to induce protective immune responses. Microbes Infect.    5:939-946.-   Schwan, T. G., and B. J. Hinnebusch. 1998. Bloodstream-versus    tick-associated variants of a Relapsing fever bacterium. Science    280:1938-1940.-   Schwan T G, Piesman J. Temporal changes in outer surface proteins A    and C of the Lyme disease-associated spirochete, Borrelia    burgdorferi, during the chain of infection in ticks and mice. J Clin    Microbiol 2000; 38(1):382-8.-   Schwan T G. Temporal regulation of outer surface proteins of the    Lyme-disease spirochaete Borrelia burgdorferi. Biochem Soc Trans    2003; 31(Pt 1):108-12.-   Schwan, T. G., J. Piesman, W. T. Golde, M. C. Dolan, and P. A.    Rosa. 1995. Induction of an outer surface protein on Borrelia    burgdorferi during tick feeding. Proc. Natl. Acad. Sci. USA    92:2909-2913.-   Seinost, G., D. E. Dykhuizen, R. J. Dattwyler, W. T. Golde, J. J.    Dunn, N. Wang, G. P. Wormser, M. E. Schriefer, and B. J. Luft. 1999.    Four clones of Borrelia burgdorferi sensu stricto cause invasive    infection in humans. Infect. Immun. 67:3518-3524.-   Shadick N A, Liang M H, Phillips C B, Fossel K, Kuntz K. The    cost-effectiveness of vaccination against Lyme disease. Arch Intern    Med 2001; 161:554-61.-   Shibaki A, Katz S I. Induction of skewed Th1/Th2 T-cell    differentiation via subcutaneous immunization with Freund's    adjuvant. Exp Dermatol 2002 April; 11(2):126-34.-   Shin J J, Bryksin A V, Godfrey H P, Cabello F C. Localization of    BmpA on the exposed outer membrane of Borrelia burgdorferi by    monospecific anti-recombinant BmpA rabbit antibodies. Infect Immun    2004; 72(4):2280-7.-   Spellberg B, Edwards J E, Jr. Type 1/Type 2 immunity in infectious    diseases. Clin Infect Dis 2001 January; 32(1):76-102.-   Steere A C, Malawista S E, Snydman D R, Shope R E, Andiman W A, Ross    M R, et al. Lyme arthritis: an epidemic of oligoarticular arthritis    in children and adults in three Connecticut communities. Arthritis    Rheum 1977b;20:7-17.-   Steere A C, Glickstein L. Elucidation of Lyme arthritis. Nat Rev    Immunol 2004; 4(2):143-52.-   Steere A C, Malawista S E, Hardin J A, Ruddy S, Askenase W, Andiman    W A. Erythema chronicum migrans and Lyme arthritis. The enlarging    clinical spectrum. Ann Intern Med 1977a; 86:685-98.-   Stevenson, B., T. G. Schwan, and P. Rosa. 1995. Temperature—related    differential expression of antigens in the Lyme Disase spirochete    Borrelia burgdorferi. Infect. Immun. 63:4535-4539.-   Stevenson B, Bockenstedt L K, Barthold S W. Expression and gene    sequence of outer surface protein C of Borrelia burgdorferi    reisolated from chronically infected mice. Infect Immun 1994;    62(8):3568-71.-   Sung, S. Y., J. McDowell, J. A. Carlyon, and R. T. Marconi. 2000.    Mutation and recombination in the upstream homology box flanked ospE    related genes of the Lyme disease spirochetes results in the    development of new antigenic variants during infection. Infect.    Immun. 68:1319-1327.-   Takayama K, Rothenberg R J, Barbour A G. Absence of    lipopolysaccharide in the Lyme disease spirochete, Borrelia    burgdorferi. Infect Immun 1987 September; 55(9):2311-3.-   ten Hagen T L, Sulzer A J, Kidd M R, Lal A A, Hunter R L. Role of    adjuvants in the modulation of antibody isotype, specificity, and    induction of protection by whole blood-stage Plasmodium yoelii    vaccines. J Immunol 1993; 151(12):7077-85.-   Theisen D M, Bouche F B, El Kasmi K C, von der Ahe I, Ammerlaan W,    Demotz S, et al. Differential antigenicity of recombinant    polyepitope-antigens based on loop- and helix-forming B and T cell    epitopes. J Immunol Methods 2000; 242(1-2):145-57.-   Theisen, M., M. Bone, M. J. Mathiesen, B. Mikkelsen, A. M. Lebech,    and K. Hansen. 1995. Evolution of the Borrelia burgdorferi outer    surface protein OspC. J. Bacteriol. 177:3036-3044.-   Theisen, M., B. Frederiksen, A.-M. Lebech, J. Vuust, and K.    Hansen. 1993. Polymorphism in ospC gene of Borrelia burgdorferi and    immunoreactivity of OspC protein: implications for taxonomy and for    use of OspC protein as a diagnostic antigen. J. Clin. Microbiol.    31:2570-2576.-   Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G.    Higgins. 1997. The ClustalX windows interface: flexible strategies    for multiple sequence alignment aided by quality analysis tools.    Nucleic Acids Res. 24:4876-4882.-   Tilly K, Elias A F, Errett J, Fischer E, Iyer R, Schwartz I, et al.    Genetics and regulation of chitobiose utilization in Borrelia    burgdorferi. J Bacteriol 2001; 183(19):5544-53.-   Tongren J E, Corran P H, Jana W, Langhorne J, Riley E M.    Epitope-specific regulation of immunoglobulin class switching in    mice immunized with malarial merozoite surface proteins. Infect    Immun 2005; 73(12):8119-29.-   Walker J R, Altman R K, Warren J W, Altman E. Using protein-based    motifs to stabilize peptides. J Pept Res 2003 November;    62(5):214-26.-   Wallich R, Siebers A, Jahraus O, Brenner C, Stehle T, Simon M M. DNA    vaccines expressing a fusion product of outer surface proteins A and    C from Borrelia burgdorferi induce protective antibodies suitable    for prophylaxis but not for resolution of Lyme disease. Infect Immun    2001; 69(4):2130-6.-   Wang, I. N., D. E. Dykhuizen, W. Qiu, J. J. Dunn, E. M. Bosler,    and B. J. Luft. 1999. Genetic diversity of ospC in a local    population of Borrelia burgdorferi sensu stricto. Genetics    151:15-30.-   Wang, X. N., G. P. Zhang, J. Y. Zhou, C. H. Feng, Y. Y. Yang, Q. M.    L1, J. Q. Guo, H. X. Qiao, J. Xi, D. Zhao, G. X. Xing, Z. L.    Wang, S. H. Wang, Z. J. Xiao, X. W. L1, and R. G. Deng. 2005.    Identification of neutralizing epitopes on the VP2 protein of    infectious bursal disease virus by phage-displayed heptapeptide    library screening and synthetic peptide mapping. Viral Immunol.    18:549-557.-   Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, Forsberg P,    et al. Borrelia-specific interferon-gamma and interleukin-4    secretion in cerebrospinal fluid and blood during Lyme borreliosis    in humans: association with clinical outcome. J Infect Dis 2004;    189(10):1881-91.-   Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, Forsberg P,    et al. Borrelia-specific interferon-gamma and interleukin-4    secretion in cerebrospinal fluid and blood during Lyme borreliosis    in humans: association with clinical outcome. J Infect Dis 2004 May    15; 189(10):1881-91.-   Willett T A, Meyer A L, Brown E L, Huber B T. An effective    second-generation outer surface protein A-derived Lyme vaccine that    eliminates a potentially autoreactive T cell epitope. Proc Natl Acad    Sci USA 2004; 101(5):1303-8.-   Wilske, B., U. Busch, V. Fingerle, S. Jauris-Heipke, V.    Preac-Mursic, D. Robler, and G. Will. 1996. Immunological and    molecular variability of OspA and OspC: implications for Borrelia    vaccine development. Infection 24:208-212.-   Wilske, B., V. Preac-Mursic, S. Jauris, A. Hofmann, I. Pradel, E.    Soutschek, E. Schwab, G. Will, and G. Wanner. 1993. Immunological    and molecular polymorphisms of OspC, an immunodominant major outer    surface protein of Borrelia burgdorferi. Infect. Immun.    61:2182-2191.-   Yang L, Ma Y, Schoenfeld R, Griffiths M, Eichwald E, Araneo B, et    al. Evidence for B-lymphocyte mitogen activity in Borrelia    burgdorferi-infected mice. Infect Immun 1992 August; 60(8):3033-41.-   Zhang G L, Khan A M, Srinivasan K N, August J T, Brusic V.    MULTIPRED: a computational system for prediction of promiscuous HLA    binding peptides. Nucleic Acids Res 2005; 33(W): 172-9.-   Zhang, H., A. Raji, M. Theisen, P. R. Hansen, and R. T.    Marconi. 2005. bdrF2 of the Lyme disease spirochetes is coexpressed    with a series of cytoplasmic proteins and is produced specifically    during early infection. J. Bacteriol. 187:175-184.-   Zhong W, Stehle T, Museteanu C, Siebers A, Gem L, Kramer M, et al.    Therapeutic passive vaccination against chronic Lyme disease in    mice. Proc Natl Acad Sci USA 1997; 94(23):12533-8.-   Zuckert W R, Kerentseva T A, Lawson C L, Barbour A G. Structural    conservation of neurotropism-associated VspA within the variable    Borrelia Vsp-OspC lipoprotein family. J Biol Chem 2001;    276(1):457-63.

We claim:
 1. A chimeric recombinant protein comprising epitopes fromloop 5 region or alpha helix 5 region, or both, of two or more outersurface protein C (OspC) types.
 2. The chimeric recombinant protein ofclaim 1, comprising epitopes from 5 to 13 OspC types.
 3. The chimericrecombinant protein of claim 1, comprising epitopes from 5 OspC types.4. The chimeric recombinant protein of claim 1, comprising epitopes from6 OspC types.
 5. The chimeric recombinant protein of claim 1, comprisingepitopes from 7 OspC types.
 6. The chimeric recombinant protein of claim1, comprising epitopes from 8 OspC types.
 7. The chimeric recombinantprotein of claim 1, comprising epitopes from 9 OspC types.
 8. Thechimeric recombinant protein of claim 1, comprising epitopes from 13OspC types.
 9. The chimeric recombinant protein of claim 1, wherein saidOspC types are selected from the group consisting of Smar, PLi, H13,PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A, 72a,F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, C and T.
 10. Thechimeric recombinant protein of claim 1, wherein said chimeric proteinhas an amino acid sequence having at least 95%, 96%, 97%, 98%, 99% ormore identity, or complete (100%) identity to an amino acid sequenceselected from the group consisting of SEQ ID NO: 250, SEQ ID NO: 251,SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ IDNO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260,SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ IDNO: 265, SEQ ID NO: 266 and SEQ ID NO:
 267. 11. The chimeric recombinantprotein of claim 1, wherein at least one of said OspC types isassociated with invasive Borrelia infection in humans.
 12. The chimericrecombinant protein of claim 1, wherein each of said OspC types isassociated with invasive Borrelia infection in humans.
 13. A method foreliciting an immune response against Borrelia in an individual in needthereof, comprising the step of providing to said individual a chimericrecombinant protein comprising epitopes from loop 5 region or alphahelix 5 region, or both, of two or more outer surface protein C (OspC)types which are different from each other.
 14. The method of claim 13,wherein said chimeric recombinant protein comprises epitopes from 5 to13 OspC types.
 15. The method of claim 13, wherein said OspC types areselected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit,PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A, 72a, F, E, M, D, U, I,L, H, Szid, PHez, PWa, B, K, N, C and T.
 16. The method of claim 13,wherein said chimeric protein has an amino acid sequence having at least95%, 96%, 97%, 98%, 99% or more identity, or complete (100%) identity toan amino acid sequence selected from the group consisting of SEQ IDNO:250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254,SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ IDNO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263,SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266 and SEQ ID NO:
 267. 17.The method of claim 13, wherein at least one of said OspC types isassociated with invasive Borrelia infection in humans.
 18. The method ofclaim 13, wherein each of said OspC types is associated with invasiveBorrelia infection in humans.
 19. A method for ascertaining whether anindividual has been exposed to or infected with Borrelia, or both,comprising the steps of obtaining a biological sample from saidindividual, exposing said biological sample to at least one recombinantchimeric protein, wherein said at least one chimeric protein comprisesepitopes from loop 5 region or alpha helix 5 region, or both, of two ormore outer surface protein C (OspC) types which are different from eachother; and determining whether antibodies in said biological sample bindto said at least one chimeric protein, wherein detection of antibodybinding is indicative of prior exposure to or infection with Borrelia.20. The method of claim 19, wherein said chimeric recombinant proteincomprises epitopes from 5 to 13 OspC types.
 21. The method of claim 19,wherein said OspC types are selected from the group consisting of Smar,PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15,HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, C and T.22. The method of claim 19, wherein said chimeric protein has an aminoacid sequence having at least 95%, 96%, 97%, 98%, 99% or more identity,or complete (100%) identity to an amino acid sequence selected from thegroup consisting of SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO:257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO:266 and SEQ ID NO:
 267. 23. The method of claim 19, wherein at least oneof said OspC types is associated with invasive Borrelia infection inhumans.
 24. The method of claim 19, wherein each of said OspC types isassociated with invasive Borrelia infection in humans.
 25. An antibodyto a chimeric recombinant protein comprising epitopes from loop 5 regionor alpha helix 5 region, or both, of two or more outer surface protein C(OspC) types.
 26. The antibody of claim 25, wherein said chimericrecombinant protein comprises epitopes from 5 to 13 OspC types.
 27. Theantibody of claim 25, wherein said OspC types are selected from thegroup consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22,Pko, PLj7, VS461, DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid,PHez, PWa, B, K, N, C and T.
 28. The antibody of claim 25, wherein saidchimeric protein has an amino acid sequence having at least 95%, 96%,97%, 98%, 99% or more identity, or complete (100%) identity to an aminoacid sequence selected from the group consisting of SEQ ID NO: 250, SEQID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO:255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO:264, SEQ ID NO: 265, SEQ ID NO: 266 and SEQ ID NO:
 267. 29. The antibodyof claim 25, wherein at least one of said OspC types is associated withinvasive Borrelia infection in humans.
 30. The antibody of claim 25,wherein each of said OspC types is associated with invasive Borreliainfection in humans.
 31. The antibody of claim 25, wherein said antibodyis bactericidal for Borrelia spirochetes.
 32. A immunogenic cocktail ofchimeric recombinant proteins, wherein each chimeric recombinant proteinin said cocktail comprises epitopes from loop 5 region or alpha helix 5region, or both, of two or more outer surface protein C (OspC) types.33. The immunogenic cocktail of claim 32, wherein each chimericrecombinant protein comprises epitopes from 6 to 13 of said OspC types.